indomethacin has been researched along with Ductus Arteriosus, Patent in 834 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Ductus Arteriosus, Patent: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patent ductus arteriosus is a risk factor for pulmonary hemorrhage; however, despite halving the incidence of patent ductus arteriosus, indomethacin prophylaxis did not reduce the rate of pulmonary hemorrhage in the Trial of Indomethacin Prophylaxis in Preterms." | 9.13 | Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. ( Alfaleh, K; Asztalos, EV; Roberts, RS; Schmidt, B; Smyth, JA; Solimano, A, 2008) |
| "We found no association between acute kidney injury during indomethacin therapy and patent ductus arteriosus closure." | 8.31 | Neonatal acute kidney injury during indomethacin therapy: does it predict ductal closure? ( Dias Maia, P; Gien, J; Rodrigues, KK; Turner, MJ, 2023) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 8.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| "A preterm male infant with a patent ductus arteriosus developed neutropenia during treatment with indomethacin." | 7.73 | Indomethacin-associated neutropenia with subsequent Gram-negative sepsis in a preterm infant. Cause or coincidence? ( Bengtsson, BO; Milstein, JM; Sherman, MP, 2006) |
| "To determine the risk of bronchopulmonary dysplasia (BPD) in subgroups of infants with and without patent ductus arteriosus (PDA) who were randomized to indomethacin prophylaxis or placebo, and to examine whether adverse drug effects on edema formation and oxygenation may explain why indomethacin prophylaxis does not reduce BPD." | 7.73 | Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). ( Davis, P; Fanaroff, A; Kirpalani, HM; Nwaesei, C; Roberts, RS; Schmidt, B; Vincer, M, 2006) |
| "Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 7.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 7.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| "To evaluate the effects of an increase in glucose infusion rate of 2 mg/kg per min from the basal infusion rate on the prevention of hypoglycemia in very low-birthweight (VLBW) infants, following indomethacin therapy for patent ductus arteriosus (PDA)." | 7.71 | Preventive management of hypoglycemia in very low-birthweight infants following indomethacin therapy for patent ductus arteriosus. ( Hosono, S; Kimoto, H; Nagoshi, R; Nozawa, M; Ohono, T; Shimizu, M, 2001) |
| "Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 7.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
| "This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 7.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
| "Indomethacin was administered to suppress premature uterine contractions in a twin pregnancy from the 27th until the 32nd week of pregnancy." | 7.67 | Patent ductus arteriosus after prolonged treatment with indomethacin during pregnancy: case report. ( Abramovici, H; Atad, J; Lissak, A; Rofe, A, 1987) |
| "Four very-low-birth-weight infants developed localized intestinal perforations after enteral administration of indomethacin." | 7.67 | Localized intestinal perforations after enteral administration of indomethacin in premature infants. ( Alpan, G; Amir, G; Eyal, F; Glick, B; Mogle, P; Udassin, R; Vinograd, I, 1985) |
| "Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 7.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
| "Five low-birth-weight neonates, ranging from 580 to 1,430 g, developed clinically significant hyponatremia (less than 130 mg/dl) within 48 h after being given indomethacin for patent ductus arteriosus closure." | 7.67 | Severe hyponatremia with indomethacin--a more serious toxicity than previously realized? ( Hammerman, C; Wu, HH; Zaia, W, 1985) |
| "This study evaluates the effects of Indomethacin (IND), Prostaglandin E1 (PGE1), and Ibuprofen (IBP) in a bowel ischemia model." | 7.66 | Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia. ( Cikrit, D; Grosfeld, JL; Gross, K; Kamman, K; Katz, S; Ross, D; Weber, TR; Wolfe, M, 1983) |
| "When Indomethacin in a dosage of 175 mg/day was used to treat threatened premature labour more than 70% of cases carried on until 37 weeks." | 6.37 | [Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients]. ( Barrat, J; Bouillie, J; Boyer, F; Keskes, J; Marpeau, L; Pigné, A; Vincenti, O, 1988) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 5.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| "Indomethacin therapy was associated with significantly higher SCr concentrations at 36, 84, and 120 h compared to controls." | 5.51 | Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus. ( Beedgen, B; Bruckner, T; Fichtner, A; Pöschl, J; Schaefer, F; Tönshoff, B; Waldherr, S; Westhoff, JH; Westhoff, TH, 2019) |
| "of indomethacin was associated with closure of PDA in 108 (77." | 5.35 | Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants. ( Lee, J; Yang, CZ, 2008) |
| "The use of indomethacin to treat patent ductus arteriosus in preterm infants may either decrease the incidence of necrotizing enterocolitis by stabilizing or closing the ductus arteriosus or increase its incidence by a direct constricting effect on mesenteric blood vessels." | 5.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
| "These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates." | 5.31 | Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. ( Brown, YL; Carlos, RQ; Davey, AM; Dimaguila, MA; Gal, P; Ransom, JL; Schall, SA; Shaffer, CL; Smith, MS, 2002) |
| "A patent ductus arteriosus is a risk factor for pulmonary hemorrhage; however, despite halving the incidence of patent ductus arteriosus, indomethacin prophylaxis did not reduce the rate of pulmonary hemorrhage in the Trial of Indomethacin Prophylaxis in Preterms." | 5.13 | Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. ( Alfaleh, K; Asztalos, EV; Roberts, RS; Schmidt, B; Smyth, JA; Solimano, A, 2008) |
| " We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of PDA closure within one week of administration of the first dose of indomethacin; bronchopulmonary dysplasia (BPD) at 28 days' postnatal age and at 36 weeks' postmenstrual age; proportion of infants requiring surgical ligation or transcatheter occlusion; all-cause neonatal mortality; necrotizing enterocolitis (NEC) (≥ Bell stage 2); and mucocutaneous or gastrointestinal bleeding." | 5.12 | Indomethacin for symptomatic patent ductus arteriosus in preterm infants. ( Evans, P; Flyer, JN; Mitra, S; O'Reilly, D; Soll, R, 2021) |
| " In view of this and with its higher incidence of necrotizing enterocolitis, we do not recommend using prolonged low-dose indomethacin for closing the patent ductus arteriosus in very low birth weight infants." | 5.10 | Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. ( Lee, J; Leong, JY; Rajadurai, VS; Tan, KW; Wong, EH; Wong, KY, 2003) |
| "Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria." | 5.09 | A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. ( Degroote, K; Langhendries, JP; Lecoutere, D; Smets, K; Van de Broek, H; Van Overmeire, B; Weyler, J, 2000) |
| "The prophylactic administration of indomethacin reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g)." | 5.09 | Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. ( Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Schmidt, B; Solimano, A; Vincer, M; Wright, LL, 2001) |
| "Ninety infants, with birth weights of 600 to 1250 gm, were entered into a prospective, randomized, controlled trial to receive either indomethacin, 0." | 5.08 | Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. ( Cabalka, AK; Couser, RJ; Ferrara, TB; Hoekstra, RE; Payne, NR; Schilling, CG; Wright, GB, 1996) |
| "In a randomized study the effect of an early prophylactic indomethacin treatment on the incidence of the patent ductus arteriosus (PDA) in very low birth weight infants (VLBWI) and their postnatal course were investigated." | 5.06 | [Effects of early therapy with indomethacin on the manifestation of a persistent ductus arteriosus in extremely underweight premature infants]. ( Böttcher, H; Grubbe, G; Ockert, C; Ruckhäberle, KE; Vogtmann, C, 1988) |
| "The impact of early prophylactic use of intravenous indomethacin on the incidence and severity of periventricular-intraventricular hemorrhage and patent ductus arteriosus in 199 oxygen-requiring premature infants (less than or equal to 1300 g birth weight) was prospectively investigated." | 5.06 | Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. ( Bancalari, E; Bandstra, ES; Ferrer, PL; Flynn, J; Goldberg, RN; Gregorios, JB; Montalvo, BM; Pacheco, I, 1988) |
| " Moderate certainty evidence showed a reduction in NEC following administration of a combination of species of probiotics, probiotics (any), antenatal corticosteroids in pregnant women at risk of preterm birth, and ibuprofen versus indomethacin for treatment of patent ductus arteriosus (PDA)." | 5.05 | An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants. ( Ei-Saie, A; Maheshwari, A; Neu, J; Pammi, M; Xiong, T, 2020) |
| "A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage." | 4.98 | Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. ( Florez, ID; Mbuagbaw, L; Mitra, S; Sadeghirad, B; Tamayo, ME; Thabane, L; Vanniyasingam, T; Veroniki, AA; Zea, AM; Zhang, Y, 2018) |
| " Oral ibuprofen is associated with lower instance of necrotizing enterocolitis." | 4.95 | Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. ( Keim-Malpass, J; Prescott, S, 2017) |
| " Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA)." | 4.81 | NSAID-induced nephrotoxicity from the fetus to the child. ( Cuzzolin, L; Dal Cerè, M; Fanos, V, 2001) |
| " These factors (immaturity, hyperoxia, hypoxia, blood transfusions, intraventricular hemorrhage, apnea, infection, hypercarbia, hypocarbia, patent ductus arteriosus, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis, prenatal complications, genetic factors) may all be present in an infant." | 4.76 | A reexamination of the role of oxygen in retrolental fibroplasia. ( Dangman, B; Lucey, JF, 1984) |
| "We found no association between acute kidney injury during indomethacin therapy and patent ductus arteriosus closure." | 4.31 | Neonatal acute kidney injury during indomethacin therapy: does it predict ductal closure? ( Dias Maia, P; Gien, J; Rodrigues, KK; Turner, MJ, 2023) |
| " Early indomethacin was associated with a lower risk of patent ductus arteriosus and bronchopulmonary dysplasia and a higher risk of spontaneous intestinal perforation." | 4.12 | Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants. ( Ambalavanan, N; Bell, EF; Carlo, WA; Chawla, S; Chowdhury, D; Das, A; Gantz, M; Harmon, HM; Laptook, AR; Natarajan, G; Shankaran, S; Tapia, JL, 2022) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 4.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| " To mitigate the extent of CS and allow the pregnancy to continue, maternal non-steroidal anti-inflammatory drug (NSAID) therapy with indomethacin was started at 33 + 5 weeks to induce DA constriction." | 4.02 | Inadvertent irreversible closure of arterial duct following therapeutic use of transplacental indomethacin in a fetus with severe Ebstein's anomaly and circular shunt. ( Arbic, N; Gill, K; Honjo, O; Jaeggi, E; Ryan, G; Seed, M, 2021) |
| " Mortality, severe neurological injury, retinopathy, necrotizing enterocolitis, bronchopulmonary dysplasia, nosocomial infection, and patent ductus arteriosus ligation rates were compared between infants who received antenatal steroids, prophylactic indomethacin, and/or prophylactic phototherapy and those who did not." | 3.81 | Prophylactic Interventions in Neonatology: How Do They Fare in Real Life? ( Harrison, A; Lee, SK; Piedbouf, B; Rolnitsky, A; Shah, PS, 2015) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| " Infants who had PDA and survived beyond 72 hours were included in multivariable logistic regression analyses that compared mortality or any severe neonatal morbidity (intraventricular hemorrhage grades ≥ 3, retinopathy of prematurity stages ≥ 3, bronchopulmonary dysplasia, or necrotizing enterocolitis stages ≥ 2) between treatment groups (conservative management, indomethacin only, surgical ligation only, or both indomethacin and ligation)." | 3.78 | Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. ( Allen, AC; Aziz, K; Lee, SK; Mirea, L; Ohlsson, A; Sankaran, K; Seshia, M; Shah, PS, 2012) |
| "In infants with VLBW, oral ibuprofen is as effective as intravenous indomethacin for closure of PDA and is associated with significantly fewer cases of necrotizing enterocolitis among infants with birth body weights <1250 g and significantly lower rates of elevated creatinine levels among neonates with birth body weights ranging from 1000 to 1500 g." | 3.78 | Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. ( Chen, HN; Hsiao, CC; Lee, CH; Lee, ML; Tsao, LY, 2012) |
| " The levels of NT-proBNP in premature neonates with hemodynamically significant patency of the ductus arteriosus (hsPDA) were assessed before and after treatment using ibuprofen, indomethacin, or both." | 3.76 | N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool? ( Bromiker, R; Hammerman, C; Kaplan, M; Nir, A; Schimmel, MS; Shchors, I, 2010) |
| " neonatologists reported that they would ligate a PDA when infants with birth weights <900 g required mechanical ventilation (and indomethacin was contraindicated or had failed to close the PDA), U." | 3.76 | Feeding practices and patent ductus arteriosus ligation preferences-are they related? ( Clyman, RI; Jhaveri, N; Soll, RF, 2010) |
| "To test the hypothesis that intrauterine inflammation increases prostaglandin production and may be a risk factor for persistent ductus arteriosus after therapy with indomethacin, a nonselective cyclooxygenase inhibitor." | 3.76 | Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. ( Choi, CW; Choi, JH; Kim, BI; Kim, EK; Kim, ES; Kim, HS; Moon, KC; Park, JS, 2010) |
| "There were no statistically significant differences between the two protocol groups when comparing percentages of neonates with gestational age≤28 weeks, birth weight≤1000 g, male gender or receiving indomethacin for the indication of PDA prophylaxis vs." | 3.76 | Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure. ( Chorne, N; Rosito, G; Sum, K, 2010) |
| "Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death." | 3.75 | [Patent ductus arteriosus in premature infants]. ( Bratlid, D; Farstad, T, 2009) |
| "The purpose of this study was to describe the fetal and newborn safety profile of prolonged indomethacin treatment during pregnancy." | 3.74 | The safety of prolonged indomethacin therapy. ( Anderson, BL; Savage, AH; Simhan, HN, 2007) |
| " The differential effects of these PDE 3 inhibitors on the near-term and preterm ductus were studied by injecting indomethacin (10 mg/kg) and PDE 3 inhibitors into 21D (21st day of pregnancy: term-21." | 3.73 | In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats. ( Imamura, S; Momma, K; Nakanishi, T; Toyoshima, K, 2006) |
| "A preterm male infant with a patent ductus arteriosus developed neutropenia during treatment with indomethacin." | 3.73 | Indomethacin-associated neutropenia with subsequent Gram-negative sepsis in a preterm infant. Cause or coincidence? ( Bengtsson, BO; Milstein, JM; Sherman, MP, 2006) |
| "To determine the risk of bronchopulmonary dysplasia (BPD) in subgroups of infants with and without patent ductus arteriosus (PDA) who were randomized to indomethacin prophylaxis or placebo, and to examine whether adverse drug effects on edema formation and oxygenation may explain why indomethacin prophylaxis does not reduce BPD." | 3.73 | Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). ( Davis, P; Fanaroff, A; Kirpalani, HM; Nwaesei, C; Roberts, RS; Schmidt, B; Vincer, M, 2006) |
| "Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 3.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 3.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| " Variables like birth weight, and sex did not have any sigiificant effect on indomethacin pharmacokinetics." | 3.72 | A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India. ( Garg, SK; Narang, A; Sharma, PK, 2003) |
| "To evaluate the effects of an increase in glucose infusion rate of 2 mg/kg per min from the basal infusion rate on the prevention of hypoglycemia in very low-birthweight (VLBW) infants, following indomethacin therapy for patent ductus arteriosus (PDA)." | 3.71 | Preventive management of hypoglycemia in very low-birthweight infants following indomethacin therapy for patent ductus arteriosus. ( Hosono, S; Kimoto, H; Nagoshi, R; Nozawa, M; Ohono, T; Shimizu, M, 2001) |
| "Digoxin was administered to an 18-day-old infant who showed evidence of cardiac failure." | 3.68 | Increase in serum digoxin concentrations after indomethacin therapy in a full-term neonate. ( Brookfield, EG; Haig, GM, 1992) |
| "To determine the relative importance of patent ductus arteriosus, indomethacin, and intestinal distension as factors that promote terminal ileum ischemia, eight near-term fetal lambs were surgically prepared by in situ cannulation of the proximal and distal ends of a loop of terminal ileum, formalin infiltration of the ductus arteriosus, and placement of a snare around the ductus arteriosus to control its patency." | 3.68 | Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. ( Alpan, G; Clyman, RI; Lin, E; Meyers, RL, 1991) |
| "Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 3.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
| "This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 3.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
| "Indomethacin was administered to suppress premature uterine contractions in a twin pregnancy from the 27th until the 32nd week of pregnancy." | 3.67 | Patent ductus arteriosus after prolonged treatment with indomethacin during pregnancy: case report. ( Abramovici, H; Atad, J; Lissak, A; Rofe, A, 1987) |
| "Four very-low-birth-weight infants developed localized intestinal perforations after enteral administration of indomethacin." | 3.67 | Localized intestinal perforations after enteral administration of indomethacin in premature infants. ( Alpan, G; Amir, G; Eyal, F; Glick, B; Mogle, P; Udassin, R; Vinograd, I, 1985) |
| "Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 3.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
| "Five low-birth-weight neonates, ranging from 580 to 1,430 g, developed clinically significant hyponatremia (less than 130 mg/dl) within 48 h after being given indomethacin for patent ductus arteriosus closure." | 3.67 | Severe hyponatremia with indomethacin--a more serious toxicity than previously realized? ( Hammerman, C; Wu, HH; Zaia, W, 1985) |
| "This study evaluates the effects of Indomethacin (IND), Prostaglandin E1 (PGE1), and Ibuprofen (IBP) in a bowel ischemia model." | 3.66 | Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia. ( Cikrit, D; Grosfeld, JL; Gross, K; Kamman, K; Katz, S; Ross, D; Weber, TR; Wolfe, M, 1983) |
| " Intravenous indomethacin was administered to 67 infants with successful closure in 91% of the patients and in 83% of those with birth weights less than 1,000 g." | 3.66 | Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants. ( Alexson, CG; Harris, JP; Longfield, L; Manning, JA; Merritt, TA, 1982) |
| " Four had severe hyaline membrane disease and one had chronic bronchopulmonary dysplasia; all received furosemide." | 3.66 | Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. ( Demers, LM; Friedman, Z; Maisels, MJ; Marks, KH; Uhrmann, S, 1978) |
| "For premature infants with respiratory failure combined with PDA, cardiopulmonary ultrasonography can better guide respiratory support." | 3.30 | Cardiopulmonary Ultrasound-Guided Treatment of Premature Infants with Respiratory Failure and Patent Ductus Arteriosus: A Randomized, Controlled Trial. ( Hua, L; Jia, X; Lou, X; Xu, L; Zhang, Z; Zhao, M, 2023) |
| " Although the use of indomethacin is the standard therapy for PDA, it is sometimes not applicable because of its adverse effects, such as renal and platelet dysfunctions." | 3.30 | iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Fukuoka, N; Honda, M; Kawada, K; Kikuchi, K; Mikami, M; Motojima, Y; Namba, F; Ogawa, K; Sakatani, S; Sako, M; Ueda, K, 2023) |
| "Acetaminophen was first proposed as a potential treatment for PDA in 2011." | 3.01 | Acetaminophen for the patent ductus arteriosus: has safety been adequately demonstrated? ( Jensen, EA; McCulley, DJ; Mitra, S; Wright, CJ, 2023) |
| "IV indomethacin was more effective than IV acetaminophen for treatment of hsPDAs." | 3.01 | A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. ( Davidson, JM; Ferguson, J; Ivey, E; Philip, R; Talati, AJ; Weems, MF, 2021) |
| " The secondary outcomes include components of the primary outcome as well as clinical outcomes related to response to treatment or adverse effects of treatment." | 3.01 | Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA). ( Abou Mehrem, A; Adie, M; Alvaro, R; Ben Fadel, N; Bhattacharya, S; Bodani, J; Canning, R; Dorling, J; Drolet, C; Gardner, CE; Hatfield, T; Hyderi, A; Jain, A; Jasani, B; Kanungo, J; Khurshid, F; Kumaran, K; Lapointe, A; Louis, D; Mitra, S; Morin, A; Shah, P; Soraisham, A; Stavel, M; Ting, JY; Weisz, D; Ye, XY, 2021) |
| "Indomethacin was more effective than acetaminophen in producing ductus constriction." | 2.90 | Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). ( Aucott, SW; Bulbul, A; Carey, WA; Clyman, RI; Derrick, M; Dong, L; Erdeve, O; Farooqi, A; Håkansson, S; Hassinger, DC; Hayashi, M; Heuchan, AM; Kaempf, J; Katheria, A; Kimball, A; Leone, T; Liebowitz, M; Lindqvist, J; Nelson, K; Perez, J; Sankar, M; Sauberan, J; Serize, A; Singh, J; Wickremasinghe, A; Wolf, IS, 2019) |
| "Optimal management of the patent ductus arteriosus (PDA) in preterm infants remains controversial." | 2.84 | Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants. ( Bell, EF; Bethany Ball, M; Boghossian, NS; Brumbaugh, JE; Dagle, JM; Das, A; Do, BT; Sanchez, PJ; Shankaran, S; Stoll, BJ; Vohr, BR; Wyckoff, MH, 2017) |
| "The indomethacin group was associated with a significantly higher chance of persistent ductal response than the ibuprofen group (66 vs." | 2.84 | Randomized Trial to Compare Renal Function and Ductal Response between Indomethacin and Ibuprofen Treatment in Extremely Low Birth Weight Infants. ( Chen, CM; Florens, A; Huang, FK; Kuo, YT; Lin, YJ; Rehan, VK; Tsai, ML; Wu, SY; Yeh, TF, 2017) |
| " However, paracetamol caused fewer adverse effects." | 2.82 | Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials. ( Chatziravdeli, VI; Dardiotis, E; Doxani, C; Katsaras, DN; Katsaras, GN; Mitsiakos, G; Papavasileiou, GN; Stefanidis, I; Touloupaki, M, 2022) |
| "The hemodynamic impact of persistent patent ductus arteriosus (PDA) is associated with neonatal morbidities and mortality in preterm newborns." | 2.82 | Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants. ( Vidavalur, R, 2022) |
| "To evaluate the efficacy of dual patent ductus arteriosus (PDA) pharmacotherapy compared to monotherapy we searched Medline, Embase, Cochrane Library, and references of relevant articles through October 20, 2021 for randomized clinical trials (RCTs) and cohort studies comparing dual PDA treatment vs." | 2.82 | Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review. ( Abdaljalil, H; Abu-Omar, R; Bin-Nun, A; Hammerman, C; Kasirer, Y; Mimouni, F; Nitzan, I; Schorrs, I, 2022) |
| "Based on low-grade evidence, high dose ibuprofen may more effectively reduce rates of PDA ligation compared to standard dose with no increase in adverse effects, neonatal morbidities and mortality." | 2.82 | Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. ( Jain, A; Jasani, B; Shahroor, M; Weisz, D; Yeung, T, 2022) |
| "The different management strategies for patent ductus arteriosus (PDA) in preterm infants are expectant management, surgery, or medical treatment with non-selective cyclo-oxygenase inhibitors." | 2.82 | Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. ( Jasani, B; Mitra, S; Shah, PS, 2022) |
| "Failure of closure of the patent ductus arteriosus (PDA) may be associated with harm." | 2.79 | A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. ( Evans, N; Gill, A; Jeffery, M; Kluckow, M, 2014) |
| " Patients were assigned to receive either oral ibuprofen at a dosage of 10, 5, 5 mg/kg every 24 h or three doses of oral indomethacin (0." | 2.79 | Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ( Agarwal, S; Anand, P; Dubey, NK; Dudeja, A; Maria, A; Yadav, DK; Yadav, S, 2014) |
| "Furosemide is known to increase renal prostaglandin synthesis." | 2.75 | Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. ( Byun, SY; Chang, JY; Chung, ML; Kim, EA; Kim, HY; Kim, KS; Lee, BS; Pi, SY, 2010) |
| "A significant patent ductus arteriosus (PDA) is a common finding in the first days of life and, if persistent, is associated with an increased morbidity and mortality in the preterm newborn." | 2.75 | Effect of indomethacin infused over 30 minutes on cerebral fractional tissue oxygen extraction in preterm newborns with a patent ductus arteriosus. ( Bos, AF; Keating, P; ter Horst, H; van Hoften, J; Verhagen, E, 2010) |
| "The proportion of infants with a treated patent ductus arteriosus or death at <28 days of age was 63% in the sterile water group vs 64% in the control group (relative risk 0." | 2.74 | Randomized trial of sterile water by gavage drip in the fluid management of extremely low birth weight infants. ( Huseby, V; Kennedy, KA; Morris, BH; Moya, FR; Stewart, CD, 2009) |
| "Indomethacin dosing was withheld in the BNP-guided group if the 12 or 24 h BNP concentrations were found to be <100 pg/ml." | 2.74 | B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. ( Attridge, JT; Kaufman, DA; Lim, DS, 2009) |
| "Increasing indomethacin concentrations above the levels achieved with a conventional dosing regimen had little effect on the rate of PDA closure but was associated with higher rates of moderate/severe ROP and renal compromise." | 2.73 | Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. ( Buchh, B; Chorne, N; Clyman, R; Ewig, A; Fields, S; Ianus, V; Jegatheesan, P; Lin, E; Milstein, J; Moon-Grady, A; Padbury, J; Schreiber, M; Tacy, T; Yoon, G, 2008) |
| "A population pharmacokinetic model was developed after administration of orogastric and/or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants." | 2.73 | Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. ( Al Za'abi, M; Charles, B; Collie, LA; Donovan, T; Tudehope, D; Woodgate, P, 2007) |
| "Ibuprofen has been proposed as a preferential alternative to indomethacin in treating patent ductus arteriosus (PDA), because it is purported to have less renal, mesenteric, and cerebral vasoconstrictive effects." | 2.73 | Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? ( Bromiker, R; Hammerman, C; Jacobson, S; Kaplan, M; Nir, A; Schimmel, MS; Shchors, I, 2008) |
| " However, increasing the dosage increases the oxidative stress." | 2.72 | Early closure mechanisms of the ductus arteriosus in immature infants. ( Aikio, O; Hallman, M; Rozé, JC; Treluyer, JM, 2021) |
| "Acetaminophen has emerged as an alternative to indomethacin and ibuprofen with less significant adverse effects, but there is no consensus regarding its use." | 2.72 | Acetaminophen Therapy for Persistent Patent Ductus Arteriosus. ( Amin, S; Manalastas, M; Nicoski, P; Weiss, MG; Zaheer, F, 2021) |
| " Observations collected in two population pharmacokinetic studies, in preterm neonates, investigating amikacin and vancomycin were used to estimate: i) the impact of ibuprofen administration on the clearance of these drugs; and ii) the difference between prophylactic and therapeutic administration of ibuprofen on this clearance." | 2.72 | Impact of ibuprofen administration on renal drug clearance in the first weeks of life. ( Allegaert, K; Anderson, BJ; Rayyan, M, 2006) |
| "Ibuprofen has the same efficiency as indomethacin for the treatment of symptomatic patent ductus arteriosus in preterm infants and less likely to induce necrotizing enterocolitis and renal toxicity than indomethacin." | 2.71 | A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. ( Chotigeat, U; Jirapapa, K; Layangkool, T, 2003) |
| "Indomethacin treatment was successful in 52 infants (93%)." | 2.71 | High efficacy and minor renal effects of indomethacin treatment during individualized fluid intake in premature infants with patent ductus arteriosus. ( Barth, H; Leonhardt, A; Seyberth, HW; Strehl, R, 2004) |
| "Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects." | 2.71 | [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. ( Cano Sánchez, A; Carrasco Moreno, JI; Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Morcillo Sopena, F, 2005) |
| "To evaluate whether a prolonged low-dose course of indomethacin would produce an improved closure rate and have fewer side effects compared with a short standard dosage schedule in the management of patent ductus arteriosus (PDA) in preterm infants." | 2.69 | Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. ( Iivainen, T; Ikonen, S; Janas, M; Koivisto, M; Lautamatti, V; Ojala, R; Pokela, ML; Tammela, O, 1999) |
| "An indomethacin treatment strategy for PDA based on measurement of the ductal flow pattern is associated with a reduction in the total doses of indomethacin administered, and a reduced rate of complications, compared with a conventional protocol." | 2.69 | Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. ( Peng, CT; Su, BH; Tsai, CH, 1999) |
| " One group received 3 doses of intravenous indomethacin at the dosage of 0." | 2.69 | Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams. ( Khowsathit, P; Patchakapati, B; Supapannachart, S, 1999) |
| "Aspirin (ASA) is an alternative, but there are no controlled trials on its efficacy." | 2.68 | Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. ( Brus, F; Elzenga, NJ; Okken, A; Schasfoort, M; van Acker, KJ; van der Auwera, JC; van Overmeire, B, 1995) |
| "Indomethacin therapy was successful in 90% after the first course, increasing to 95% after the second course." | 2.68 | Prolonged low-dose indomethacin therapy for patent ductus arteriosus in very low birthweight infants. ( Kumar, RK; Yu, VY, 1997) |
| "Ibuprofen treatment seems to be as efficient as indomethacin in closing PDA on the third day of life in preterm infants with respiratory distress syndrome and seems to have fewer renal side effects." | 2.68 | Treatment of patent ductus arteriosus with ibuprofen. ( Creten, WL; Follens, I; Hartmann, S; Van Acker, KJ; Van Overmeire, B, 1997) |
| "Fourteen preterm infants with patent ductus arteriosus were studied during three subsequent indomethacin bolus administrations with intervals of 12 and 24 h." | 2.67 | Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: combined near infrared spectrophotometry and Doppler ultrasound study. ( Hopman, JC; Kollée, LA; Liem, KD; Oeseburg, B, 1994) |
| "In addition, indomethacin closes the patent ductus arteriosus and is not associated with significant adverse drug events in very low birth weight neonates." | 2.67 | Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. ( Allan, W; Duncan, CC; Ehrenkranz, RA; Katz, KH; Ment, LR; Oh, W; Philip, AG; Scott, DT; Taylor, KJ; Vohr, B, 1994) |
| "Four indomethacin-treated and three saline solution-treated infants had parenchymal extension of the hemorrhage." | 2.67 | Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. ( Allan, W; Ehrenkranz, RA; Katz, KH; Makuch, RW; Ment, LR; Oh, W; Phillip, AG; Schneider, KC; Taylor, KJ; Vohr, B, 1994) |
| " Thirty-six infants were selected to receive a continuous infusion of either placebo or dopamine at either a low dosage of 2 micrograms/kg per minute or a higher dosage of 5 micrograms/kg per minute, beginning 6 hours before the use of indomethacin and continuing until 12 hours after the third dose of indomethacin." | 2.67 | Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. ( Fajardo, CA; Steele, BT; Whyte, RK, 1992) |
| "In infants with patent ductus arteriosus, LTV was lower than in controls." | 2.67 | Long-term variability of heart rate increases with successful closure of patent ductus arteriosus in preterm infants. ( Maier, R; Obladen, M; Prietsch, V; Schmitz, L, 1992) |
| "This study examined the response of the patent ductus arteriosus (PDA) to intravenous Indomethacin using serial two dimensional and Doppler echocardiography and documented the complications associated with therapy." | 2.67 | Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. ( Rajadurai, VS; Yu, VY, 1991) |
| " A one-compartment open model was used for pharmacokinetic analysis." | 2.67 | Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. ( Brown, Y; Brundage, RC; Gal, PS; Pinson, JB; Purohit, D; Ransom, JL; Schall, S; Weaver, RL; Wiest, DB, 1991) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.66 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2020) |
| "Over a 4-year period, 63 premature babies presenting with patent ductus arteriosus were treated with indomethacin at two different dosage levels (0." | 2.66 | [Treatment of patent ductus arteriosus in premature infants by indomethacin]. ( Bianchetti, G; Marchal, F; Monin, P; Morselli, P; Vert, P, 1987) |
| "Two indomethacin-treated infants and three infants given placebo had significant urinary output difficulties, requiring that the study medication be withheld." | 2.66 | Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. ( Duncan, CC; Ehrenkranz, RA; Gettner, P; Kleinman, CS; Ment, LR; Scott, DT; Sherwonit, E; Taylor, KJ; Williams, J, 1988) |
| "Indomethacin has proven effective in closing the patent ductus arteriosus (PDA) in most low birth weight (LBW) neonates with this disorder." | 2.66 | Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. ( Ferguson, MG; Gibson, J; Joransen, JA; Reddy, NS; Rhodes, PG, 1988) |
| "Prophylactic closure of the patent ductus arteriosus has been recommended as a means of decreasing the morbidity of the very low birth weight neonate." | 2.66 | The silent ductus: its precursors and its aftermath. ( Hammerman, C; Strates, E; Valaitis, S, 1986) |
| "Treatment with indomethacin prolonged bleeding time, raised serum creatinine concentrations, and was associated with gastrointestinal haemorrhage in seven infants." | 2.66 | Early administration of indomethacin to preterm infants. ( Cooke, RW; Doyle, J; Rennie, JM, 1986) |
| "Prophylactic closure of the patent ductus arteriosus (PDA) has been recommended as a means of decreasing early respiratory distress, and thereby chronic respiratory sequelae in the very low birth weight (VLBW) neonate." | 2.66 | Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant. ( Bui, K; Hammerman, C; Komar, K; Strates, E, 1987) |
| "The indomethacin-treated group had significant decreases in serum prostaglandin values 30 hours after the initiation of therapy." | 2.66 | Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. ( Duncan, CC; Ehrenkranz, RA; Gettner, P; Kleinman, CS; Ment, LR; Pitt, BR; Scott, DT; Stewart, WB; Taylor, KJ, 1985) |
| "Indomethacin plasma levels were obtained in 6 patients in the treatment group." | 2.65 | Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. ( Arrington, RW; Beard, AG; Dungan, WT; Hill, DE; Lau, PY; Nestrud, RM; Norton, JB; Readinger, RI, 1980) |
| "The 75% patent ductus arteriosus closure rate with indomethacin treatment in phase 1 was not statistically significant due to a 44% spontaneous closure rate in the control group." | 2.65 | Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. ( Aziz, KU; Hunt, CE; Newfeld, EA; Wilson, A; Yanagi, RM, 1981) |
| "A clinically significant patent ductus arteriosus (PDA) is associated with significant morbidity and mortality in premature newborns." | 2.61 | Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis. ( Abou-Setta, AM; Dingwall, O; Elsayed, YN; Farooqui, MA; Jeyaraman, MM; Rabbani, R; Tagin, M; Zarychanski, R, 2019) |
| " Although promising, acetaminophen treatment requires further studies regarding long-term safety as well as ideal dosing and route of administration." | 2.61 | Pharmacotherapy for patent ductus arteriosus closure. ( Ferguson, JM, 2019) |
| "Ibuprofen appears to be a better choice for PDA closure, with a better side effect profile and efficacy that equals that of indomethacin." | 2.53 | Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration. ( Agarwal, R; Sivanandan, S, 2016) |
| "The clinical management of a patent ductus arteriosus (PDA) in preterm newborns is a controversial topic, and despite nearly three decades of research, varying opinions remain." | 2.53 | Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates. ( Baral, VR; Tan, ZH, 2016) |
| "Management of the patent ductus arteriosus (PDA) represents an ongoing challenge in the care of extremely premature neonates." | 2.53 | Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions. ( McPherson, CC; Rostas, SE, 2016) |
| "In premature neonates, patent ductus arteriosus (PDA) is associated with significant morbidity and mortality [1,2]." | 2.53 | Pathophysiology of Patent Ductus Arteriosus in the Preterm Infant. ( Vettukattil, JJ, 2016) |
| "The patency of the ductus arteriosus is very common in extremely premature infants." | 2.53 | Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes. ( Bancalari, E, 2016) |
| " On the other hand, several adverse effects have been reported with such medications, including peripheral vasoconstriction, gastrointestinal bleeding and perforation, weakened platelet aggregation, hyperbilirubinemia and renal failure." | 2.52 | Safety of therapeutics used in management of patent ductus arteriosus in preterm infants. ( Erdeve, O; Oncel, MY, 2015) |
| "The treatment with ibuprofen reduces the urine output and increases the serum creatinine concentrations less extensively than indomethacin." | 2.50 | Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ( Pacifici, GM, 2014) |
| "Indomethacin is a non-steroidal anti-inflammatory drug that is a potent inhibitor of prostaglandin E(2) synthesis." | 2.49 | Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. ( Pacifici, GM, 2013) |
| "Pharmacological closure of patent ductus arteriosus (PDA) is commonly achieved by intravenous (IV) administration of ibuprofen or indomethacin." | 2.48 | Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. ( Bührer, C; Neumann, R; Schulzke, SM, 2012) |
| "Although ongoing patency of the ductus arteriosus is common in small extremely preterm infants, consensus is lacking regarding its clinical significance and treatment strategies." | 2.48 | The ductus arteriosus: a refined approach! ( McNamara, PJ; Sehgal, A, 2012) |
| "Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period." | 2.48 | Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? ( Clyman, RI; Couto, J; Murphy, GM, 2012) |
| ""Patent ductus arteriosus is one of most common problems that physicians caring for preterm infants have to face." | 2.47 | Patent ductus arteriosus: wait and see? ( Ciarmoli, E; Mosca, F; Schena, F, 2011) |
| "Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants." | 2.46 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW; McGuire, W, 2010) |
| "Indomethacin has long been the drug of choice." | 2.45 | Therapeutic closure of the ductus arteriosus: benefits and limitations. ( Boubred, F; Mercanti, I; Simeoni, U, 2009) |
| "Ibuprofen lysine has demonstrated significantly less effects on cerebral, renal, and mesenteric blood flow in premature neonates when compared with indomethacin." | 2.44 | Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus. ( Pai, VB; Puthoff, TD; Sakadjian, A, 2008) |
| "Indomethacin is a prostaglandin inhibitor used to treat patent ductus arteriosus (PDA) in preterm infants." | 2.44 | Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Davis, P; Herrera, C; Holberton, J, 2007) |
| "Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin." | 2.44 | [Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis]. ( Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Modesto Alapont, V; Morcillo Sopena, F, 2007) |
| "Ibuprofen treatment was associated with statistically significantly lower serum creatinine levels after treatment (6 trials, 336 infants; WMD - 8." | 2.44 | Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, S; Walia, R, 2008) |
| "Indomethacin is a prostaglandin inhibitor used for the prevention and the treatment of patent ductus arteriosus (PDA)." | 2.44 | Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. ( Bracken, MB; Ehrenkranz, RA; Görk, AS, 2008) |
| "Indomethacin has a protective effect on the incidence of intraventricular hemorrhage (IVH) but reduces the blood flow to the kidneys and the brain." | 2.44 | Treatment of patent ductus arteriosus: indomethacin or ibuprofen? ( Corff, KE; Sekar, KC, 2008) |
| "Ibuprofen (IBU) has previously been shown to be as effective as indomethacin (INDO) in closing the patent ductus arteriosus (PDA) of preterm infants, without severely affecting renal hemodynamics or basal cerebral blood flow." | 2.43 | A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. ( Aranda, JV; Parker, GC; Thomas, RL; Van Overmeire, B, 2005) |
| " The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate." | 2.43 | Systematic review: intravenous Ibuprofen in preterm newborns. ( Aranda, JV; Thomas, R, 2006) |
| "Indomethacin has long been used to treat patent ductus arteriosus but it is associated with a relatively high risk of adverse effects; recent evidence suggests that ibuprofen is effective and may be safer." | 2.42 | The use of ibuprofen in neonates in the treatment of patent ductus arteriosus. ( Van Overmeire, B, 2003) |
| "Indomethacin is an effective treatment to close a PDA, and has been used for many years with several treatment regimes, including prophylactic use in all at risk premature infants." | 2.42 | Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. ( Cooke, L; Steer, P; Woodgate, P, 2003) |
| "Indomethacin is a prostaglandin inhibitor used to treat patent ductus arteriosus (PDA) in preterm infants." | 2.42 | Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Davis, P; Herrera, C; Holberton, J, 2004) |
| "Indomethacin has been used successfully to treat symptomatic PDA and may also prevent or limit IVH in the neonatal period." | 2.41 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW, 2002) |
| "Indomethacin therapy for closure of patent ductus arteriosus frequently causes oliguria, and occasionally more serious renal dysfunction." | 2.41 | Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. ( Barrington, K; Brion, LP, 2002) |
| "Indomethacin is used to treat symptomatic patent ductus arteriosus and may prevent or limit intraventricular haemorrhage in the neonatal period." | 2.41 | Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. ( Fowlie, PW, 2000) |
| "The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled estimate of risk difference -0." | 2.39 | Prophylactic indomethacin: systematic review and meta-analysis. ( Fowlie, PW, 1996) |
| "When Indomethacin in a dosage of 175 mg/day was used to treat threatened premature labour more than 70% of cases carried on until 37 weeks." | 2.37 | [Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients]. ( Barrat, J; Bouillie, J; Boyer, F; Keskes, J; Marpeau, L; Pigné, A; Vincenti, O, 1988) |
| " This study explored whether higher concentrations of the biologically active S-enantiomer or increased R- to S-conversion following oral dosing could explain this finding." | 1.91 | Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why? ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Pfister, M; Samiee-Zafarghandy, S; Simons, SHP; Smit, C; van den Anker, JN; van Donge, T, 2023) |
| "Management of persistently patent ductus arteriosus (PDA) in extremely low-birth-weight infants (ELBWIs) requires attention due to the risk of tissue hypoperfusion." | 1.91 | Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience. ( Ibara, S; Ieiri, S; Ikee, T; Ikoma, S; Kawano, M; Kawano, T; Machigashira, S; Masuya, R; Matsukubo, M; Murakami, M; Muto, M; Nakame, K; Noguchi, H; Sugita, K; Torikai, M, 2023) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 1.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "What is Known: • Patent ductus arteriosus (PDA) incidence is inversely related to gestational age." | 1.72 | Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity. ( de Boode, WP; El-Khuffash, A; Hundscheid, T; McNamara, PJ, 2022) |
| "Indomethacin was used for median (IQR) 3 (2-5) days while ibuprofen was given for 3 (2-4) days, at a median of 8 and 10 days after birth, respectively; surgical treatment was used later at 33 (24-45) days after birth." | 1.72 | Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. ( Al-Turkait, A; Choonara, I; Ojha, S; Szatkowski, L, 2022) |
| "Indomethacin has been proven to be more effective than other tocolytic agents in terms of delaying birth but is often prescribed with caution because of its potential association with adverse neonatal outcomes." | 1.62 | The relationship between antenatal indomethacin as a tocolytic drug and neonatal outcomes: a retrospective cohort study. ( Dieleman, JP; Janssen, LCE; Lingius, S; Niemarkt, HJ; Rovers, JFJ; Thomissen, IJC; van Runnard Heimel, PJ; Wieland, BV, 2021) |
| "Symptomatic patent ductus arteriosus (sPDA) is the most common heart abnormality in preterm infants." | 1.62 | High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity. ( Atkinson, A; Berger, MR; Gerull, R; Nelle, M; Waldvogel, S; Wilbeaux, M, 2021) |
| "Indomethacin treatment success was defined as: (i) where PDA closed or became haemodynamically insignificant (hisPDA) after treatment and (ii) only including neonates where PDA had complete closure after treatment." | 1.62 | Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates. ( Dey, A; Jain, A; Louis, D, 2021) |
| "Ibuprofen (IBU) has been used recently for the treatment of patent ductus arteriosus (PDA) in Japan." | 1.56 | The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants. ( Matsuda, A; Nishizaki, N; Obinata, K; Shimizu, T; Watanabe, A; Yoneyama, T, 2020) |
| "Indomethacin treatment for patent ductus arteriosus (PDA) is associated with acute kidney injury (AKI)." | 1.56 | Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. ( Berger, CD; Boatwright, N; Crockett, SL; Harris, M; Reese, J; Segar, JL; Shelton, EL; Su, RL; Yarboro, MT, 2020) |
| "The treatment of patent ductus arteriosus (PDA) in very low birth weight (VLBW) infants remains a challenge." | 1.51 | Base excess and hematocrit predict response to indomethacin in very low birth weight infants with patent ductus arteriosus. ( Mydam, J; Naheed, ZJ; Rastogi, A, 2019) |
| "Few studies exist that have evaluated the effects of indomethacin dosing frequency as a factor associated with successful patent ductus arteriosus closure in very low birth weight neonates." | 1.51 | Indomethacin dosing strategy and neonatal patent ductus arteriosus closure. ( Messina, C; Mintzer, JP; Rathi, P, 2019) |
| "Indomethacin therapy was associated with significantly higher SCr concentrations at 36, 84, and 120 h compared to controls." | 1.51 | Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus. ( Beedgen, B; Bruckner, T; Fichtner, A; Pöschl, J; Schaefer, F; Tönshoff, B; Waldherr, S; Westhoff, JH; Westhoff, TH, 2019) |
| "To evaluate whether the presence of patent ductus arteriosus (PDA) in preterm infants worsens long-term neurodevelopmental outcomes." | 1.48 | Long-Term Neurodevelopment of Low-Birthweight, Preterm Infants with Patent Ductus Arteriosus. ( Casey, PH; Collins, RT; Gossett, JM; Lyle, RE; Rettiganti, M; Robbins, JM, 2018) |
| "The symptomatic patent ductus arteriosus (sPDA) is common in extremely premature infants (EPI)." | 1.46 | [Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus]. ( Lavín, P; López, M; Miranda, J; Rincón, Y; Salas, R, 2017) |
| "To examine yearly trends of patent ductus arteriosus (PDA) diagnosis and treatment in very low birth weight infants." | 1.46 | Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants. ( Gould, JB; Lee, HC; Ngo, S; Profit, J, 2017) |
| "BackgroundPatent ductus arteriosus (PDA) is a common complication seen in preterm infants." | 1.46 | Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus. ( Bahr, TM; Dagle, JM; Ryckman, KK; Smith, CJ, 2017) |
| "Spontaneous closure of patent ductus arteriosus (PDA) occurs frequently in very preterm infants and despite the lack of evidence for treatment benefits, treatment for PDA is common in neonatal medicine." | 1.46 | Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes. ( Bonet, M; Boyle, EM; Edstedt Bonamy, AK; Fenton, A; Gortner, L; Gudmundsdottir, A; Hasselager, AB; Maier, RF; Milligan, D; Norman, M; Toome, L; van Heijst, A; Van Reempts, P; Zeitlin, J, 2017) |
| "Closing patent ductus arteriosus (PDA) is a widely accepted approach in the management of very low birth weight (VLBW) infants." | 1.46 | Patent ductus arteriosus in premature infants: to treat or not to treat? ( Alqahtani, S; Aly, H; Alyami, K; El-Dib, M; Ibrahim, AN; Mohamed, MA, 2017) |
| "Management of patent ductus arteriosus (PDA) in preterm infants is one of the most controversial topics in neonatal medicine." | 1.43 | Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: a protocol for a systematic review and network meta-analysis. ( Aune, D; Florez, ID; Mbuagbaw, L; Mitra, S; Tamayo, ME; Thabane, L; Veroniki, AA, 2016) |
| "Indomethacin was administered to all of the cases as the medical closing agent." | 1.43 | Bedside PDA ligation in premature infants less than 28 weeks and 1000 grams. ( Avsar, MK; Celiksular, C; Demir, T; Zeybek, C, 2016) |
| "Indomethacin was more efficacious for ductal closure although did not impact outcomes." | 1.42 | Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach. ( Malikiwi, A; Roufaeil, C; Sehgal, A; Tan, K, 2015) |
| "The optimal timing of pharmacological treatment for patent ductus arteriosus (PDA) in extremely preterm infants is unknown." | 1.42 | Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. ( Bonamy, AK; Gudmundsdottir, A; Håkansson, S; Johansson, S; Källen, K; Norman, M, 2015) |
| "The aim of this study is to compare patent ductus arteriosus (PDA) management strategies and outcomes between the Neonatal Research Network of Japan (NRNJ) with proactive functional echocardiography and the Canadian Neonatal Network (CNN) with selective conventional echocardiography practice." | 1.42 | Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. ( Fujimura, M; Isayama, T; Kusuda, S; Lee, SK; Mirea, L; Mori, R; Shah, PS, 2015) |
| "The management of a patent ductus arteriosus in preterm infants continues to be debated among neonatologists due to the absence of concrete evidence that precisely weighs the long term outcomes of active, early intervention against a conservative approach." | 1.42 | A prospective study of maternal preference for indomethacin prophylaxis versus symptomatic treatment of a patent ductus arteriosus in preterm infants. ( AlFaleh, K; AlKharfi, T; Alluwaimi, E; AlOsaimi, A; AlOtaibi, B; Alrajebah, S; AlRasheed, F; Paes, B, 2015) |
| "Persistent patent ductus arteriosus (PDA) during hospitalization is thought to be associated with adverse pulmonary outcomes in very preterm infants." | 1.42 | Lung function in very preterm infants with patent ductus arteriosus under conservative management: an observational study. ( Chen, HL; Dai, ZK; Hsu, JH; Lee, PL; Lee, WT; Wu, JR; Yang, RC, 2015) |
| "Indomethacin was administered to 18 infants born at a median gestational age of 25." | 1.40 | Cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus: effects on cardiac and vascular indices. ( Doctor, T; Menahem, S; Sehgal, A, 2014) |
| "Pretreatment with indomethacin and N-(G)-nitro-L-arginine methyl ester did not prevent gentamicin-induced DA relaxation." | 1.40 | Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA. ( Brown, N; Clark, RH; Cotton, RB; Ehinger, NJ; Goettel, JA; Paria, BC; Poole, SD; Reese, J; Rojas, MA; Shelton, EL; Slaughter, JC; Vucovich, MM; Wynn, JL, 2014) |
| "Haemodynamically significant patent ductus arteriosus (hsPDA) is frequently observed in premature infants." | 1.39 | B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. ( Hirabayashi, M; Kaneko, K; Mine, K; Nakashima, J; Ohashi, A; Tsuji, S, 2013) |
| "Although oliguria was observed in 43 infants (51%) and slight gastrointestinal bleeding was observed in 12 (14%), no infants had severe complications such as intracranial bleeding." | 1.39 | Effects of indomethacin on patent ductus arteriosus in neonates with genetic disorders and/or congenital anomalies. ( Hoshika, A; Ishida, T; Kawakami, T; Kondo, A; Morichi, S; Sunohara, D; Takami, T; Yoda, H, 2013) |
| "Multiple indomethacin courses using the standard dosing approach result in high PDA closure rates for infants < 29 weeks gestation." | 1.38 | Patent ductus arteriosus in infants <29 weeks gestation--outcomes and factors affecting closure. ( Kapoor, V; Popat, H; Travadi, J, 2012) |
| "The effect of patent ductus arteriosus (PDA) treatment with cyclooxygenase (COX) inhibitors (indomethacin [INDO] and ibuprofen [IBU]) on regional oxygenation requires further clarification." | 1.38 | Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation? ( Bhatt, M; Mehta, R; Petrova, A, 2012) |
| "Persistent patency of the ductus arteriosus is a major cause of morbidity and mortality in premature infants." | 1.38 | Patent ductus arteriosus in premature neonates. ( Agarwal, G; Maheshwari, A; Mezu-Ndubuisi, OJ; Ohler, KH; Pham, JT; Raghavan, A, 2012) |
| " The explanation of the reduced pharmacodymanic effect in such population is unclear; so far, studies using increased dosing of ibuprofen have failed to show a clear benefit." | 1.38 | Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know. ( Boubred, F; Buffat, C; Fayol, L; Grandvuillemin, I; Ligi, I; Mercanti, I; Millet, V; Simeoni, U, 2012) |
| "Treatment with indomethacin led to ductal closure and concomitant restoration of diastolic flow and resolution of symptoms." | 1.37 | Doppler manifestations of ductal steal: role in decision making. ( Carse, E; Sehgal, A; Tran, H, 2011) |
| "In ibuprofen group, there was no correlation of AQP2 level with urinary osmolality." | 1.37 | Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus. ( Aperia, A; Casper, C; Li, Y; Marcoux, MO; Plat-Willson, G; Zelenina, M, 2011) |
| "Indomethacin prophylaxis has been shown to significantly prevent such outcomes." | 1.37 | Indomethacin prophylaxis revisited: changing practice and supportive evidence. ( AlFaleh, K, 2011) |
| "The clinical decision to treat the patent ductus arteriosus is complicated by the lack of evidence available regarding clinical conditions under which closure should be attempted." | 1.37 | Treatment of patent ductus arteriosus with bidirectional flow in neonates. ( Cotten, CM; Ethington, PN; Goldberg, RN; Katakam, L; Smith, PB, 2011) |
| "Indomethacin therapy was given if plasma NT-proBNP level was ≥10,180 pg/mL, the cut-off for predicting hemodynamic significant PDA (hsPDA)." | 1.37 | N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants. ( Chongkongkiat, P; Khositseth, A; Nuntnarumit, P, 2011) |
| "Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects." | 1.37 | Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts. ( Kushnir, A; Pinheiro, JM, 2011) |
| "Furosemide was also s." | 1.36 | In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. ( Momma, K; Nakanishi, T; Toyoshima, K, 2010) |
| "Treatment with ibuprofen is safer, decreasing the risk of renal failure, thrombocytopenia, and hyponatremia." | 1.36 | Treatment of patent ductus arteriosus: indomethacin or ibuprofen? ( Bello, R; Birk, E; Hernandez, A; Klinger, G; Linder, N; Pushkov, Y; Rosen, C; Sirota, L, 2010) |
| "The effect of surfactant administration for respiratory distress syndrome (RDS) on indomethacin (INDO) pharmacodynamics and dosing requirements for patent ductus arteriosus (PDA) closure and renal toxicity was evaluated." | 1.36 | Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability. ( Carlos, RQ; Davonzo, C; Dimaguila, MA; Gal, P; McPherson, C; Ransom, JL; Smith, M; Wimmer, JE, 2010) |
| "Necropsy revealed patent ductus arteriosus with normal intimal thickening but dilated cardiac chambers." | 1.36 | Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. ( Chang, HY; Locker, J; Lu, R; Schuster, VL, 2010) |
| "Indomethacin is a very effective drug for patent ductus arteriosus (PDA)." | 1.36 | Relation between infusion rate of indomethacin and cerebral blood flow velocity. ( Isobe, K; Itoh, S; Kondo, M; Kunikata, T; Okazaki, K; Yasuda, S, 2010) |
| "Respiratory distress and patent ductus arteriosus (PDA) in neonates are mutually perpetuating." | 1.36 | Management of patent ductus arteriosus in term or near-term neonates with respiratory distress. ( Chen, TJ; Chung, HT; Huang, HR; Lien, R; Lin, YC; Liu, WH; Su, WJ; Yang, PH, 2010) |
| "of indomethacin was associated with closure of PDA in 108 (77." | 1.35 | Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants. ( Lee, J; Yang, CZ, 2008) |
| "Indomethacin is accepted therapy for patent ductus arteriosus (PDA) in ELBW infants (<1000 g)." | 1.35 | Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. ( Alexander, F; Chiu, L; Hammel, J; Kroh, M; Moore, J, 2009) |
| "Optimal time to surgical ligation of patent ductus arteriosus (PDA) in very-low-birth-weight (< 1500 g) premature infants remains an area of controversy." | 1.35 | Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants. ( Chang, WC; Hsiao, CC; Tsao, LY; Wung, JT, 2009) |
| "Indomethacin is used to close the patent ductus arteriosus in premature infants and for tocolysis of preterm labor." | 1.35 | Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat. ( Imamura, S; Ito, K; Momma, K; Nakanishi, T; Sugiyama, K; Sun, F; Toyoshima, K, 2009) |
| "Ibuprofen has been shown to be as effective as indomethacin with fewer renal side effects." | 1.35 | Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys. ( Abad-Santos, M; Abad-Santos, P; Aranda, JV; Beharry, KD; Gharraee, Z; Hasan, J; Modanlou, HD; Stavitsky, Y, 2008) |
| "Subsequent and adequate treatment of a patent ductus arteriosus may prevent diminished cerebral perfusion and subsequent decreased oxygen delivery, which reduces the change of damage to the vulnerable immature brain." | 1.35 | Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. ( Lemmers, PM; Toet, MC; van Bel, F, 2008) |
| "We sought to analyze the effect of patent ductus arteriosus diameter on treatment success in premature neonates." | 1.35 | The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates: size matters. ( Arlettaz-Mieth, R; Baenziger, O; Balmer, C; Dodge-Khatami, A; Doell, C; Prêtre, R; Rousson, V; Tschuppert, S, 2008) |
| "Indomethacin was used as a tocolytic at a median dose of 250 mg, for a duration of 2 days, and ending 1 day before delivery." | 1.34 | The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants. ( Cordero, L; Gardner, D; Giannone, PJ; Nankervis, CA, 2007) |
| "This study compares the rates of patent ductus arteriosus treatment failure during a) the index period from June 2, 2003, to August 22, 2003, when all very low birthweight infants with a peripherally inserted central venous catheter received continuous infusion of heparinized parenteral nutrition; b) the baseline period of 1 yr before the index period; and c) the postindex period of 1 yr after the index period." | 1.34 | A preliminary report--heparin counteracts indomethacin effect on ductus arteriosus in very low birthweight infants. ( Lehtonen, L; Ojala, TH, 2007) |
| "To test the hypothesis that patent ductus arteriosus that fail to close with prostaglandin inhibition may be regulated by mechanisms that act independently of prostaglandin production." | 1.34 | Risk factors for persistent ductus arteriosus patency during indomethacin treatment. ( Chorne, N; Clyman, RI; Jegatheesan, P; Lin, E; Shi, R, 2007) |
| "The use of indomethacin to treat patent ductus arteriosus in preterm infants may either decrease the incidence of necrotizing enterocolitis by stabilizing or closing the ductus arteriosus or increase its incidence by a direct constricting effect on mesenteric blood vessels." | 1.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
| "To find a better treatment for patent ductus arteriosus (PDA) in premature infants, the present study investigated the synergism of clinical doses of dexamethasone, indomethacin, and rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on the fetal ductus arteriosus (DA) in rats." | 1.33 | Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. ( Imamura, S; Momma, K; Takami, T, 2005) |
| " The total dosage was the same for both groups." | 1.33 | Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants. ( Bos, AF; de Vries, NK; Elzenga, NJ; Jaarsma, AS; Jagroep, FK, 2005) |
| "Indomethacin is commonly used for the treatment of patent ductus arteriosus (PDA) but has renal failure as a main side-effect." | 1.33 | Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. ( Benini, D; Cuzzolin, L; Errico, G; Fanos, V; Verlato, G, 2005) |
| "Surgical ligation of patent ductus arteriosus (PDA) is widely practised in preterm infants despite no clear evidence that this improves outcomes." | 1.33 | Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. ( Brooks, JM; Doherty, DA; Patole, SK; Simmer, K; Travadi, JN, 2005) |
| "Ibuprofen treatment caused a significant decrease in urinary AVP (UAVP/Ucr 24." | 1.33 | Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. ( Faggian, D; Favaro, F; Lago, P; Plebani, M; Trevisanuto, D; Vedovato, S; Zanardo, V, 2005) |
| "Symptomatic patent ductus arteriosus (sPDA) is a common problem in premature infants and can be treated effectively with intravenous indomethacin, leading to permanent ductal closure in 70% to 80% of infants." | 1.33 | Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. ( Beedgen, B; Brüssau, J; Feneberg, R; Huppertz, C; Linderkamp, O; Pöschl, J; Sperandio, M, 2005) |
| "Treatment with indomethacine improves ductal closure and is associated with few reversible adverse effects." | 1.33 | Management of patent ductus arteriosus in preterm infants. ( Arsan, S; Atalay, S; Atasay, B; Ekici, F; Eyileten, Z; Günlemez, A; Naçar, N; Tutar, E; Uysalel, A, 2006) |
| "Indomethacin was commenced at postnatal age <7 days and >or=7 days in 60 (group 1) and 30 (group 2) neonates, respectively." | 1.33 | Renal impairment associated with indomethacin treatment for patent ductus arteriosus in extremely preterm neonates--is postnatal age at start of treatment important? ( Doherty, DA; Nathan, EA; Patole, SK; Srinivasjois, RM, 2006) |
| "Frequency of side effects and recurrent patent ductus arteriosus did not differ between treatment groups." | 1.32 | Prophylactic indomethacin reduces grades III and IV intraventricular hemorrhages when compared to early indomethacin treatment of a patent ductus arteriosus. ( Baker, RW; Sobchak Brozanski, B; Yanowitz, TD, 2003) |
| "Indomethacin has been reported to cause short-term reduction in glomerular filtration that resolves after cessation of the drug." | 1.32 | Indomethacin and renal impairment in neonates. ( Akima, S; Falk, MC; Gallagher, M; Kent, A; Reynolds, GJ, 2004) |
| "The objective of this study was to determine the rate of patent ductus arteriosus (PDA) closure in premature infants using an adjustable indomethacin (INDO) dosing strategy, based on a second-dose peak plasma INDO level." | 1.32 | Indomethacin therapy for patent ductus arteriosus in premature infants: efficacy of a dosing strategy based on a second-dose peak plasma indomethacin level and estimated plasma indomethacin levels. ( Adams, JM; Adams, K; Fernandes, CJ; Nguyen, NY; O'Donovan, DJ, 2004) |
| " Population analysis of the 185 plasma concentrations obtained was conducted using NONMEM and pharmacokinetic and demographic differences between responders and nonresponders were compared." | 1.32 | Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. ( Collier, PS; Darwish, M; Halliday, HL; McElnay, JC; Millership, JS; Petersen, S; Smyth, JM, 2004) |
| "To determine in preterm infants with a patent ductus arteriosus (PDA) the effect of indomethacin treatment on spontaneous motor activity." | 1.31 | Spontaneous motility in preterm infants treated with indomethacin. ( Bergervoet, M; Bos, AF; Pratl, B; van Eykern, LA; Venema, IM; Zweens, MJ, 2000) |
| "We conducted a comparative study to evaluate whether the low-dose continuous indomethacin therapy in the early days of age would reduce incidence of the symptomatic patent ductus arteriosus (PDA) without the adverse effects." | 1.31 | Low-dose continuous indomethacin in early days of age reduce the incidence of symptomatic patent ductus arteriosus without adverse effects. ( Kadowaki, S; Nakamura, T; Sasano, T; Tamura, M, 2000) |
| "We confirm that lower indomethacin treatment of patent ductus arteriosus in premature neonates are as effective as standard protocols." | 1.31 | Minimal effective dose of indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Babre, F; Demarquez, JL; Dumas de la Roque, E; Fayon, M; Pedespan, L, 2002) |
| "The indomethacin treatment cost was $95,157 and that of the control groups was $99,955." | 1.31 | Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants. ( Goldberg, RN; Moya, MP, 2002) |
| "These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates." | 1.31 | Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. ( Brown, YL; Carlos, RQ; Davey, AM; Dimaguila, MA; Gal, P; Ransom, JL; Schall, SA; Shaffer, CL; Smith, MS, 2002) |
| "The patent ductus arteriosus was confirmed by echocardiography." | 1.31 | [Dopplersonographic findings in neonates with significant persistent ductus arteriosus]. ( Knüpfer, M; Pulzer, F; Robel-Tillig, E; Vogtmann, C, 2002) |
| "The reasons for referral were hydrops (2), cardiomegaly (1), polyhydramnios and choroid plexus cyst (1), and polyhydramnios and teratoma of the neck (1)." | 1.30 | Isolated ductal closure in utero diagnosed by fetal echocardiography. ( Cavallé-Garrido, T; Farine, D; Heilbut, M; Leal, SD; Ryan, G; Smallhorn, JF, 1997) |
| "To identify the patent ductus arteriosus (PDA) shunt flow pattern using Doppler echocardiography; and to assess whether it could be used to predict the development of clinically significant PDA." | 1.30 | Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants. ( Shimizu, M; Su, BH; Watanabe, T; Yanagisawa, M, 1997) |
| "Persistent patent ductus arteriosus was more common in those infants delivered within 48 hours of maternal indomethacin exposure (40% versus 20% (p<0." | 1.30 | Antenatal indomethacin--adverse fetal effects confirmed. ( Baxendale, H; Harding, J; McCowan, L; McLeay, E; O'Donnell, C; Souter, D, 1998) |
| "The diagnosis of patent ductus arteriosus (PDA) has also increased." | 1.30 | Symptomatic patent ductus arteriosus in very low birth weight infants. ( Chen, SJ; Hwang, B; Lee, CS; Lu, JH; Soong, WJ, 1998) |
| "Indomethacin treatment was successful in 27 infants." | 1.30 | Surgical ligation of patent ductus arteriosus in very low birth weight infants: is it safe? ( Atkinson, JB; Bustorff-Silva, JM; Fonkalsrud, EW; Perez, CA; Villasenor, E, 1998) |
| "Indomethacin tocolysis has been reported to increase the incidence of persistent PDA in premature infants." | 1.30 | Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. ( Eidelman, AI; Ferber, B; Glaser, J; Hammerman, C; Kaplan, M; Schimmel, MS, 1998) |
| "9 percent, P = 0." | 1.29 | Neonatal complications after the administration of indomethacin for preterm labor. ( Clyman, RI; Cooper, BA; Kuller, JA; Merrill, J; Norton, ME, 1993) |
| "Indomethacin was directly associated with intestinal perforation in 3 patients, and acute renal failure in 1; all 4 died." | 1.29 | Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. ( Langer, JC; Lau, GY; Pipe, S; Shah, J; Trus, T; Winthrop, AL, 1993) |
| "Allopurinol may prevent reperfusion injury by inhibiting formation of xanthine oxidase generated, oxygen-derived free radicals and may be valuable in pretreating premature infants with patent ductus arteriosus who have had an ischemic episode in whom INDO use is contemplated." | 1.29 | Allopurinol protects the bowel from necrosis caused by indomethacin and temporary intestinal ischemia in mice. ( Krasna, IH; Lee, RT, 1993) |
| "The effect of indomethacin treatment of patent ductus arteriosus (PDA) on blood pressure was studied in 24 preterm infants." | 1.29 | Change in blood pressure after treatment of patent ductus arteriosus with indomethacin. ( Evans, N; Iyer, P, 1993) |
| "The indomethacin-treated infants had a lower incidence of NEC and IVH." | 1.29 | Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight? ( Garcia-Prats, JA; Jaksic, T; Pokorny, WJ; Robie, DK; Waltrip, T, 1996) |
| "Indomethacin treatment at 3 mg/kg/day from day 18 to day 20 of gestation significantly decreased the activity of 15-PGDH in neonatal lungs." | 1.29 | Inhibitory effect of indomethacin on neonatal lung catabolism of prostaglandin E2: possible mechanism of the re-opening of the ductus arteriosus after indomethacin therapy. ( Akahori, F; Arishima, K; Ikeda, Y; Masaoka, T; Takizawa, T; Togashi, H; Yamamoto, M, 1996) |
| "Only one patient had recurrence of the PDA, and the PDA was closed again in this case without problems using the same regimen." | 1.29 | Treatment of patent ductus arteriosus with low-dose indomethacin in very low birth weight neonates with impairment of renal function: report of three cases. ( Kuo, CY, 1996) |
| "The indomethacin was prepared by diluting the content of the commercially available 25-mg indomethacin capsule with lactose by the method of trituration." | 1.28 | Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin. ( Fok, TF; Ho, JK; So, LY; Sung, RY, 1992) |
| "In 18 infants the patent ductus arteriosus closed after one course of indomethacin; atrial natriuretic peptide levels decreased from median 1240 pg/ml (range 201-5483 pg/ml) to 266 pg/ml (range 62-1108 pg/ml)." | 1.28 | Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. ( Carter, N; Hamilton, PA; Littleton, P; Smith, A; Weir, FJ, 1992) |
| "Indomethacin infusion was associated with a significant reduction in time averaged mean velocity (TAMV), peak systolic velocity (PSV), and end diastolic velocity in both the anterior cerebral artery and middle cerebral artery." | 1.28 | Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. ( Austin, NC; Hall, MA; Hames, TK; Pairaudeau, PW, 1992) |
| " We recommend the use of MA for closure of symptomatic PDA in preterms, especially in those cases where indomethacin is not tolerated or when minute titration of its dosage is impracticable." | 1.28 | Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. ( Merchant, RH; Sakhalkar, VS, 1992) |
| "Symptomatic patent ductus arteriosus (sPDA) may occur in up to 50% of very-low-birth-weight (VLBW, less than or equal to 1500 g) infants." | 1.28 | Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. ( Mouzinho, AI; Risser, R; Rosenfeld, CR, 1991) |
| "Infants with a symptomatic patent ductus arteriosus had lower LTV than controls with the same severity of RDS." | 1.28 | The influence of respiratory distress syndrome on heart rate variability in very preterm infants. ( Hopman, JC; Kollée, LA; Stoelinga, GB; van Amen, JP; van Geijn, HP; van Ravenswaaij-Arts, CM, 1991) |
| "38 preterm infants with symptomatic patent ductus arteriosus received indomethacin intravenously." | 1.28 | Metabolism and disposition of indomethacin in preterm infants. ( Friedman, CA; Parks, BR; Rawson, JE; Temple, DM; Wender, DF, 1991) |
| "Indomethacin was administered at a dosage of 0." | 1.28 | Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. ( Abbasi, S; Bhutani, VK; Esterly, KL; Pearlman, SA; Spear, ML; Stefano, JL, 1991) |
| "Twenty cases of symptomatic patent ductus arteriosus (PDA) in preterm inborn infants were studied retrospectively." | 1.28 | Clinical profile and management of symptomatic patent ductus arteriosus in premature infants. ( Bhakoo, ON; Bidwai, PS; Narang, A; Shenoi, A, 1991) |
| " INDO pharmacokinetic parameters varied from dose-to-dose within the same patient, and wide interpatient variability was also observed." | 1.28 | Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. ( Brown, Y; Carlos, RQ; Gal, P; Ransom, JL; Schall, S; Weaver, RL; Wyble, LE, 1991) |
| "In 15 preterm infants with symptomatic patent ductus arteriosus, blood flow velocity changes in the superior mesenteric artery were investigated with Doppler ultrasound just before and during the first 12 hours after a single dose of indomethacin." | 1.28 | Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants. ( Baan, J; Guit, GL; Schipper, J; Van Bel, F; Van Zoeren, D, 1990) |
| "In the presence of patent ductus arteriosus the range of velocities in the superior mesenteric artery before indomethacin was given was characterised by pronounced abnormalities including absent--or in some cases even retrograde--diastolic flow." | 1.28 | Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. ( Booth, IW; Coombs, RC; Durbin, GM; McNeish, AS; Morgan, ME, 1990) |
| "Indomethacin was given as part of tocolytic management to mothers with a high incidence of early rupture of membranes and preterm labour; and 76 fetuses were exposed to the drug as a result." | 1.28 | Cerebral lesions in preterm infants after tocolytic indomethacin. ( Baerts, W; Fetter, WP; Hop, WC; Sauer, PJ; Spritzer, R; Wallenburg, HC, 1990) |
| "Indomethacin was associated with successful PDA closure in 81 infants (79%), with 59 infants (58%) closing after a single dose." | 1.28 | The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. ( Davis, JM; Hagberg, D; Hendricks-Munoz, KD; Manning, JA, 1990) |
| " We compared a novel indomethacin dosing approach using individual pharmacokinetic and pharmacodynamic information (group A) with a control group from our institution (group B) and a level 3 university-based intensive care nursery (group C) who were dosed using current dosing guidelines." | 1.28 | Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. ( Bird, A; Brown, Y; Gal, P; Ransom, JL; Schall, S; Weaver, RL, 1990) |
| "We present pharmacokinetic data of prolonged, intra-arterial indomethacin treatment (i." | 1.28 | Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ( Pollak, A; Salzer, HR; Salzer-Muhar, U; Vergesslich, KA; Weninger, M, 1989) |
| "The incidence and evolution of patent ductus arteriosus (PDA) was evaluated in twins and preterm singletons with birth weight less than or equal to 1750 g admitted to our Department in 1987 for respiratory distress syndrome (RDS)." | 1.28 | Does the respiratory distress syndrome in twins and singletons run different risks of persistent ductus arteriosus? ( Foti, P; Milanesi, O; Stellin, G; Trevisanuto, D; Zambon, P; Zanardo, V, 1989) |
| "A haemodynamically significant, patent ductus arteriosus in mechanically ventilated preterm infants can be closed by two means today, either medical or surgical." | 1.28 | [Indomethacin or ligation in the treatment of persistent ductus arteriosus: a report of clinical experiences]. ( Fürnkranz, H; Sterniste, W, 1989) |
| " In an attempt to maintain high plasma level in these infants of advanced postnatal age (greater than or equal to 6 weeks), indomethacin was administered intravenously at a dosage of 0." | 1.28 | Does indomethacin affect the control of breathing in premature infants? ( Wilks, A; Yeh, TF, 1989) |
| "The necessity of an early closure of a patent ductus arteriosus is now admitted in the very premature infant, but the use of indomethacin in the first days of life is often impossible because of its side-effects." | 1.27 | [Surgical ligation of patent ductus arteriosus in the very-low-birth-weight premature infant]. ( Couturier, C; Estève, C; Laguenie, G; Murat, I; Saint-Maurice, JP, 1983) |
| "Infants who experienced a recurrence of symptomatic PDA had lower birth weights and had received indomethacin at an earlier postnatal age than did infants with a sustained effect." | 1.27 | Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. ( Cotton, RB; Graham, TP; Leheup, B; Lindstrom, DP; Mellander, M; Palme, C; Stahlman, MT, 1984) |
| "Digoxin half-life was significantly prolonged (mean 97 +/- 17 hour) following indomethacin therapy as compared with an age matched control group (mean half-life 43 +/- 19 hour) (P less than 0." | 1.27 | Effects of indomethacin on digoxin pharmacokinetics in preterm infants. ( Koren, G; MacLeod, SM; Perlman, M; Zarfin, Y, 1984) |
| " The margin between closure of the ductus arteriosus and the deterioration of kidney function in preterm infants treated with a presently recommended indomethacin dosage is too narrow." | 1.27 | [Therapeutic problems with indomethacin in preterm infants with persistent ductus arteriosus]. ( Müller, H; Plückthun, H; Seyberth, HW; Ulmer, HE; Wille, L; Wolf, D, 1983) |
| "To examine the independent effects of a patent ductus arteriosus and of indomethacin therapy on the renal function of the preterm newborn, we created a preterm lamb model in which ductus diameter could be regulated." | 1.27 | Indomethacin and patent ductus arteriosus: effects on renal function in preterm lambs. ( Clyman, RI; Gleason, CA; Heymann, MA; Leake, R; Mauray, F; Roman, C, 1988) |
| "Indomethacin sodium promotes closure of the patent ductus arteriosus in premature infants." | 1.27 | Indomethacin-associated sepsis in very-low-birth-weight infants. ( Eisenfeld, LI; Herson, VC; Krause, PJ; Maderazo, EG; Pontius, L, 1988) |
| "Indomethacin treatment for 1 week monitored by drug level determinations was evaluated in 32 preterm infants with symptomatic patent ductus arteriosus (sPDA)." | 1.27 | Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection. ( Isken, V; Kühl, PG; Leonhardt, A; Seyberth, HW, 1987) |
| " Patients with this renal disorder require a permanent high dosed indomethacin therapy." | 1.27 | [The significance of renal prostaglandins for kidney function in early childhood]. ( Seyberth, HW, 1987) |
| " Dose-response curves were studied at 4 h following administration of indomethacin on the 19th, 20th, and 21st days, and flurbiprofen on the 20th and 21st days." | 1.27 | In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats. ( Momma, K; Takao, A, 1987) |
| "Indomethacin was infused intravenously in five infants." | 1.27 | The effect of indomethacin on cerebral blood-flow velocity in premature infants. ( Archer, LN; Evans, DH; Levene, MI, 1987) |
| " In an attempt to maintain the desired plasma level, indomethacin was given at a dosage of 0." | 1.27 | Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus. ( Achanti, B; Pildes, RS; Yeh, TF, 1986) |
| " Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
| "Seventeen infants had a patent ductus arteriosus and were treated with indomethacin after the initial intracranial hemorrhage was diagnosed." | 1.27 | Does indomethacin cause extension of intracranial hemorrhages: a preliminary study. ( Ballard, R; Clyman, RI; Lane, B; Maher, P; Piecuch, R, 1985) |
| "Indomethacin was given by suppository to 18 neonates for the treatment of patent ductus arteriosus." | 1.27 | Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels. ( Harvey, DP; Lewis, IG; Maxwell, GM, 1985) |
| " However, the margin between closure of the ductus arteriosus and the deterioration of kidney function in preterm infants treated with a presently recommended indomethacin dosage was narrow." | 1.26 | Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. ( Müller, H; Plückthun, H; Seyberth, HW; Ulmer, HE; Wille, L; Wolf, D, 1982) |
| "The pharmacokinetic profile of indomethacin administered either orally or intravenously in 13 preterm infants with significant patent ductus arteriosus (PDA) is reported." | 1.26 | Pharmacokinetics of oral and intravenous indomethacin in preterm infants. ( Bhat, R; Burns, L; Evans, M; Fisher, E; Hastreiter, A; Ramirez, JL; Vidyasagar, D, 1980) |
| "Fifteen preterm infants with patent ductus arteriosus and respiratory distress syndrome were given indomethacin (0." | 1.26 | Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants. ( Imbeck, H; Mrongovius, R; Müller, H; Seyberth, HW; Wille, L, 1982) |
| "Our present policy for patent ductus arteriosus with respiratory distress syndrome in the premature baby is to initiate early treatment with indomethacin." | 1.26 | Management of patent ductus arteriosus in preterm babies. ( Alvarez, F; Burgueros, M; Gómez, R; Moreno, F; Quero, J; Sanchez, PA, 1980) |
| "Indomethacin was used orally 12 of these patients without effect to close the ductus." | 1.26 | [Ductus ligation in idiopathic respiratory distress syndrome of the premature infant]. ( Beitzke, A; Metzler, W; Müller, WD; Rigler, B; Schober, P, 1980) |
| " The mean half-life of elimination (20." | 1.26 | Pharmacokinetics of intravenously administered indomethacin in premature infants. ( Carr, I; Luken, JA; Pildes, RS; Raval, D; Thalji, AA; Yeh, TF, 1980) |
| "Patent ductus arteriosus was diagnosed in 239 neonates of low birth weight (less than 2500 g) referred to the Hospital for Sick Children in a 21/2-year period." | 1.26 | Patent ductus arteriosus in infants of low birth weight. ( Cook, DH; Izukawa, T; Olley, PM; Rowe, RD; Smith, DR; Swyer, PR, 1980) |
| "9 pre-term babies with patent ductus arteriosus (P." | 1.26 | Plasma-prostaglandins in pre-term neonates before and after treatment for patient ductus arteriosus. ( Lucas, A; Mitchell, MD, 1978) |
| "Indomethacin has been most effective but not free of significant complications." | 1.26 | Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem. ( Altmiller, DH; Altshuler, G; Krous, HF; Sharpe, GL, 1979) |
| "Indomethacin was administered to most patients in two doses of 0." | 1.26 | Age-dependent closure of the patent ductus arteriosus by indomethacin. ( Gelband, H; McCarthy, JS; Zies, LG, 1978) |
| "Indomethacin constricts the patent ductus arteriosus in approximately 70% of premature infants, but temporarily inhibits synthesis of all prostaglandins." | 1.26 | Operation or indomethacin for the premature ductus. ( Edmunds, LH, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 260 (31.18) | 18.7374 |
| 1990's | 122 (14.63) | 18.2507 |
| 2000's | 179 (21.46) | 29.6817 |
| 2010's | 207 (24.82) | 24.3611 |
| 2020's | 66 (7.91) | 2.80 |
| Authors | Studies |
|---|---|
| Katsaras, DN | 1 |
| Katsaras, GN | 1 |
| Chatziravdeli, VI | 1 |
| Papavasileiou, GN | 1 |
| Touloupaki, M | 1 |
| Mitsiakos, G | 1 |
| Doxani, C | 1 |
| Stefanidis, I | 1 |
| Dardiotis, E | 1 |
| Vidavalur, R | 1 |
| Chawla, S | 1 |
| Natarajan, G | 1 |
| Laptook, AR | 2 |
| Chowdhury, D | 1 |
| Bell, EF | 3 |
| Ambalavanan, N | 1 |
| Carlo, WA | 1 |
| Gantz, M | 1 |
| Das, A | 3 |
| Tapia, JL | 1 |
| Harmon, HM | 1 |
| Shankaran, S | 3 |
| Hundscheid, T | 3 |
| El-Khuffash, A | 4 |
| McNamara, PJ | 8 |
| de Boode, WP | 4 |
| Hammerman, C | 15 |
| Bin-Nun, A | 2 |
| Abdaljalil, H | 1 |
| Nitzan, I | 1 |
| Kasirer, Y | 1 |
| Abu-Omar, R | 1 |
| Schorrs, I | 1 |
| Mimouni, F | 1 |
| Yeung, T | 1 |
| Shahroor, M | 1 |
| Jain, A | 9 |
| Weisz, D | 2 |
| Jasani, B | 5 |
| Cambonie, G | 1 |
| Rozé, JC | 2 |
| Marchand-Martin, L | 1 |
| Marret, S | 1 |
| Durrmeyer, X | 1 |
| Torchin, H | 1 |
| Ancel, PY | 1 |
| Shah, SD | 1 |
| Makker, K | 1 |
| Zhang, M | 1 |
| Harnett, S | 1 |
| Aziz, KB | 1 |
| Hudak, ML | 2 |
| Al-Turkait, A | 1 |
| Szatkowski, L | 1 |
| Choonara, I | 1 |
| Ojha, S | 1 |
| Bai, C | 1 |
| Chang, Q | 1 |
| Wu, H | 1 |
| Meng, F | 1 |
| Clyman, RI | 40 |
| Hills, NK | 3 |
| Olowoyeye, A | 3 |
| Nnamdi-Nwosu, O | 3 |
| Manalastas, M | 4 |
| Okwundu, C | 3 |
| Onland, W | 2 |
| Kooi, EMW | 2 |
| Vijlbrief, DC | 2 |
| de Vries, WB | 2 |
| Dijkman, KP | 2 |
| van Kaam, AH | 2 |
| Villamor, E | 3 |
| Kroon, AA | 2 |
| Visser, R | 2 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 2 |
| Zecic, A | 2 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 2 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 11 |
| Mulder, AL | 2 |
| Smit, C | 2 |
| Engbers, AGJ | 2 |
| Samiee-Zafarghandy, S | 2 |
| van Donge, T | 2 |
| Simons, SHP | 2 |
| Flint, RB | 2 |
| Pfister, M | 2 |
| Knibbe, CAJ | 3 |
| van den Anker, JN | 3 |
| Mitra, S | 11 |
| Shah, PS | 15 |
| Utsumi, M | 1 |
| Motoki, N | 1 |
| Yokota, S | 1 |
| Kobayashi, H | 1 |
| Yamazaki, S | 1 |
| Miyosawa, Y | 1 |
| Sharma, P | 1 |
| Beam, K | 1 |
| Levy, P | 1 |
| Beam, AL | 1 |
| Muto, M | 1 |
| Sugita, K | 1 |
| Murakami, M | 1 |
| Ikoma, S | 1 |
| Kawano, M | 1 |
| Masuya, R | 1 |
| Matsukubo, M | 1 |
| Kawano, T | 1 |
| Machigashira, S | 1 |
| Nakame, K | 1 |
| Torikai, M | 1 |
| Ikee, T | 1 |
| Noguchi, H | 1 |
| Ibara, S | 1 |
| Ieiri, S | 1 |
| Hatfield, T | 2 |
| Campbell-Yeo, M | 1 |
| Dorling, J | 2 |
| Johnston, BC | 1 |
| Shelton, EL | 8 |
| Reese, J | 15 |
| Borges-Luján, M | 1 |
| González-Luis, G | 1 |
| Weisz, DE | 2 |
| Sallmon, H | 4 |
| Delaney, CA | 1 |
| Zhang, Z | 1 |
| Lou, X | 1 |
| Hua, L | 1 |
| Jia, X | 1 |
| Xu, L | 1 |
| Zhao, M | 1 |
| Namba, F | 2 |
| Honda, M | 1 |
| Sakatani, S | 1 |
| Motojima, Y | 1 |
| Kikuchi, K | 1 |
| Sako, M | 1 |
| Ogawa, K | 1 |
| Mikami, M | 1 |
| Kawada, K | 1 |
| Fukuoka, N | 1 |
| Ueda, K | 1 |
| Steflik, HJ | 1 |
| Wessler, LA | 1 |
| Shugart, WW | 1 |
| Wagner, CL | 1 |
| Selewski, DT | 1 |
| Twombley, KE | 1 |
| Newman, JC | 1 |
| Atz, AM | 1 |
| Annibale, DJ | 1 |
| Al-Shaibi, S | 1 |
| Abushanab, D | 1 |
| Abounahia, F | 1 |
| Awaisu, A | 1 |
| Al-Badriyeh, D | 1 |
| Dias Maia, P | 1 |
| Rodrigues, KK | 1 |
| Gien, J | 1 |
| Turner, MJ | 1 |
| Wright, CJ | 2 |
| McCulley, DJ | 1 |
| Jensen, EA | 2 |
| Hanke, K | 1 |
| Fortmann, I | 1 |
| Humberg, A | 1 |
| Faust, K | 1 |
| Kribs, A | 1 |
| Prager, S | 1 |
| Felderhoff-Müser, U | 2 |
| Krüger, M | 1 |
| Heckmann, M | 1 |
| Jäger, A | 1 |
| Andres, O | 1 |
| Spiegler, J | 1 |
| Härtel, C | 2 |
| Herting, E | 2 |
| Göpel, W | 2 |
| Han, X | 1 |
| Cui, S | 1 |
| Cheema, HA | 1 |
| Majeed, Z | 1 |
| Hayat, T | 1 |
| Ahmed, A | 1 |
| Tariq, MH | 1 |
| Shahid, A | 1 |
| Titus, A | 1 |
| Minhas, AMK | 1 |
| Ijaz, SH | 1 |
| Ghelani, SJ | 1 |
| Kulkarni, A | 1 |
| Dani, SS | 1 |
| Mydam, J | 1 |
| Rastogi, A | 1 |
| Naheed, ZJ | 1 |
| Rooney, SR | 1 |
| Aka, I | 1 |
| Shaffer, CM | 1 |
| Dagle, JM | 4 |
| Ryckman, K | 1 |
| Lewis, TR | 2 |
| Van Driest, SL | 2 |
| Kannankeril, PJ | 2 |
| Rathi, P | 1 |
| Messina, C | 1 |
| Mintzer, JP | 1 |
| Gillam-Krakauer, M | 6 |
| Hagadorn, JI | 3 |
| Rovers, JFJ | 1 |
| Thomissen, IJC | 1 |
| Janssen, LCE | 1 |
| Lingius, S | 1 |
| Wieland, BV | 1 |
| Dieleman, JP | 1 |
| Niemarkt, HJ | 1 |
| van Runnard Heimel, PJ | 1 |
| Su, BH | 4 |
| Lin, HY | 1 |
| Chiu, HY | 2 |
| Tsai, ML | 2 |
| Chen, YT | 1 |
| Lu, IC | 1 |
| Nishizaki, N | 1 |
| Matsuda, A | 1 |
| Yoneyama, T | 1 |
| Watanabe, A | 1 |
| Obinata, K | 1 |
| Shimizu, T | 1 |
| Crockett, SL | 1 |
| Harris, M | 1 |
| Boatwright, N | 1 |
| Su, RL | 1 |
| Yarboro, MT | 1 |
| Berger, CD | 1 |
| Segar, JL | 1 |
| Xiong, T | 1 |
| Maheshwari, A | 2 |
| Neu, J | 2 |
| Ei-Saie, A | 1 |
| Pammi, M | 1 |
| Waldvogel, S | 1 |
| Atkinson, A | 1 |
| Wilbeaux, M | 1 |
| Nelle, M | 1 |
| Berger, MR | 1 |
| Gerull, R | 1 |
| Martini, S | 1 |
| Aceti, A | 1 |
| Galletti, S | 1 |
| Beghetti, I | 1 |
| Faldella, G | 1 |
| Corvaglia, L | 1 |
| Ohlsson, A | 16 |
| Shah, SS | 5 |
| Isayama, T | 2 |
| Kusuda, S | 2 |
| Reichman, B | 3 |
| Lee, SK | 5 |
| Lehtonen, L | 2 |
| Norman, M | 4 |
| Adams, M | 1 |
| Bassler, D | 1 |
| Helenius, K | 1 |
| Hakansson, S | 5 |
| Yang, J | 1 |
| AlRyalat, SA | 1 |
| Al Oweidat, K | 1 |
| Al-Amer, A | 1 |
| Khader, A | 1 |
| Ajaj, A | 1 |
| Alessa, Z | 1 |
| Roto, A | 1 |
| Davidson, JM | 1 |
| Ferguson, J | 1 |
| Ivey, E | 1 |
| Philip, R | 1 |
| Weems, MF | 1 |
| Talati, AJ | 1 |
| Shen, X | 1 |
| Huang, Y | 1 |
| Guo, H | 1 |
| Peng, H | 1 |
| Yao, S | 1 |
| Zhou, M | 1 |
| Liu, H | 2 |
| Lin, HC | 2 |
| Zhou, P | 1 |
| Iacobelli, S | 1 |
| Lorrain, S | 1 |
| Gouyon, B | 1 |
| Gambacorta, S | 1 |
| Laforgia, N | 1 |
| Gouyon, JB | 2 |
| Bonsante, F | 1 |
| Marissen, J | 1 |
| Erdmann, H | 1 |
| Böckenholt, K | 1 |
| Hoppenz, M | 1 |
| Rausch, TK | 1 |
| Gephart, SM | 1 |
| Underwood, MA | 2 |
| Rosito, S | 1 |
| Kim, JH | 1 |
| Caplan, MS | 1 |
| Vaidya, R | 1 |
| Knee, A | 1 |
| Paris, Y | 1 |
| Singh, R | 1 |
| Slaughter, JC | 3 |
| Cotton, RB | 10 |
| Robinson, BE | 1 |
| Maitre, NL | 1 |
| Louis, D | 5 |
| Dey, A | 1 |
| Faim, DRO | 1 |
| Tiago, JAM | 1 |
| Castelo, RJS | 1 |
| Francisco, ASS | 1 |
| Alves, RR | 1 |
| Pires, AMGS | 1 |
| Matsumura, S | 1 |
| Masutani, S | 2 |
| Oshima, A | 1 |
| Kanai, M | 1 |
| Ishiguro, A | 1 |
| Kabe, K | 1 |
| Pini, A | 1 |
| Fazi, C | 1 |
| Nardini, P | 1 |
| Calvani, M | 1 |
| Fabbri, S | 1 |
| Guerrini, A | 1 |
| Forni, G | 1 |
| La Marca, G | 1 |
| Rosa, AC | 1 |
| Filippi, L | 1 |
| Scrivens, A | 1 |
| von Kursell, AM | 1 |
| Disher, T | 1 |
| Evans, P | 1 |
| O'Reilly, D | 1 |
| Flyer, JN | 1 |
| Soll, R | 1 |
| Hallman, M | 3 |
| Treluyer, JM | 1 |
| Aikio, O | 1 |
| Bussmann, N | 2 |
| Smith, A | 2 |
| Breatnach, CR | 1 |
| McCallion, N | 1 |
| Cleary, B | 1 |
| Franklin, O | 1 |
| Lopata, SM | 1 |
| Ishida, S | 1 |
| Yamaguchi, A | 2 |
| Ooka, M | 2 |
| Kenmochi, M | 1 |
| Nakanishi, H | 1 |
| Zaheer, F | 1 |
| Nicoski, P | 1 |
| Weiss, MG | 1 |
| Amin, S | 2 |
| Ting, JY | 1 |
| Ben Fadel, N | 1 |
| Drolet, C | 1 |
| Abou Mehrem, A | 1 |
| Soraisham, A | 1 |
| Lapointe, A | 1 |
| Khurshid, F | 1 |
| Hyderi, A | 1 |
| Kumaran, K | 1 |
| Bodani, J | 1 |
| Alvaro, R | 2 |
| Adie, M | 1 |
| Stavel, M | 1 |
| Morin, A | 1 |
| Bhattacharya, S | 1 |
| Kanungo, J | 1 |
| Canning, R | 1 |
| Ye, XY | 2 |
| Gardner, CE | 1 |
| Shah, P | 1 |
| Gowda, SH | 1 |
| Patil, MS | 1 |
| Gill, K | 1 |
| Arbic, N | 1 |
| Seed, M | 2 |
| Honjo, O | 1 |
| Ryan, G | 3 |
| Jaeggi, E | 2 |
| Wong, C | 1 |
| Liebowitz, M | 4 |
| Salas, R | 1 |
| Lavín, P | 1 |
| Rincón, Y | 1 |
| Miranda, J | 1 |
| López, M | 1 |
| Bhombal, S | 2 |
| Benitz, WE | 4 |
| Ngo, S | 1 |
| Profit, J | 1 |
| Gould, JB | 1 |
| Lee, HC | 3 |
| Bixler, GM | 1 |
| Powers, GC | 1 |
| Clark, RH | 3 |
| Walker, MW | 1 |
| Tolia, VN | 1 |
| Smith, CJ | 1 |
| Ryckman, KK | 1 |
| Bahr, TM | 1 |
| Nelin, TD | 1 |
| Pena, E | 1 |
| Giacomazzi, T | 1 |
| Lee, S | 2 |
| Logan, JW | 1 |
| Moallem, M | 1 |
| Bapat, R | 1 |
| Shepherd, EG | 1 |
| Nelin, LD | 1 |
| Boghossian, NS | 1 |
| Do, BT | 1 |
| Brumbaugh, JE | 1 |
| Stoll, BJ | 3 |
| Vohr, BR | 3 |
| Sanchez, PJ | 1 |
| Wyckoff, MH | 1 |
| Bethany Ball, M | 1 |
| ElSayed, YN | 2 |
| Ojah, C | 2 |
| Dunn, M | 1 |
| Hu, Y | 1 |
| Jin, H | 1 |
| Jiang, Y | 1 |
| Du, J | 1 |
| Wyllie, JP | 1 |
| Gupta, S | 2 |
| Florez, ID | 2 |
| Tamayo, ME | 2 |
| Mbuagbaw, L | 2 |
| Vanniyasingam, T | 1 |
| Veroniki, AA | 2 |
| Zea, AM | 1 |
| Zhang, Y | 1 |
| Sadeghirad, B | 1 |
| Thabane, L | 2 |
| Juszczak, E | 1 |
| Shanahan, KH | 1 |
| Yu, X | 1 |
| Miller, LG | 1 |
| Freedman, SD | 1 |
| Martin, CR | 1 |
| Stremming, JE | 1 |
| Brown, LD | 1 |
| Singh, GK | 1 |
| Nichols, CG | 1 |
| Foglia, EE | 1 |
| Schmidt, B | 9 |
| Khuwuthyakorn, V | 2 |
| Jatuwattana, C | 1 |
| Silvilairat, S | 2 |
| Tantiprapha, W | 1 |
| Romagnoli, V | 1 |
| Pedini, A | 1 |
| Santoni, M | 1 |
| Scutti, G | 1 |
| Colaneri, M | 1 |
| Pozzi, M | 1 |
| Cogo, PE | 1 |
| Carnielli, VP | 1 |
| Lewis, T | 1 |
| Van Haandel, L | 1 |
| Scott, A | 1 |
| Leeder, JS | 1 |
| Farooqui, MA | 1 |
| Jeyaraman, MM | 1 |
| Dingwall, O | 1 |
| Tagin, M | 1 |
| Zarychanski, R | 1 |
| Rabbani, R | 1 |
| Abou-Setta, AM | 1 |
| Collins, RT | 1 |
| Lyle, RE | 1 |
| Rettiganti, M | 1 |
| Gossett, JM | 1 |
| Robbins, JM | 2 |
| Casey, PH | 1 |
| Kaempf, J | 2 |
| Erdeve, O | 4 |
| Bulbul, A | 2 |
| Lindqvist, J | 2 |
| Farooqi, A | 2 |
| Katheria, A | 2 |
| Sauberan, J | 2 |
| Singh, J | 3 |
| Nelson, K | 2 |
| Wickremasinghe, A | 4 |
| Dong, L | 2 |
| Hassinger, DC | 3 |
| Aucott, SW | 2 |
| Hayashi, M | 2 |
| Heuchan, AM | 2 |
| Carey, WA | 4 |
| Derrick, M | 3 |
| Fernandez, E | 1 |
| Sankar, M | 2 |
| Leone, T | 2 |
| Perez, J | 2 |
| Serize, A | 2 |
| Torigoe, T | 1 |
| Mawad, W | 1 |
| Marini, D | 1 |
| Golding, F | 1 |
| VAN Mieghem, T | 1 |
| Handley, SC | 1 |
| Passarella, M | 1 |
| Lorch, SA | 1 |
| Ferguson, JM | 1 |
| Kaur, S | 1 |
| Stritzke, A | 1 |
| Soraisham, AS | 3 |
| Kumar, J | 1 |
| Yadav, A | 1 |
| Waldherr, S | 1 |
| Fichtner, A | 1 |
| Beedgen, B | 2 |
| Bruckner, T | 1 |
| Schaefer, F | 1 |
| Tönshoff, B | 1 |
| Pöschl, J | 2 |
| Westhoff, TH | 1 |
| Westhoff, JH | 1 |
| Seaton, R | 1 |
| Williams, C | 1 |
| Peredo, J | 1 |
| Wolf, IS | 1 |
| Kimball, A | 1 |
| Lei, C | 1 |
| Wang, H | 1 |
| Liu, C | 1 |
| Cristea, S | 1 |
| Allegaert, K | 2 |
| Falcao, AC | 1 |
| Falcao, F | 1 |
| Silva, R | 1 |
| Smits, A | 1 |
| Krekels, EHJ | 1 |
| Kemmochi, M | 1 |
| Senzaki, H | 1 |
| Miyaji, K | 1 |
| Hashimoto, M | 1 |
| Yokozeki, Y | 1 |
| Ishii, M | 1 |
| Aydin, T | 1 |
| Hort, S | 1 |
| Kubinski, A | 1 |
| Bode, C | 1 |
| Klippstein, T | 1 |
| Endesfelder, S | 1 |
| Bührer, C | 5 |
| Koehne, P | 5 |
| Tantiprabha, W | 1 |
| Pavageau, L | 1 |
| Brion, LP | 5 |
| Rosenfeld, CR | 3 |
| Brown, LS | 1 |
| Ramaciotti, C | 2 |
| Burchfield, PJ | 1 |
| Jaleel, MA | 1 |
| Chiba, H | 1 |
| Toyoshima, K | 5 |
| Mori, R | 2 |
| Kaempf, JW | 2 |
| Mondal, T | 1 |
| Chaudhuri, D | 1 |
| Li, B | 1 |
| Shivananda, S | 1 |
| Dutta, S | 1 |
| Clyman, R | 6 |
| Jhaveri, N | 3 |
| Attridge, JT | 2 |
| Sanocka, U | 1 |
| Polin, R | 1 |
| Mammel, M | 1 |
| Couser, R | 1 |
| Mulrooney, N | 1 |
| Yanowitz, TD | 3 |
| Jegatheesan, P | 4 |
| Walsh, M | 2 |
| Fujii, A | 2 |
| Porta, N | 1 |
| Swanson, JR | 1 |
| Arora, R | 1 |
| Ridha, M | 1 |
| Lee, DS | 1 |
| Elliott, J | 1 |
| Rosenberg, HC | 1 |
| Diop, M | 1 |
| Lee, TY | 2 |
| St Lawrence, K | 1 |
| Malviya, MN | 1 |
| Mine, K | 1 |
| Ohashi, A | 2 |
| Tsuji, S | 1 |
| Nakashima, J | 1 |
| Hirabayashi, M | 1 |
| Kaneko, K | 2 |
| Walia, R | 5 |
| Pacifici, GM | 3 |
| Li, D | 1 |
| Rosito, G | 2 |
| Slagle, T | 1 |
| Saida, K | 1 |
| Nakamura, T | 2 |
| Hiroma, T | 1 |
| Takigiku, K | 1 |
| Yasukochi, S | 1 |
| Kluckow, M | 2 |
| Jeffery, M | 1 |
| Gill, A | 1 |
| Evans, N | 5 |
| Cochran, CM | 1 |
| Lau, J | 1 |
| Tran, VT | 1 |
| Fabio, A | 1 |
| Nagasawa, H | 2 |
| Terazawa, D | 1 |
| Kohno, Y | 2 |
| Yamamoto, Y | 2 |
| Kondo, M | 2 |
| Sugawara, M | 1 |
| Koyama, T | 1 |
| Miura, R | 1 |
| Yadav, S | 1 |
| Agarwal, S | 1 |
| Maria, A | 1 |
| Dudeja, A | 1 |
| Dubey, NK | 1 |
| Anand, P | 1 |
| Yadav, DK | 1 |
| Coceani, F | 6 |
| Chan, NM | 1 |
| Law, CW | 1 |
| Kwan, KF | 1 |
| Sehgal, A | 6 |
| Doctor, T | 1 |
| Menahem, S | 1 |
| Corcoran, D | 1 |
| Hooper, CW | 1 |
| Brown, N | 2 |
| Poole, SD | 2 |
| Milne, GL | 1 |
| Vucovich, MM | 1 |
| Goettel, JA | 1 |
| Ehinger, NJ | 1 |
| Wynn, JL | 1 |
| Paria, BC | 1 |
| Rojas, MA | 1 |
| Durand, DJ | 1 |
| Danielsen, B | 1 |
| Dueñas, GV | 1 |
| Powers, RJ | 1 |
| ElHassan, NO | 1 |
| Bird, TM | 1 |
| King, AJ | 1 |
| Ambadwar, PB | 1 |
| Jaquiss, RD | 1 |
| Kaiser, JR | 1 |
| Oncel, MY | 1 |
| Malikiwi, A | 1 |
| Roufaeil, C | 1 |
| Tan, K | 1 |
| Gudmundsdottir, A | 3 |
| Johansson, S | 3 |
| Källen, K | 2 |
| Bonamy, AK | 2 |
| Kirtsman, M | 1 |
| Yoon, EW | 1 |
| Cieslak, Z | 1 |
| Chhina, AS | 1 |
| Sharma, BK | 1 |
| Raja, M | 1 |
| Singhal, M | 1 |
| Shenoi, A | 3 |
| Inayat, M | 1 |
| Bany-Mohammed, F | 1 |
| Valencia, A | 1 |
| Tay, C | 1 |
| Jacinto, J | 1 |
| Aranda, JV | 7 |
| Beharry, KD | 4 |
| Meyer, S | 1 |
| Mirea, L | 2 |
| Fujimura, M | 1 |
| Ahamed, MF | 1 |
| Verma, P | 1 |
| Vega, M | 1 |
| Wang, D | 1 |
| Kim, M | 1 |
| Fuloria, M | 1 |
| AlFaleh, K | 3 |
| Alluwaimi, E | 1 |
| AlOsaimi, A | 1 |
| Alrajebah, S | 1 |
| AlOtaibi, B | 1 |
| AlRasheed, F | 1 |
| AlKharfi, T | 1 |
| Paes, B | 1 |
| Olsson, KW | 1 |
| Sindelar, R | 1 |
| Rolnitsky, A | 1 |
| Piedbouf, B | 1 |
| Harrison, A | 1 |
| Santhanam, S | 1 |
| Kumar, M | 1 |
| Yurttutan, S | 2 |
| Dash, SK | 1 |
| Kabra, NS | 2 |
| Avasthi, BS | 1 |
| Sharma, SR | 1 |
| Padhi, P | 1 |
| Ahmed, J | 1 |
| Waleh, N | 3 |
| Barrette, AM | 1 |
| Momany, A | 1 |
| Jin, C | 1 |
| Gulack, BC | 1 |
| Laughon, MM | 2 |
| Sankar, MN | 1 |
| Hornik, CP | 1 |
| Smith, PB | 3 |
| Chen, HL | 2 |
| Yang, RC | 1 |
| Lee, WT | 1 |
| Lee, PL | 1 |
| Hsu, JH | 2 |
| Wu, JR | 2 |
| Dai, ZK | 2 |
| Lainwala, S | 2 |
| Hussain, N | 1 |
| Mirza, H | 1 |
| Oh, W | 5 |
| Kandefer, S | 1 |
| Stonestreet, BS | 1 |
| Razak, A | 1 |
| Nagesh, NK | 1 |
| Kabra, N | 1 |
| Hansmann, G | 2 |
| Slaughter, JL | 1 |
| Reagan, PB | 1 |
| Bapat, RV | 1 |
| Newman, TB | 1 |
| Klebanoff, MA | 1 |
| Torgalkar, R | 1 |
| Shah, J | 2 |
| Sivanandan, S | 2 |
| Agarwal, R | 2 |
| Iwashima, S | 1 |
| Ishikawa, T | 1 |
| Vettukattil, JJ | 2 |
| Tan, ZH | 1 |
| Baral, VR | 1 |
| Samuel, BP | 1 |
| Stuive, AJ | 1 |
| Eding, DM | 1 |
| Rostas, SE | 1 |
| McPherson, CC | 1 |
| Haw, MP | 1 |
| Sung, SI | 1 |
| Chang, YS | 1 |
| Chun, JY | 1 |
| Yoon, SA | 1 |
| Yoo, HS | 1 |
| Ahn, SY | 1 |
| Park, WS | 1 |
| Aune, D | 1 |
| Tofé Valera, I | 1 |
| Jaraba Caballero, MP | 1 |
| Ruiz González, MD | 1 |
| Rodríguez Benítez, MV | 1 |
| Parraga Quiles, MJ | 1 |
| Brownell, EA | 1 |
| Trzaski, JM | 1 |
| Johnson, KR | 1 |
| Campbell, BT | 1 |
| Herbst, KW | 1 |
| Bancalari, E | 3 |
| Avsar, MK | 1 |
| Demir, T | 1 |
| Celiksular, C | 1 |
| Zeybek, C | 1 |
| Prescott, S | 1 |
| Keim-Malpass, J | 1 |
| Lin, YJ | 1 |
| Chen, CM | 1 |
| Rehan, VK | 1 |
| Florens, A | 1 |
| Wu, SY | 1 |
| Kuo, YT | 1 |
| Huang, FK | 1 |
| Yeh, TF | 16 |
| Koo, J | 1 |
| Allen, IE | 1 |
| El-Mashad, AE | 1 |
| El-Mahdy, H | 1 |
| El Amrousy, D | 1 |
| Elgendy, M | 1 |
| Jain, D | 1 |
| Kalani, M | 1 |
| Shariat, M | 1 |
| Khalesi, N | 1 |
| Farahani, Z | 1 |
| Ahmadi, S | 1 |
| Edstedt Bonamy, AK | 1 |
| Maier, RF | 1 |
| Toome, L | 1 |
| Zeitlin, J | 1 |
| Bonet, M | 1 |
| Fenton, A | 1 |
| Hasselager, AB | 1 |
| van Heijst, A | 1 |
| Gortner, L | 1 |
| Milligan, D | 1 |
| Van Reempts, P | 1 |
| Boyle, EM | 1 |
| Mohamed, MA | 1 |
| El-Dib, M | 1 |
| Alqahtani, S | 1 |
| Alyami, K | 1 |
| Ibrahim, AN | 1 |
| Aly, H | 2 |
| Zanardo, V | 5 |
| Vedovato, S | 2 |
| Chiozza, L | 1 |
| Faggian, D | 2 |
| Favaro, F | 2 |
| Trevisanuto, D | 5 |
| Ianus, V | 1 |
| Buchh, B | 1 |
| Yoon, G | 1 |
| Chorne, N | 4 |
| Ewig, A | 1 |
| Lin, E | 3 |
| Fields, S | 2 |
| Moon-Grady, A | 2 |
| Tacy, T | 2 |
| Milstein, J | 1 |
| Schreiber, M | 1 |
| Padbury, J | 1 |
| Giardini, A | 1 |
| Derrick, G | 1 |
| Baragatti, B | 1 |
| Sodini, D | 1 |
| Uematsu, S | 1 |
| Yang, CZ | 2 |
| Lee, J | 4 |
| Pai, VB | 1 |
| Sakadjian, A | 1 |
| Puthoff, TD | 1 |
| Stewart, CD | 1 |
| Morris, BH | 1 |
| Huseby, V | 1 |
| Kennedy, KA | 1 |
| Moya, FR | 2 |
| McAdams, RM | 1 |
| Rheinlaender, C | 2 |
| Helfenstein, D | 2 |
| Walch, E | 2 |
| Berns, M | 1 |
| Obladen, M | 4 |
| Busalt, M | 1 |
| Kaufman, DA | 1 |
| Lim, DS | 1 |
| Golombek, SG | 1 |
| Sola, A | 1 |
| Baquero, H | 1 |
| Borbonet, D | 1 |
| Cabañas, F | 1 |
| Fajardo, C | 1 |
| Goldsmit, G | 1 |
| Lemus, L | 1 |
| Miura, E | 1 |
| Pellicer, A | 1 |
| Pérez, JM | 1 |
| Rogido, M | 1 |
| Zambosco, G | 1 |
| Alexander, F | 1 |
| Chiu, L | 1 |
| Kroh, M | 1 |
| Hammel, J | 1 |
| Moore, J | 1 |
| Hsiao, CC | 2 |
| Wung, JT | 1 |
| Tsao, LY | 2 |
| Chang, WC | 1 |
| Andriessen, P | 1 |
| Struis, NC | 1 |
| Niemarkt, H | 1 |
| Oetomo, SB | 1 |
| Tanke, RB | 1 |
| Momma, K | 8 |
| Ito, K | 2 |
| Sugiyama, K | 1 |
| Imamura, S | 3 |
| Sun, F | 1 |
| Nakanishi, T | 4 |
| Hoellering, AB | 1 |
| Cooke, L | 2 |
| Carmo, KB | 1 |
| Paradisis, M | 1 |
| Gebrekristos, B | 1 |
| Brock, RS | 1 |
| Kuniyoshi, K | 1 |
| Abad-Santos, P | 2 |
| Abad-Santos, M | 2 |
| Modanlou, HD | 3 |
| Bratlid, D | 1 |
| Farstad, T | 1 |
| Darlow, BA | 1 |
| Yoshimoto, S | 1 |
| Sakai, H | 1 |
| Ueda, M | 1 |
| Yoshikata, M | 1 |
| Mizobuchi, M | 1 |
| Nakao, H | 1 |
| Shchors, I | 2 |
| Schimmel, MS | 5 |
| Bromiker, R | 2 |
| Kaplan, M | 6 |
| Nir, A | 2 |
| Noori, S | 1 |
| Seri, I | 4 |
| Mercanti, I | 2 |
| Boubred, F | 2 |
| Simeoni, U | 2 |
| Valencia, GB | 1 |
| Echtler, K | 1 |
| Stark, K | 1 |
| Lorenz, M | 1 |
| Kerstan, S | 1 |
| Walch, A | 1 |
| Jennen, L | 1 |
| Rudelius, M | 1 |
| Seidl, S | 1 |
| Kremmer, E | 1 |
| Emambokus, NR | 1 |
| von Bruehl, ML | 1 |
| Frampton, J | 1 |
| Isermann, B | 1 |
| Genzel-Boroviczény, O | 1 |
| Schreiber, C | 1 |
| Mehilli, J | 1 |
| Kastrati, A | 1 |
| Schwaiger, M | 1 |
| Shivdasani, RA | 1 |
| Massberg, S | 1 |
| Linder, N | 1 |
| Bello, R | 1 |
| Hernandez, A | 1 |
| Rosen, C | 1 |
| Birk, E | 1 |
| Sirota, L | 1 |
| Pushkov, Y | 1 |
| Klinger, G | 1 |
| Katakam, LI | 1 |
| Cotten, CM | 2 |
| Goldberg, RN | 4 |
| Dang, CN | 1 |
| McPherson, C | 1 |
| Gal, P | 7 |
| Ransom, JL | 6 |
| Carlos, RQ | 4 |
| Dimaguila, MA | 2 |
| Smith, M | 1 |
| Davonzo, C | 1 |
| Wimmer, JE | 1 |
| Chang, HY | 1 |
| Locker, J | 1 |
| Lu, R | 1 |
| Schuster, VL | 1 |
| Tsao, PC | 1 |
| Chen, SJ | 3 |
| Yang, CF | 1 |
| Lee, YS | 1 |
| Jeng, MJ | 1 |
| Soong, WJ | 2 |
| Lee, PC | 1 |
| Lu, JH | 2 |
| Hwang, B | 4 |
| Tang, RB | 1 |
| Pees, C | 1 |
| Czernik, C | 2 |
| Soll, RF | 1 |
| Yang, SN | 1 |
| Tseng, HI | 2 |
| Lee, BS | 1 |
| Byun, SY | 1 |
| Chung, ML | 1 |
| Chang, JY | 1 |
| Kim, HY | 1 |
| Kim, EA | 1 |
| Kim, KS | 1 |
| Pi, SY | 1 |
| Kunikata, T | 1 |
| Okazaki, K | 1 |
| Yasuda, S | 1 |
| Isobe, K | 1 |
| Itoh, S | 1 |
| Chen, S | 1 |
| Keating, P | 1 |
| Verhagen, E | 1 |
| van Hoften, J | 1 |
| ter Horst, H | 1 |
| Bos, AF | 3 |
| Sharma, R | 1 |
| Tepas, JJ | 1 |
| Wludyka, PS | 1 |
| Teng, RJ | 1 |
| Hastings, LK | 1 |
| Renfro, WH | 2 |
| Marvin, WJ | 1 |
| Flisberg, A | 1 |
| Kjellmer, I | 1 |
| Löfhede, J | 1 |
| Löfgren, N | 1 |
| Rosa-Zurera, M | 1 |
| Lindecrantz, K | 1 |
| Thordstein, M | 1 |
| Dalgleish, S | 1 |
| Singhal, N | 1 |
| Katayama, Y | 1 |
| Minami, H | 1 |
| Enomoto, M | 1 |
| Takano, T | 1 |
| Hayashi, S | 1 |
| Lee, YK | 1 |
| Bajaj, R | 1 |
| Narasimhan, R | 1 |
| Laughon, M | 4 |
| Bose, C | 3 |
| Kim, ES | 1 |
| Kim, EK | 1 |
| Choi, CW | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Choi, JH | 1 |
| Park, JS | 1 |
| Moon, KC | 1 |
| Fowlie, PW | 5 |
| Davis, PG | 2 |
| McGuire, W | 2 |
| Lu, CW | 1 |
| Wu, MH | 1 |
| Lin, YC | 1 |
| Huang, HR | 2 |
| Lien, R | 2 |
| Yang, PH | 1 |
| Su, WJ | 1 |
| Chung, HT | 1 |
| Chen, TJ | 1 |
| Liu, WH | 1 |
| Sum, K | 1 |
| Uchiyama, A | 1 |
| Tatebayashi, K | 1 |
| Suzuki, H | 1 |
| Yamada, K | 1 |
| Arai, M | 1 |
| Jones, LJ | 1 |
| Craven, PD | 1 |
| Attia, J | 1 |
| Thakkinstian, A | 1 |
| Wright, I | 1 |
| Sekar, KC | 2 |
| Feng, X | 1 |
| Krebs, LT | 1 |
| Gridley, T | 1 |
| Tran, H | 1 |
| Carse, E | 1 |
| Li, Y | 1 |
| Zelenina, M | 1 |
| Plat-Willson, G | 1 |
| Marcoux, MO | 1 |
| Aperia, A | 1 |
| Casper, C | 1 |
| Shah, NA | 1 |
| McCurnin, D | 1 |
| Seidner, S | 1 |
| Chemtob, S | 3 |
| El-Khuffash, AF | 1 |
| DeMauro, SB | 1 |
| Roberts, RS | 6 |
| Brissaud, O | 1 |
| Guichoux, J | 1 |
| Ethington, PN | 1 |
| Katakam, L | 1 |
| Nuntnarumit, P | 1 |
| Chongkongkiat, P | 1 |
| Khositseth, A | 1 |
| Sasi, A | 1 |
| Deorari, A | 1 |
| Chock, VY | 1 |
| Ramamoorthy, C | 1 |
| Van Meurs, KP | 1 |
| Kushnir, A | 1 |
| Pinheiro, JM | 1 |
| Ramsden, CA | 1 |
| Wu, YX | 1 |
| Kaempf, AJ | 1 |
| Kaempf, AM | 1 |
| Wang, L | 1 |
| Grunkemeier, G | 1 |
| Schena, F | 1 |
| Ciarmoli, E | 1 |
| Mosca, F | 2 |
| Alfaleh, KM | 1 |
| Al Luwaimi, E | 1 |
| Alkharfi, TM | 1 |
| Al-Alaiyan, SA | 1 |
| Dani, C | 1 |
| Fanos, V | 3 |
| Pusceddu, M | 1 |
| Dessì, A | 1 |
| Marcialis, MA | 1 |
| Adrouche-Amrani, L | 1 |
| Green, RS | 1 |
| Gluck, KM | 1 |
| Lin, J | 1 |
| Popat, H | 1 |
| Kapoor, V | 1 |
| Travadi, J | 1 |
| Johnston, PG | 1 |
| Fuller, MP | 1 |
| Maruyama, K | 1 |
| Fujiu, T | 1 |
| Neumann, R | 1 |
| Schulzke, SM | 1 |
| Couto, J | 1 |
| Murphy, GM | 1 |
| Walther, FJ | 1 |
| Kent, AL | 1 |
| Brown, L | 1 |
| Broom, M | 1 |
| Broomfield, A | 1 |
| Dahlstrom, JE | 1 |
| Saldeño, YP | 1 |
| Favareto, V | 1 |
| Mirpuri, J | 1 |
| Bhatt, M | 1 |
| Petrova, A | 1 |
| Mehta, R | 1 |
| Mezu-Ndubuisi, OJ | 1 |
| Agarwal, G | 1 |
| Raghavan, A | 1 |
| Pham, JT | 1 |
| Ohler, KH | 1 |
| Ligi, I | 1 |
| Grandvuillemin, I | 1 |
| Buffat, C | 1 |
| Fayol, L | 1 |
| Millet, V | 1 |
| Wadhawan, R | 2 |
| Saha, S | 2 |
| Laptook, A | 1 |
| Walsh, MC | 1 |
| Higgins, R | 1 |
| Sankaran, K | 1 |
| Seshia, M | 1 |
| Allen, AC | 1 |
| Aziz, K | 1 |
| Metze, B | 1 |
| Müller, C | 1 |
| Ozdemir, R | 1 |
| Dilmen, U | 1 |
| Wickremasinghe, AC | 1 |
| Rogers, EE | 1 |
| Piecuch, RE | 1 |
| Johnson, BC | 1 |
| Golden, S | 1 |
| Moon-Grady, AJ | 1 |
| Weber, SC | 1 |
| Hüning, B | 1 |
| Stein, A | 1 |
| Horn, PA | 1 |
| Metze, BC | 1 |
| Dame, C | 1 |
| Davis, JS | 1 |
| Ryan, ML | 2 |
| Shields, JM | 1 |
| Sola, JE | 1 |
| Perez, EA | 1 |
| Neville, HL | 1 |
| Rodriguez, MM | 1 |
| Candel-Pau, J | 1 |
| Linde Sillo, Á | 1 |
| Castillo Salinas, F | 1 |
| Coma Redon, E | 1 |
| Ferrer Menduiña, Q | 1 |
| Albert, DC | 1 |
| Heo, MJ | 1 |
| Lee, OS | 1 |
| Lim, SC | 1 |
| Chiang, PJ | 1 |
| Hsu, JF | 1 |
| Tsai, MH | 1 |
| Chiang, MC | 1 |
| Chiang, CC | 1 |
| Liang, HF | 1 |
| Chu, SM | 1 |
| Takami, T | 2 |
| Yoda, H | 1 |
| Ishida, T | 1 |
| Morichi, S | 1 |
| Kondo, A | 1 |
| Sunohara, D | 1 |
| Hoshika, A | 1 |
| Kawakami, T | 1 |
| Knott, EM | 1 |
| Zamora, A | 1 |
| Cavett, C | 1 |
| Wattsman, TA | 1 |
| Lee, CH | 1 |
| Chen, HN | 1 |
| Lee, ML | 1 |
| Zhang, CC | 1 |
| Cheng, GQ | 1 |
| Bali, V | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Barrington, K | 1 |
| Wright, LL | 2 |
| Davis, P | 5 |
| Solimano, A | 3 |
| Suarez, VR | 1 |
| Thompson, LL | 1 |
| Jain, V | 1 |
| Olson, GL | 1 |
| Hankins, GD | 1 |
| Belfort, MA | 1 |
| Saade, GR | 1 |
| Supapannachart, S | 2 |
| Limrungsikul, A | 1 |
| Khowsathit, P | 2 |
| Little, DC | 1 |
| Pratt, TC | 1 |
| Blalock, SE | 1 |
| Krauss, DR | 1 |
| Cooney, DR | 1 |
| Custer, MD | 1 |
| Hansen, TW | 1 |
| Seyberth, HW | 15 |
| Müller, H | 4 |
| Wille, L | 8 |
| Plückthun, H | 2 |
| Wolf, D | 4 |
| Ulmer, HE | 6 |
| O'Donovan, DJ | 2 |
| Baetiong, A | 1 |
| Adams, K | 2 |
| Chen, A | 1 |
| Smith, EO | 1 |
| Adams, JM | 3 |
| Weisman, LE | 1 |
| Baker, RW | 1 |
| Sobchak Brozanski, B | 1 |
| Steer, P | 1 |
| Woodgate, P | 2 |
| Rajadurai, VS | 2 |
| Tan, KW | 1 |
| Wong, KY | 1 |
| Wong, EH | 1 |
| Leong, JY | 1 |
| Treszl, A | 1 |
| Szabo, M | 1 |
| Dunai, G | 1 |
| Nobilis, A | 1 |
| Kocsis, I | 1 |
| Machay, T | 1 |
| Tulassay, T | 2 |
| Vasarhelyi, B | 1 |
| Malviya, M | 2 |
| Shah, S | 5 |
| Watanabe, K | 1 |
| Tomita, H | 1 |
| Ono, Y | 1 |
| Yamada, O | 1 |
| Kurosaki, K | 1 |
| Echigo, S | 1 |
| Keller, RL | 2 |
| Itabashi, K | 1 |
| Ohno, T | 3 |
| Nishida, H | 1 |
| Bellander, M | 1 |
| Ley, D | 1 |
| Polberger, S | 1 |
| Hellström-Westas, L | 1 |
| Osborn, DA | 1 |
| Sharma, PK | 1 |
| Garg, SK | 1 |
| Narang, A | 3 |
| Taniguchi, T | 1 |
| Muramatsu, I | 1 |
| Su, PH | 1 |
| Chen, JY | 1 |
| Su, CM | 1 |
| Huang, TC | 1 |
| Lee, HS | 1 |
| Swartz, EN | 1 |
| Kawata, H | 1 |
| Kishimoto, H | 1 |
| Miura, T | 1 |
| Nakajima, T | 1 |
| Kitajima, H | 1 |
| Chotigeat, U | 1 |
| Jirapapa, K | 1 |
| Layangkool, T | 1 |
| Herrera, C | 2 |
| Holberton, J | 2 |
| Akima, S | 1 |
| Kent, A | 1 |
| Reynolds, GJ | 1 |
| Gallagher, M | 1 |
| Falk, MC | 1 |
| Leonhardt, A | 2 |
| Strehl, R | 1 |
| Barth, H | 1 |
| Fernandes, CJ | 1 |
| Nguyen, NY | 1 |
| Lubetzky, R | 1 |
| Mandel, D | 1 |
| Mimouni, FB | 1 |
| Diamant, S | 1 |
| Birger, A | 1 |
| Barak, M | 1 |
| Dollberg, S | 2 |
| Brown, DW | 1 |
| Lee, D | 1 |
| Kumaran, VS | 1 |
| Smyth, JM | 1 |
| Collier, PS | 1 |
| Darwish, M | 1 |
| Millership, JS | 1 |
| Halliday, HL | 4 |
| Petersen, S | 4 |
| McElnay, JC | 1 |
| Lusky, A | 2 |
| Thomas, RL | 1 |
| Parker, GC | 1 |
| de Vries, NK | 1 |
| Jagroep, FK | 1 |
| Jaarsma, AS | 1 |
| Elzenga, NJ | 2 |
| Distefano, G | 1 |
| Benini, D | 1 |
| Verlato, G | 1 |
| Errico, G | 1 |
| Cuzzolin, L | 2 |
| Brooks, JM | 2 |
| Travadi, JN | 2 |
| Patole, SK | 3 |
| Doherty, DA | 3 |
| Simmer, K | 1 |
| Doyle, NM | 1 |
| Gardner, MO | 2 |
| Wells, L | 1 |
| Qualls, C | 1 |
| Papile, LA | 1 |
| Lago, P | 2 |
| Plebani, M | 2 |
| Gimeno Navarro, A | 2 |
| Cano Sánchez, A | 1 |
| Fernández Gilino, C | 2 |
| Carrasco Moreno, JI | 1 |
| Izquierdo Macián, I | 2 |
| Gutiérrez Laso, A | 2 |
| Morcillo Sopena, F | 2 |
| Tacy, TA | 1 |
| Ofenstein, JP | 1 |
| Lin, SJ | 1 |
| Chen, YR | 1 |
| Su, YH | 1 |
| Chen, SH | 1 |
| Sperandio, M | 1 |
| Feneberg, R | 1 |
| Huppertz, C | 1 |
| Brüssau, J | 1 |
| Linderkamp, O | 2 |
| Al Za'abi, MA | 1 |
| Dehghanzadeh, GH | 1 |
| Norris, RL | 1 |
| Charles, BG | 1 |
| Jaillard, S | 1 |
| Larrue, B | 1 |
| Rakza, T | 1 |
| Magnenant, E | 1 |
| Warembourg, H | 1 |
| Storme, L | 1 |
| Zupancic, JA | 1 |
| Richardson, DK | 1 |
| O'Brien, BJ | 1 |
| Cronin, CG | 1 |
| Roberts, R | 1 |
| Weinstein, MC | 1 |
| Ekici, F | 1 |
| Atasay, B | 1 |
| Günlemez, A | 1 |
| Naçar, N | 1 |
| Tutar, E | 1 |
| Atalay, S | 1 |
| Eyileten, Z | 1 |
| Uysalel, A | 1 |
| Arsan, S | 1 |
| Koch, J | 1 |
| Hensley, G | 1 |
| Roy, L | 1 |
| Brown, S | 1 |
| Hermes-DeSantis, ER | 1 |
| Miller, SP | 1 |
| Mayer, EE | 1 |
| Glidden, DV | 1 |
| Hamrick, SE | 1 |
| Barkovich, AJ | 1 |
| Manzar, S | 1 |
| Bengtsson, BO | 1 |
| Milstein, JM | 2 |
| Sherman, MP | 2 |
| Bose, CL | 1 |
| Fanaroff, A | 2 |
| Kirpalani, HM | 1 |
| Nwaesei, C | 1 |
| Vincer, M | 2 |
| Paquette, L | 1 |
| Friedlich, P | 1 |
| Ramanathan, R | 1 |
| Kumaran, V | 1 |
| Thomas, R | 1 |
| Boo, NY | 1 |
| Mohd-Amin, I | 1 |
| Bilkis, AA | 1 |
| Yong-Junina, F | 1 |
| Cordero, L | 2 |
| Nankervis, CA | 2 |
| Gardner, D | 1 |
| Giannone, PJ | 2 |
| Godambe, S | 1 |
| Newby, B | 1 |
| Shah, V | 1 |
| Kandasamy, Y | 1 |
| Alcock, G | 1 |
| Koh, TH | 1 |
| Rayyan, M | 1 |
| Anderson, BJ | 1 |
| Jobe, A | 1 |
| Srinivasjois, RM | 1 |
| Nathan, EA | 1 |
| Clark, R | 1 |
| Delooze, D | 1 |
| Doyle, LW | 1 |
| Papile, L | 1 |
| Sarkar, S | 1 |
| Dechert, R | 1 |
| Schumacher, RE | 1 |
| Donn, SM | 1 |
| Savage, AH | 1 |
| Anderson, BL | 1 |
| Simhan, HN | 1 |
| Lotfy, W | 1 |
| Badrawi, N | 1 |
| Ghawas, M | 1 |
| Abdel-Meguid, IE | 1 |
| Hammad, TA | 1 |
| Ojala, TH | 1 |
| Cherif, A | 1 |
| Jabnoun, S | 1 |
| Khrouf, N | 1 |
| Roman, C | 4 |
| Hsieh, HY | 1 |
| Chen, HH | 1 |
| Tsai, YC | 1 |
| Fakhraee, SH | 1 |
| Badiee, Z | 1 |
| Mojtahedzadeh, S | 1 |
| Kazemian, M | 1 |
| Kelishadi, R | 1 |
| Modesto Alapont, V | 1 |
| Shi, R | 1 |
| Al Za'abi, M | 1 |
| Donovan, T | 1 |
| Tudehope, D | 1 |
| Collie, LA | 1 |
| Charles, B | 1 |
| Sangem, M | 1 |
| Asthana, S | 1 |
| Hasan, J | 1 |
| Gharraee, Z | 1 |
| Stavitsky, Y | 1 |
| Lemmers, PM | 1 |
| Toet, MC | 1 |
| van Bel, F | 7 |
| Tschuppert, S | 1 |
| Doell, C | 1 |
| Arlettaz-Mieth, R | 1 |
| Baenziger, O | 1 |
| Rousson, V | 1 |
| Balmer, C | 1 |
| Prêtre, R | 1 |
| Dodge-Khatami, A | 1 |
| Madan, J | 1 |
| Fiascone, J | 1 |
| Balasubramanian, V | 1 |
| Griffith, J | 1 |
| Smyth, JA | 1 |
| Asztalos, EV | 1 |
| Görk, AS | 1 |
| Ehrenkranz, RA | 5 |
| Bracken, MB | 1 |
| Knight, DB | 3 |
| Deorari, AK | 2 |
| Paul, VK | 2 |
| Kimura, R | 1 |
| Lee, KS | 1 |
| Corff, KE | 1 |
| Herrman, K | 1 |
| Lewis, K | 1 |
| Jacobson, S | 1 |
| Firth, J | 1 |
| Pickering, D | 3 |
| Burnard, ED | 2 |
| Versmold, HT | 1 |
| Raval, D | 6 |
| Lilien, LD | 3 |
| Srinivasan, G | 3 |
| Pildes, RS | 13 |
| Mahony, L | 3 |
| Heymann, MA | 11 |
| Carnero, V | 2 |
| Brett, C | 2 |
| Kääpä, P | 1 |
| Lanning, P | 1 |
| Koivisto, M | 2 |
| Rudd, P | 1 |
| Montanez, P | 1 |
| Hallidie-Smith, K | 1 |
| Silverman, M | 1 |
| Gersony, WM | 5 |
| Peckham, GJ | 2 |
| Ellison, RC | 3 |
| Miettinen, OS | 2 |
| Nadas, AS | 5 |
| Pyati, S | 2 |
| Drummond, WH | 1 |
| Bucciarelli, RL | 1 |
| Gessner, IH | 1 |
| Rascher, W | 2 |
| Hackenthal, R | 1 |
| Knapp, G | 2 |
| Monset-Couchard, M | 1 |
| Dias-Mançano, D | 1 |
| Murat, I | 2 |
| Relier, JP | 1 |
| Wagner, HR | 1 |
| Zierler, S | 2 |
| Lang, P | 2 |
| Purohit, DM | 1 |
| Behrendt, D | 1 |
| Waldhausen, JA | 1 |
| Hackenthal, E | 1 |
| Kraybill, EN | 1 |
| Gracián Gómez, M | 1 |
| Rodríguez Caamaño, J | 1 |
| Guía Torrent, JM | 1 |
| Kiszel, J | 1 |
| Csömör, S | 1 |
| Lucey, JF | 1 |
| Dangman, B | 1 |
| Furst, DE | 1 |
| Regazzi, MB | 1 |
| Rondanelli, R | 1 |
| Vidale, E | 1 |
| Chirico, G | 1 |
| Rondini, G | 1 |
| Chiara, A | 1 |
| Piccolo, A | 1 |
| Zarfin, Y | 3 |
| Koren, G | 3 |
| Perlman, M | 4 |
| Turner, GR | 1 |
| Levin, DL | 1 |
| Dooley, KJ | 1 |
| Smallhorn, JF | 2 |
| Gow, R | 1 |
| Olley, PM | 7 |
| Freedom, RM | 1 |
| Swyer, PR | 5 |
| Rowe, RD | 5 |
| Atik, E | 1 |
| Moromizato, JH | 1 |
| Zan, R | 1 |
| Ajzenberg, M | 1 |
| Esher, R | 1 |
| Diniz, EM | 1 |
| Souza, AT | 1 |
| Martins, CO | 1 |
| Bastos, JC | 1 |
| Pedersen, S | 1 |
| Frost, L | 1 |
| Vázquez, C | 1 |
| Cabrera, A | 2 |
| Pastor, E | 2 |
| Valls y Soler, A | 1 |
| Mavroudis, C | 1 |
| Cook, LN | 2 |
| Fleischaker, JW | 1 |
| Nagaraj, HS | 2 |
| Shott, RJ | 1 |
| Howe, WR | 1 |
| Gray, LA | 1 |
| Christensen, NC | 3 |
| Lauridsen, P | 2 |
| Pedersen, SA | 2 |
| Ryssing, E | 3 |
| Laguenie, G | 1 |
| Estève, C | 1 |
| Couturier, C | 1 |
| Saint-Maurice, JP | 1 |
| Zerella, JT | 1 |
| Spies, RJ | 1 |
| Deaver, DC | 1 |
| Dailry, WJ | 1 |
| Haple, DC | 1 |
| Trump, DS | 1 |
| Yu, VY | 7 |
| Obeyesekere, HI | 2 |
| Mitvalsky, J | 1 |
| Grosfeld, JL | 2 |
| Kamman, K | 1 |
| Gross, K | 1 |
| Cikrit, D | 1 |
| Ross, D | 1 |
| Wolfe, M | 1 |
| Katz, S | 1 |
| Weber, TR | 1 |
| Bolling, J | 1 |
| Feman, SS | 1 |
| Mellander, M | 3 |
| Cotton, R | 2 |
| Rigby, ML | 1 |
| Wilkinson, A | 1 |
| Ou, CN | 1 |
| Frawley, VL | 1 |
| Leheup, B | 1 |
| Lindstrom, DP | 1 |
| Palme, C | 1 |
| Graham, TP | 3 |
| Stahlman, MT | 2 |
| John, EG | 1 |
| Vasan, U | 1 |
| Hastreiter, AR | 1 |
| Bhat, R | 6 |
| Evans, MA | 2 |
| MacLeod, SM | 1 |
| Smith, IJ | 1 |
| Goss, I | 1 |
| Congdon, PJ | 1 |
| Corazza, MS | 1 |
| Davis, RF | 1 |
| Merritt, TA | 12 |
| Bejar, R | 2 |
| Cvetnic, W | 1 |
| Nestrud, RM | 1 |
| Hill, DE | 1 |
| Arrington, RW | 1 |
| Beard, AG | 1 |
| Dungan, WT | 1 |
| Lau, PY | 1 |
| Norton, JB | 1 |
| Readinger, RI | 1 |
| Zaorska, B | 1 |
| Niebyl, JR | 2 |
| Chiswick, ML | 1 |
| Blinova, EI | 1 |
| Aleksi-Meskhishvili, VV | 1 |
| Liu, L | 1 |
| Jaffe, R | 1 |
| Borowski, GD | 1 |
| Rose, LI | 1 |
| Luken, J | 2 |
| Thalji, A | 3 |
| Carr, I | 3 |
| Strauss, A | 1 |
| Gyepes, M | 1 |
| Wittner, R | 1 |
| Taylor, WJ | 1 |
| Alpert, BS | 3 |
| Jacob, J | 3 |
| Gluck, L | 6 |
| DiSessa, T | 1 |
| Edwards, D | 2 |
| Kulovich, M | 1 |
| Kurlinski, J | 3 |
| Friedman, WF | 15 |
| Betkerur, MV | 1 |
| Miller, K | 1 |
| Glasser, RJ | 1 |
| Vidyasagar, D | 5 |
| Fisher, E | 4 |
| Hastreiter, A | 4 |
| Ramirez, JL | 1 |
| Burns, L | 1 |
| Evans, M | 3 |
| Bianchetti, G | 3 |
| Monin, P | 3 |
| Marchal, F | 3 |
| Dubruc, C | 1 |
| Boutroy, MJ | 1 |
| Morselli, PL | 2 |
| Vert, P | 3 |
| DiSessa, TG | 5 |
| Feldman, BH | 4 |
| Fitzpatrick, KM | 2 |
| Kitterman, JA | 1 |
| Luken, JA | 2 |
| Rudolph, AM | 5 |
| Sharykin, AS | 1 |
| O'Loughlin, JE | 1 |
| Harris, JP | 2 |
| Roghmann, K | 1 |
| Wood, B | 1 |
| Campanella, V | 1 |
| Alexson, C | 1 |
| Manning, J | 1 |
| Shapiro, DL | 1 |
| Yanagi, RM | 1 |
| Wilson, A | 1 |
| Newfeld, EA | 1 |
| Aziz, KU | 1 |
| Hunt, CE | 1 |
| Hencz, P | 1 |
| Kertész, E | 2 |
| Beviz, J | 1 |
| Szeleczki, T | 1 |
| Szekeres, Z | 1 |
| Mullett, MD | 3 |
| Croghan, TW | 1 |
| Myerberg, DZ | 1 |
| Krall, JM | 1 |
| Neal, WA | 3 |
| Scanlon, JW | 1 |
| White, CL | 2 |
| Coen, RW | 1 |
| Rosenberg, M | 1 |
| Mrongovius, R | 1 |
| Imbeck, H | 1 |
| Thomas, DB | 1 |
| Grattan-Smith, P | 1 |
| Wilks, A | 3 |
| Betkerur, M | 1 |
| Lilien, L | 1 |
| Sweet, AY | 1 |
| Goldbarg, HR | 1 |
| Henek, T | 1 |
| Friedman, CA | 2 |
| Parks, BR | 2 |
| Rawson, JE | 2 |
| Serwer, GA | 1 |
| Anderson, PA | 2 |
| Alexson, CG | 1 |
| Longfield, L | 1 |
| Manning, JA | 2 |
| Jaso, E | 1 |
| Tejedor, JC | 1 |
| Quero, J | 2 |
| Pérez Rodríguez, J | 1 |
| Agustí, B | 1 |
| Castro, J | 1 |
| García Frías, E | 1 |
| Frisch, H | 1 |
| Hammerer, I | 1 |
| Heinz-Erian, P | 1 |
| Gschnitzer, F | 1 |
| Raju, TN | 1 |
| Sturc, M | 1 |
| Turek, J | 1 |
| Wawreczka, K | 1 |
| Lozano González, CH | 1 |
| Holden, AM | 1 |
| Hurtado del Río, D | 1 |
| Segura, MA | 1 |
| Brash, AR | 1 |
| Hickey, DE | 1 |
| Oates, JA | 1 |
| Møller Jensen, K | 1 |
| Sandhu, AS | 1 |
| Buchino, JJ | 1 |
| Groff, DB | 1 |
| Ariagno, RL | 1 |
| Johnson, JD | 1 |
| Pitlick, PT | 2 |
| Cohen, RS | 1 |
| Beets, CL | 1 |
| Sunshine, P | 1 |
| Patel, M | 1 |
| Gittenberger-de Groot, AC | 3 |
| van Ertbruggen, I | 2 |
| Moulaert, AJ | 2 |
| Harinck, E | 2 |
| Catterton, Z | 1 |
| Sellers, B | 1 |
| Gray, B | 1 |
| Lewins, MJ | 2 |
| Rowland, DW | 2 |
| Grant, MJ | 2 |
| Soldin, SJ | 3 |
| Gómez, R | 1 |
| Moreno, F | 1 |
| Burgueros, M | 1 |
| Sanchez, PA | 1 |
| Alvarez, F | 1 |
| Polgár, M | 2 |
| Kemény, J | 2 |
| Szirmai, Z | 2 |
| Gray, PH | 1 |
| Pemberton, PJ | 1 |
| Pankhurst, S | 1 |
| Inwood, RJ | 1 |
| Eidelman, AI | 3 |
| Eylath, U | 1 |
| Procianoy, RS | 1 |
| Garcia-Prats, JA | 3 |
| Hittner, HM | 1 |
| Rudolph, AJ | 1 |
| Beitzke, A | 2 |
| Rigler, B | 1 |
| Müller, WD | 2 |
| Metzler, W | 1 |
| Schober, P | 1 |
| Yaffe, SJ | 1 |
| Rogers, D | 1 |
| Ragni, M | 1 |
| Saccar, C | 1 |
| Thalji, AA | 1 |
| Smith, DR | 1 |
| Cook, DH | 1 |
| Izukawa, T | 1 |
| Patel, J | 2 |
| Marks, KA | 1 |
| Roberts, I | 2 |
| Azzopardi, D | 2 |
| Edwards, AD | 3 |
| Varsila, E | 1 |
| Venge, P | 1 |
| Andersson, S | 1 |
| Weiss, H | 2 |
| Cooper, B | 3 |
| Brook, M | 1 |
| Schlueter, M | 2 |
| Glaser, J | 3 |
| Ferber, B | 2 |
| Chouchane, M | 1 |
| Françoise, M | 1 |
| Bottu, J | 1 |
| Govan, J | 1 |
| Fong, K | 1 |
| Myhr, T | 1 |
| Liem, KD | 2 |
| Hopman, JC | 2 |
| Kollée, LA | 2 |
| Oeseburg, B | 1 |
| Barrington, KJ | 1 |
| Fox, M | 1 |
| Ment, LR | 4 |
| Philip, AG | 1 |
| Vohr, B | 2 |
| Allan, W | 2 |
| Duncan, CC | 3 |
| Scott, DT | 3 |
| Taylor, KJ | 4 |
| Katz, KH | 2 |
| Iyer, P | 2 |
| Hebel, A | 1 |
| Grasser, S | 1 |
| Phillip, AG | 1 |
| Makuch, RW | 1 |
| Schneider, KC | 1 |
| Norton, ME | 1 |
| Merrill, J | 1 |
| Cooper, BA | 1 |
| Kuller, JA | 1 |
| Brezinka, C | 1 |
| Wladimiroff, JW | 1 |
| Archer, N | 3 |
| Gilman, JT | 1 |
| Trus, T | 1 |
| Winthrop, AL | 1 |
| Pipe, S | 1 |
| Langer, JC | 1 |
| Lau, GY | 1 |
| Krasna, IH | 1 |
| Lee, RT | 1 |
| Eronen, M | 2 |
| Kari, A | 1 |
| Pesonen, E | 1 |
| Burr, JM | 1 |
| Rawlings, J | 1 |
| Satur, CM | 1 |
| Ashraf, SS | 1 |
| Walker, DR | 2 |
| Benders, MJ | 2 |
| Dorrepaal, CA | 1 |
| van de Bor, M | 5 |
| Brus, F | 1 |
| van Acker, KJ | 2 |
| van der Auwera, JC | 1 |
| Schasfoort, M | 1 |
| Okken, A | 1 |
| Couser, RJ | 2 |
| Ferrara, TB | 2 |
| Wright, GB | 2 |
| Cabalka, AK | 2 |
| Schilling, CG | 1 |
| Hoekstra, RE | 2 |
| Payne, NR | 1 |
| Shaffer, CL | 2 |
| Smith, MS | 2 |
| Brown, Y | 4 |
| Schall, S | 4 |
| Pomeranz, A | 1 |
| Korzets, Z | 1 |
| Dolfin, Z | 1 |
| Eliakim, A | 1 |
| Bernheim, J | 1 |
| Wolach, B | 1 |
| Kirsten, D | 1 |
| Cleary, GM | 1 |
| Higgins, ST | 1 |
| Merton, DA | 1 |
| Cullen, JA | 1 |
| Gottlieb, RP | 1 |
| Baumgart, S | 1 |
| Chaet, M | 1 |
| Molinari, F | 1 |
| Engle, W | 1 |
| Engum, SA | 1 |
| West, KW | 1 |
| Rescorla, FJ | 1 |
| Scherer, LR | 1 |
| Robie, DK | 1 |
| Waltrip, T | 1 |
| Pokorny, WJ | 1 |
| Jaksic, T | 1 |
| Takizawa, T | 2 |
| Ikeda, Y | 1 |
| Togashi, H | 1 |
| Yamamoto, M | 1 |
| Arishima, K | 1 |
| Akahori, F | 1 |
| Masaoka, T | 1 |
| Owen, J | 1 |
| Skelly, S | 1 |
| Hauth, JC | 1 |
| Kumar, RK | 1 |
| Yaseen, H | 1 |
| al Umran, K | 1 |
| Ali, H | 1 |
| Rustum, M | 1 |
| Darwich, M | 1 |
| al-Faraidy, A | 1 |
| Kuo, CY | 1 |
| Follens, I | 1 |
| Hartmann, S | 1 |
| Creten, WL | 1 |
| Sato, J | 1 |
| Amizuka, T | 1 |
| Niida, Y | 1 |
| Umetsu, M | 1 |
| Leal, SD | 1 |
| Cavallé-Garrido, T | 1 |
| Farine, D | 1 |
| Heilbut, M | 1 |
| Watanabe, T | 1 |
| Shimizu, M | 4 |
| Yanagisawa, M | 1 |
| Romagnoli, C | 2 |
| Zecca, E | 2 |
| Papacci, P | 2 |
| De Carolis, MP | 2 |
| Giannini, R | 1 |
| Gallini, F | 1 |
| Tortorolo, G | 2 |
| Ng, PC | 1 |
| So, KW | 1 |
| Fok, TF | 2 |
| Yam, MC | 1 |
| Wong, MY | 1 |
| Wong, W | 1 |
| Nguyen, M | 1 |
| Camenisch, T | 1 |
| Snouwaert, JN | 1 |
| Hicks, E | 1 |
| Coffman, TM | 1 |
| Malouf, NN | 1 |
| Koller, BH | 1 |
| Bray, M | 1 |
| Lattanzio, M | 1 |
| Fumagalli, M | 1 |
| Tosetto, C | 1 |
| Hein, HA | 1 |
| Walker, SE | 1 |
| Gray, S | 1 |
| Souter, D | 1 |
| Harding, J | 1 |
| McCowan, L | 1 |
| O'Donnell, C | 1 |
| McLeay, E | 1 |
| Baxendale, H | 1 |
| Lee, CS | 1 |
| Farina, A | 1 |
| Di Luzio, L | 1 |
| Carinci, P | 1 |
| Black, SM | 1 |
| Riemer, RK | 1 |
| Mauray, F | 5 |
| Chen, YQ | 3 |
| Bell, SG | 1 |
| Gupta, P | 1 |
| Humphrey, M | 1 |
| King, G | 1 |
| Perez, CA | 1 |
| Bustorff-Silva, JM | 1 |
| Villasenor, E | 1 |
| Fonkalsrud, EW | 1 |
| Atkinson, JB | 1 |
| Fugelseth, D | 1 |
| Lindemann, R | 1 |
| Liestøl, K | 1 |
| Kiserud, T | 1 |
| Langslet, A | 1 |
| Horigome, H | 1 |
| Patole, S | 1 |
| Whitehall, J | 1 |
| Tammela, O | 2 |
| Ojala, R | 2 |
| Iivainen, T | 1 |
| Lautamatti, V | 1 |
| Pokela, ML | 1 |
| Janas, M | 1 |
| Ikonen, S | 1 |
| Campbell, DE | 3 |
| Narayanan, M | 2 |
| Kang, NS | 1 |
| Yoo, KH | 1 |
| Cheon, H | 1 |
| Choi, BM | 1 |
| Hong, YS | 1 |
| Lee, JW | 1 |
| Kim, SK | 1 |
| Peng, CT | 1 |
| Tsai, CH | 1 |
| Hosono, S | 3 |
| Kimoto, H | 3 |
| Nagoshi, R | 3 |
| Nozawa, M | 3 |
| Hamilton, P | 1 |
| Watterberg, KL | 1 |
| Scott, SM | 1 |
| Backstrom, C | 1 |
| Gifford, KL | 1 |
| Cook, KL | 1 |
| Patchakapati, B | 1 |
| Zaninotto, M | 1 |
| Lachin, M | 1 |
| Altinier, S | 1 |
| Ferrarese, P | 1 |
| Polimeni, V | 1 |
| Piersigilli, F | 1 |
| Delogu, AB | 1 |
| Connett, JE | 1 |
| SoRelle, R | 1 |
| Smets, K | 1 |
| Lecoutere, D | 1 |
| Van de Broek, H | 2 |
| Weyler, J | 2 |
| Degroote, K | 1 |
| Langhendries, JP | 1 |
| Ojima, K | 1 |
| Venema, IM | 1 |
| Bergervoet, M | 1 |
| Zweens, MJ | 1 |
| Pratl, B | 1 |
| van Eykern, LA | 1 |
| Tamura, M | 1 |
| Kadowaki, S | 1 |
| Sasano, T | 1 |
| Van Laer, P | 1 |
| Vanhaesebrouck, P | 1 |
| Edstedt-Bonamy, AK | 1 |
| Milerad, J | 1 |
| Dal Cerè, M | 1 |
| Casalaz, D | 1 |
| Kohl, T | 1 |
| Varma, DR | 1 |
| Suzumura, H | 1 |
| Nitta, A | 1 |
| Tanaka, G | 1 |
| Arisaka, O | 1 |
| Ruuska, T | 1 |
| Karikoski, R | 1 |
| Ikonen, RS | 1 |
| Adamska, E | 1 |
| Weintraub, Z | 1 |
| Solovechick, M | 1 |
| Rotschild, A | 1 |
| Waisman, D | 1 |
| Davkin, O | 1 |
| Bental, Y | 1 |
| Moddemann, D | 1 |
| Saigal, S | 1 |
| Kihara, T | 1 |
| Kamata, A | 1 |
| Niinikoski, H | 1 |
| Alanen, M | 1 |
| Parvinen, T | 1 |
| Aantaa, R | 1 |
| Ekblad, H | 1 |
| Kero, P | 1 |
| Koehne, PS | 1 |
| Bein, G | 1 |
| Alexi-Meskhishvili, V | 1 |
| Weng, Y | 1 |
| Arlettaz, R | 1 |
| Wilkinson, AR | 3 |
| Ohono, T | 1 |
| Goldbarg, SH | 1 |
| Takahashi, Y | 1 |
| Cruz, C | 1 |
| Kajino, H | 1 |
| Liu, BM | 1 |
| Aggarwal, R | 1 |
| Bajpai, A | 1 |
| Jan, SL | 1 |
| Fu, YC | 1 |
| Chai, JW | 1 |
| Chi, CS | 1 |
| Dumas de la Roque, E | 1 |
| Fayon, M | 1 |
| Babre, F | 1 |
| Demarquez, JL | 1 |
| Pedespan, L | 1 |
| Moya, MP | 1 |
| Davey, AM | 1 |
| Brown, YL | 1 |
| Schall, SA | 1 |
| Rubin, LP | 1 |
| Bettiol, T | 1 |
| Salvadori, S | 1 |
| Pitassi, I | 1 |
| Vianello, A | 1 |
| Chiandetti, L | 1 |
| Saia, OS | 1 |
| Robel-Tillig, E | 1 |
| Knüpfer, M | 1 |
| Pulzer, F | 1 |
| Vogtmann, C | 2 |
| Christmann, V | 1 |
| Semmekrot, BA | 1 |
| Quinn, D | 1 |
| Szymankiewicz, M | 1 |
| Gadzinowski, J | 1 |
| Elliott, RB | 1 |
| Starling, MB | 1 |
| Neutze, JM | 1 |
| Sharpe, GL | 3 |
| Senders, RC | 1 |
| Lucas, A | 1 |
| Mitchell, MD | 1 |
| Menzel, K | 1 |
| Schambach, K | 1 |
| Töpke, B | 1 |
| Edwards, DK | 1 |
| Higgins, CB | 2 |
| Altshuler, G | 2 |
| Krous, HF | 1 |
| Altmiller, DH | 1 |
| Kirkpatrick, SE | 4 |
| Ivey, HH | 1 |
| Kattwinkel, J | 1 |
| Park, TS | 1 |
| Krovetz, LJ | 1 |
| Imre, S | 1 |
| Katalin, P | 1 |
| Bartel, J | 1 |
| Kaplan, S | 1 |
| Gaum, WE | 1 |
| Benzing, G | 1 |
| Meyer, RA | 1 |
| Schwartz, DC | 1 |
| Molony, DA | 1 |
| Dipalma, JR | 1 |
| Cooke, RW | 3 |
| Vadapalli, M | 2 |
| Whalley, C | 1 |
| Hirata, T | 2 |
| Brady, JP | 2 |
| Cifuentes, RF | 1 |
| Balfe, JW | 1 |
| Radde, IC | 1 |
| Martin, J | 1 |
| Printz, MP | 2 |
| Messer, J | 1 |
| de Geeter, B | 1 |
| Zach, M | 1 |
| Stix, H | 1 |
| Rosegger, H | 1 |
| Danilevicius, Z | 1 |
| Schrager, GO | 1 |
| Hirschklau, MJ | 2 |
| Csaba, IF | 1 |
| Sulyok, E | 1 |
| Ertl, T | 1 |
| Higgins, C | 1 |
| Friedman, W | 1 |
| Nyhan, WL | 1 |
| Chicoine, R | 1 |
| Rosenfeld, R | 1 |
| Spigelblatt, L | 1 |
| François, J | 1 |
| Hausser, C | 1 |
| Medou, L | 1 |
| Friedman, Z | 1 |
| Demers, LM | 1 |
| Marks, KH | 1 |
| Uhrmann, S | 1 |
| Maisels, MJ | 1 |
| Hoffman, JI | 1 |
| McCarthy, JS | 1 |
| Zies, LG | 1 |
| Gelband, H | 1 |
| Powell, JG | 1 |
| Cochrane, RL | 1 |
| Edmunds, LH | 1 |
| Lines, DR | 1 |
| Söderlund, S | 1 |
| Kyle, JM | 1 |
| Silverman, NH | 1 |
| So, LY | 1 |
| Sung, RY | 1 |
| Ho, JK | 1 |
| Weir, FJ | 1 |
| Littleton, P | 1 |
| Carter, N | 1 |
| Hamilton, PA | 1 |
| Fajardo, CA | 1 |
| Whyte, RK | 1 |
| Steele, BT | 1 |
| Haig, GM | 1 |
| Brookfield, EG | 1 |
| Austin, NC | 1 |
| Pairaudeau, PW | 1 |
| Hames, TK | 1 |
| Hall, MA | 1 |
| Saenger, JS | 1 |
| Mayer, DC | 1 |
| D'Angelo, LJ | 1 |
| Manci, EA | 1 |
| Crawshaw, A | 1 |
| Prietsch, V | 1 |
| Maier, R | 1 |
| Schmitz, L | 1 |
| Sakhalkar, VS | 1 |
| Merchant, RH | 1 |
| Jurko, A | 2 |
| Hlaucová, E | 1 |
| Fedor, M | 1 |
| Klein, T | 1 |
| Balsan, MJ | 1 |
| Jones, JG | 1 |
| Guthrie, RD | 1 |
| Noerr, B | 1 |
| Haywood, JL | 1 |
| FitzGerald, GA | 1 |
| Skinner, JR | 1 |
| Matthes, J | 1 |
| Hey, EN | 1 |
| Hunter, S | 1 |
| Mouzinho, AI | 1 |
| Risser, R | 1 |
| van Ravenswaaij-Arts, CM | 1 |
| van Amen, JP | 1 |
| Stoelinga, GB | 1 |
| van Geijn, HP | 1 |
| Temple, DM | 1 |
| Wender, DF | 1 |
| Satur, CR | 1 |
| Dickinson, DF | 1 |
| Meyers, RL | 1 |
| Alpan, G | 2 |
| Reller, MD | 1 |
| Buffkin, DC | 1 |
| Colasurdo, MA | 1 |
| Rice, MJ | 1 |
| McDonald, RW | 1 |
| Bruckheimer, E | 1 |
| Le Guennec, JC | 1 |
| Lauzière, M | 1 |
| Black, R | 1 |
| Sirois, P | 1 |
| Marino, AJ | 1 |
| Anwar, M | 1 |
| Koons, A | 1 |
| Hiatt, M | 1 |
| Hegyi, T | 1 |
| Ellis, LJ | 1 |
| Coombs, RC | 2 |
| Morgan, ME | 2 |
| Durbin, GM | 2 |
| Booth, IW | 2 |
| McNeish, AS | 2 |
| Flores-Nava, G | 1 |
| Joachín-Roy, H | 1 |
| González-Aguado, ML | 1 |
| Milanesi, O | 2 |
| Rizzo, M | 1 |
| Ronconi, M | 1 |
| Stellin, G | 2 |
| Cantarutti, F | 1 |
| Wyatt, JS | 1 |
| Richardson, C | 1 |
| Potter, A | 1 |
| Cope, M | 1 |
| Delpy, DT | 1 |
| Reynolds, EO | 1 |
| Mardoum, R | 1 |
| Berry, C | 1 |
| Stefano, JL | 1 |
| Abbasi, S | 1 |
| Pearlman, SA | 1 |
| Spear, ML | 1 |
| Esterly, KL | 1 |
| Bhutani, VK | 1 |
| Rennie, JM | 2 |
| Guit, GL | 2 |
| Schipper, J | 2 |
| Baan, J | 3 |
| Wiest, DB | 1 |
| Pinson, JB | 1 |
| Gal, PS | 1 |
| Brundage, RC | 1 |
| Weaver, RL | 3 |
| Purohit, D | 1 |
| Bhakoo, ON | 2 |
| Bidwai, PS | 1 |
| Padmini, P | 1 |
| Wyble, LE | 1 |
| Gilbert, WM | 1 |
| Van Zoeren, D | 1 |
| Van Zwieten, PH | 1 |
| Den Ouden, LL | 1 |
| Aramburo, MJ | 1 |
| Baerts, W | 1 |
| Fetter, WP | 1 |
| Hop, WC | 1 |
| Wallenburg, HC | 1 |
| Spritzer, R | 2 |
| Sauer, PJ | 2 |
| Steinberg, JD | 1 |
| Bambang Oetomo, S | 1 |
| Martijn, A | 1 |
| Davis, JM | 1 |
| Hendricks-Munoz, KD | 1 |
| Hagberg, D | 1 |
| Bird, A | 1 |
| Schuster, V | 1 |
| von Stockhausen, HB | 1 |
| Lundell, BP | 2 |
| Sonesson, SE | 2 |
| Sundell, H | 1 |
| Weninger, M | 2 |
| Pollak, A | 2 |
| Salzer-Muhar, U | 2 |
| Vergesslich, KA | 1 |
| Salzer, HR | 2 |
| Bhatt, V | 1 |
| Nahata, MC | 1 |
| Barst, RJ | 1 |
| Stijnen, T | 1 |
| Ruys, JH | 1 |
| Foti, P | 1 |
| Zambon, P | 1 |
| Strasser, T | 1 |
| Vogel, M | 1 |
| Wolf, WM | 1 |
| Snover, DC | 1 |
| Leonard, AS | 1 |
| Sterniste, W | 1 |
| Fürnkranz, H | 1 |
| Achanti, B | 3 |
| Patel, H | 1 |
| Atad, J | 1 |
| Lissak, A | 1 |
| Rofe, A | 1 |
| Abramovici, H | 1 |
| Krauss, AN | 1 |
| Fatica, N | 1 |
| Lewis, BS | 1 |
| Cooper, R | 1 |
| Thaler, HT | 1 |
| Cirrincione, C | 1 |
| O'Loughlin, J | 1 |
| Levin, A | 1 |
| Engle, MA | 1 |
| Auld, PA | 1 |
| Takao, A | 2 |
| Colditz, P | 1 |
| Murphy, D | 1 |
| Rolfe, P | 1 |
| Morselli, P | 1 |
| Douidar, SM | 1 |
| Richardson, J | 1 |
| Snodgrass, WR | 1 |
| Grubbe, G | 1 |
| Ruckhäberle, KE | 1 |
| Böttcher, H | 1 |
| Ockert, C | 1 |
| Witter, FR | 1 |
| Walters, M | 1 |
| Bandstra, ES | 1 |
| Montalvo, BM | 1 |
| Pacheco, I | 1 |
| Ferrer, PL | 1 |
| Flynn, J | 1 |
| Gregorios, JB | 1 |
| Cassady, G | 1 |
| Gracián, M | 1 |
| Castro, FJ | 1 |
| Nieves, G | 1 |
| Martínez-Villalta, E | 1 |
| Mula, JA | 1 |
| Guia, JM | 1 |
| Szczapa, J | 1 |
| Twarowska, I | 1 |
| Rychlik, K | 1 |
| Sokołowska, K | 1 |
| Hsieh, KS | 1 |
| Tsuei, DH | 1 |
| Meng, CC | 1 |
| Gleason, CA | 1 |
| Leake, R | 1 |
| Marpeau, L | 1 |
| Keskes, J | 1 |
| Vincenti, O | 1 |
| Boyer, F | 1 |
| Bouillie, J | 1 |
| Pigné, A | 1 |
| Barrat, J | 1 |
| Weesner, KM | 1 |
| Dillard, RG | 1 |
| Boyle, RJ | 1 |
| Block, SM | 1 |
| Krueger, E | 1 |
| Bratton, D | 1 |
| Kresch, MJ | 1 |
| Ascuitto, RJ | 1 |
| Ross-Ascuitto, NT | 1 |
| Heusser, F | 1 |
| Appleton, RS | 1 |
| Moreau, GA | 1 |
| Boucek, RJ | 1 |
| Herson, VC | 1 |
| Krause, PJ | 1 |
| Eisenfeld, LI | 1 |
| Pontius, L | 1 |
| Maderazo, EG | 1 |
| Strengers, JL | 1 |
| Kleinman, CS | 2 |
| Gettner, P | 2 |
| Sherwonit, E | 1 |
| Williams, J | 1 |
| Pryds, O | 1 |
| Greisen, G | 1 |
| Johansen, KH | 1 |
| Pongiglione, G | 1 |
| Marasini, M | 1 |
| Silvestri, G | 1 |
| Tuo, P | 1 |
| Ribaldone, D | 1 |
| Bertolini, A | 1 |
| Garello-Cantoni, L | 1 |
| Rhodes, PG | 1 |
| Ferguson, MG | 1 |
| Reddy, NS | 1 |
| Joransen, JA | 1 |
| Gibson, J | 1 |
| Palder, SB | 1 |
| Schwartz, MZ | 1 |
| Tyson, KR | 1 |
| Marr, CC | 1 |
| Zaia, W | 2 |
| Berger, S | 1 |
| Strates, E | 3 |
| Aldousany, A | 1 |
| Valaitis, S | 1 |
| Doyle, J | 1 |
| Anker, R | 1 |
| Quezada, A | 1 |
| Isken, V | 1 |
| Kühl, PG | 2 |
| Maragno, I | 1 |
| Alitto, F | 1 |
| Santostasi, G | 1 |
| Sandri, R | 1 |
| Neri, G | 1 |
| Dorigo, P | 1 |
| Szymonowicz, W | 1 |
| Evans, WN | 1 |
| Cass, KA | 1 |
| Daniel, M | 1 |
| Ho, NK | 1 |
| Valls i Soler, A | 1 |
| Benito, J | 1 |
| López Heredia, I | 1 |
| Santiago, M | 1 |
| Closa Monasterolo, R | 1 |
| Casasín Edo, T | 1 |
| Martín Mesonero, D | 1 |
| Moralejo Beneitez, J | 1 |
| Gómez Papi, A | 1 |
| Allue Martínez, X | 1 |
| Campbell, D | 2 |
| Komar, K | 1 |
| Bui, K | 1 |
| Evans, DH | 1 |
| Levene, MI | 1 |
| Archer, LN | 1 |
| Cowan, F | 1 |
| Spivey, JM | 1 |
| Vargas-Origel, A | 1 |
| Cruz-Anguiano, V | 1 |
| López-Montaño, E | 1 |
| Ho, LY | 1 |
| Silove, ED | 1 |
| Reinhardt, D | 1 |
| Kusenbach, G | 1 |
| Goldberg, SJ | 1 |
| Ramsay, JM | 1 |
| Murphy, DJ | 1 |
| Vick, GW | 1 |
| Courtney, JT | 1 |
| Huhta, JC | 1 |
| Soeding, K | 1 |
| Page, GG | 1 |
| Maher, P | 1 |
| Lane, B | 1 |
| Ballard, R | 1 |
| Piecuch, R | 1 |
| Honda, S | 1 |
| Keller, MS | 1 |
| Chawla, HS | 1 |
| Pitt, BR | 1 |
| Stewart, WB | 1 |
| Sandor, GG | 1 |
| Kashani, IA | 1 |
| Nulton, GD | 1 |
| Sahn, DJ | 1 |
| Eyal, F | 1 |
| Vinograd, I | 1 |
| Udassin, R | 1 |
| Amir, G | 1 |
| Mogle, P | 1 |
| Glick, B | 1 |
| Maresky, D | 1 |
| MacLeod, S | 1 |
| Kühl, G | 1 |
| Bolkenius, M | 1 |
| Caldwell, RL | 1 |
| Girod, DA | 1 |
| Hurwitz, RA | 1 |
| Jansen, RD | 1 |
| Lemons, JA | 1 |
| Schreiner, RL | 1 |
| Wu, HH | 1 |
| Lewis, IG | 1 |
| Harvey, DP | 1 |
| Maxwell, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Utilization Patterns in Neonatal Units in the UK: a Retrospective Pharmaco-epidemiological Study[NCT03773289] | 642,729 participants (Actual) | Observational | 2018-04-20 | Completed | |||
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
| Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)[NCT01630278] | Phase 3 | 363 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Relative Effectiveness and Safety of Pharmacotherapeutic Agents for Patent Ductus Arteriosus (PDA) in Preterm Infants: A National Comparative Effectiveness Research (CER) Project[NCT04347720] | 1,350 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Recruiting | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| Clinical Profile of Neonates Diagnosed by Echocardiography as Having Patent Ductus Arteriousus in Assiut University Hospital for Children[NCT04672629] | 30 participants (Anticipated) | Observational | 2021-04-01 | Not yet recruiting | |||
| Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial[NCT01958320] | Phase 2 | 202 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Should Very Low Birth Weight Infants Receive Enteral Nutrition During Indomethacin or Ibuprofen Treatment of a Patent Ductus Arteriosus? A Multi-Center Randomized Controlled Trial[NCT00728117] | 177 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial[NCT04037514] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants[NCT03537144] | Phase 3 | 37 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Difficulty enrolling patients) | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications[NCT03289390] | 11 participants (Actual) | Observational | 2017-08-01 | Completed | |||
| The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial[NCT02602054] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study[NCT01593163] | Phase 3 | 49 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants[NCT01755728] | Phase 3 | 19 participants (Actual) | Interventional | 2013-01-01 | Completed | ||
| New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates[NCT00616382] | Phase 2 | 68 participants (Anticipated) | Interventional | 2008-03-31 | Not yet recruiting | ||
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
| Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-08-01 | Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.) | ||
| The United States Patent Ductus Arteriosus Registry[NCT04205877] | 5,000 participants (Anticipated) | Observational | 2020-01-01 | Not yet recruiting | |||
| Protecting Brains and Saving Futures - the PBSF Protocol: a Prospective Multicenter and Observational Study on the Use of Telemedicine for Neurocritical Care in High-risk Newborns in Brazil.[NCT03786497] | 2,268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Not yet recruiting | |||
| Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus[NCT00642330] | Phase 4 | 62 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [NCT00000494] | Phase 3 | 0 participants | Interventional | 1978-09-30 | Completed | ||
| Pharmacological Closure of Patent Ductus Arteriosus in Extreme Low Birth Weight Infants. A Comparison of Efficacy, Side Effects and Outcomes Between Indomethacin and Ibuprofen[NCT01758913] | 110 participants (Actual) | Interventional | 2007-02-28 | Completed | |||
| Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial[NCT00033917] | Phase 3 | 630 participants (Actual) | Interventional | 1989-09-30 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study[NCT00589953] | Phase 2 | 22 participants (Actual) | Interventional | 2007-07-31 | Terminated | ||
| Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage[NCT00665769] | 103 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Recruitment was proceeding too slowly) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
duration of gavage feeding assistance (NCT01958320)
Timeframe: up to 20 weeks of age
| Intervention | days (Median) |
|---|---|
| Early Treatment | 76 |
| Conservative Treatment | 80 |
incidence of bacteremia (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 31 |
| Conservative Treatment | 21 |
incidence of bronchopulmonary dysplasia or death (NCT01958320)
Timeframe: determined between 36-37 weeks corrected age
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 60 |
| Conservative Treatment | 56 |
incidence of death (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 20 |
| Conservative Treatment | 10 |
incidence of necrotizing enterocolitis or spontaneous perforation (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 17 |
| Conservative Treatment | 19 |
incidence of pulmonary hemorrhage (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 2 |
| Conservative Treatment | 2 |
number of infants receiving ≥ 14 days of diuretic treatment (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 36 |
| Conservative Treatment | 45 |
number of infants who received dopamine for ≥3 days (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 14 |
| Conservative Treatment | 25 |
Number of infants who undergo in hospital PDA ligations or who have an open ductus at the time of discharge (that need future outpatient cardiology follow-up visits) (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 33 |
| Conservative Treatment | 38 |
the average daily weight gain (NCT01958320)
Timeframe: up to 20 weeks of age
| Intervention | gm/kg/day (Mean) |
|---|---|
| Early Treatment | 22.5 |
| Conservative Treatment | 22.8 |
"the incidence of persistent moderate-to-large PDA shunt 10 days after enrollment The echocardiographic studies included two dimensional imaging, M-mode, color flow mapping and Doppler interrogation as previously described. A moderate-to-large PDA was defined by a ductus internal diameter ≥ 1.5mm (or PDA:left pulmonary artery diameter ratio ≥0.5) and one or more of the following echocardiographic criteria: a) left atrium-to-aortic root (LA/Ao) ratio ≥1.6, b) ductus flow velocity ≤2.5m/sec or mean pressure gradient across the ductus ≤8mm, c) left pulmonary artery diastolic flow velocity > 0.2 m/sec, and/or d) reversed diastolic flow in the descending aorta. Ductus that failed to meet these criteria were considered to be constricted (small or closed) and not eligible for enrollment or treatment." (NCT01958320)
Timeframe: 10 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 43 |
| Conservative Treatment | 78 |
"Infants were eligible for rescue PDA drug treatment if they met one or more of the following prespecified Rescue criteria: 1) Inotrope-dependent hypotension for at least 3 days. 2) Oliguria that persisted for at least 2 days with no obvious cause, other than the moderate PDA, to explain the condition. 3) Requirement for gavage feedings beyond 35 weeks corrected age due to increased work of breathing. 4) Respiratory support needed after the following postnatal ages that surpassed specific minimal ventilation and FiO2 requirements: >15 days (if still required intubation and FiO2 >0.30), >20 days (if still required intubation and FiO2 ≤0.30; or still required Nasal CPAP or Nasal ventilation and FiO2 >0.30), >30 days (if still required Nasal CPAP or Nasal ventilation and FiO2 0.25-0.30), and >45 days (if still required Nasal CPAP or Nasal ventilation and FiO2 <0.25)." (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 32 |
| Conservative Treatment | 61 |
Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age (NCT00033917)
Timeframe: at 5 days
| Intervention | IVH (Number) |
|---|---|
| Indomethacin | 25 |
| Placebo | 40 |
"Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.~There are no subscales to the PPVT. The measurement unit is points on a scale. A score < 70 indicates severely abnormal language function." (NCT00033917)
Timeframe: at 8 years
| Intervention | participants with PPVT score < 70 (Number) |
|---|---|
| Indomethacin - no IVH | 12 |
| Indomethacin - IVH | 5 |
| Placebo - no IVH | 24 |
| Placebo - IVH | 7 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
145 reviews available for indomethacin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen | 2022 |
Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Infa | 2022 |
Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2022 |
Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2022 |
Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2022 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Association of patent ductus arteriosus with fetal factors and endotypes of prematurity.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2023 |
Combination pharmacotherapy for patent ductus arteriosus: Rationale and evidence.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2023 |
Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2023 |
Acetaminophen for the patent ductus arteriosus: has safety been adequately demonstrated?
Topics: Acetaminophen; Cytochrome P-450 CYP2E1; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2023 |
Expectant management of patent ductus arteriosus for preterm infants: A meta-analysis of randomized controlled trials.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2023 |
Therapeutic strategy of patent ductus arteriosus in extremely preterm infants.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Extremely | 2020 |
An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants.
Topics: Administration, Oral; Adrenal Cortex Hormones; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2020 |
To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus | 2019 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2020 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duc | 2020 |
Grading the evidence to identify strategies to modify risk for necrotizing enterocolitis.
Topics: Adrenal Cortex Hormones; Anemia; Anti-Bacterial Agents; Ductus Arteriosus, Patent; Enterocolitis, Ne | 2020 |
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebral Intraventricular Hemorrhage; Chron | 2020 |
Indomethacin for symptomatic patent ductus arteriosus in preterm infants.
Topics: Bias; Bronchopulmonary Dysplasia; Cause of Death; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2021 |
Early closure mechanisms of the ductus arteriosus in immature infants.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Newbo | 2021 |
Acetaminophen Therapy for Persistent Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extremely Prematu | 2021 |
Changes in PDA treatment strategy and respiratory outcomes: Optimal timing of intervention … continuing the long conversation.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin | 2021 |
The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2017 |
Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.
Topics: Biomarkers, Pharmacological; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; | 2018 |
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
Topics: Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to | 2018 |
Prophylactic and early targeted treatment of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature | 2018 |
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Bayes Theorem; Cerebral Hemorrhage | 2018 |
Continued uncertainty regarding treatment of patent ductus arteriosus in premature infants and the role of clinical trials.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 2018 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2018 |
Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus; Ductus Arteriosu | 2018 |
Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: A systematic review and meta-analysis of observational studies.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Ductus Arteriosus, | 2018 |
Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofen; Indometha | 2019 |
Pharmacotherapy for patent ductus arteriosus closure.
Topics: Acetaminophen; Administration, Oral; Antipyretics; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pat | 2019 |
Indomethacin for preterm infants with intracranial hemorrhage.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2013 |
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 2013 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; | 2013 |
Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Blood Flow Velocity; Ductus Arteriosus, Patent | 2013 |
Therapeutic manipulation of the ductus arteriosus: current options and future prospects.
Topics: Ductus Arteriosus, Patent; Female; Forecasting; Hemodynamics; Humans; Ibuprofen; Indomethacin; Infan | 2014 |
Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Dinoprostone; Drug Administration Schedule; Ductus Arteriosus, Patent; Fe | 2014 |
Safety of therapeutics used in management of patent ductus arteriosus in preterm infants.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indo | 2015 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizi | 2015 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2015 |
Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents, Non-Ster | 2016 |
Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Decision Making; Drug Administra | 2016 |
Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates.
Topics: Acetaminophen; Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echoc | 2016 |
Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Extremely Low Bi | 2016 |
Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions.
Topics: Acetaminophen; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; | 2016 |
Pathophysiology of Patent Ductus Arteriosus in the Preterm Infant.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant | 2016 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Hemodynamics; Humans; Ibuprofen; Indomethacin | 2016 |
Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options.
Topics: Biomarkers; Cardiac Catheterization; Conservative Treatment; Cyclooxygenase Inhibitors; Ductus Arter | 2017 |
Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Fetus; Humans; Ib | 2008 |
Therapeutic closure of the ductus arteriosus: benefits and limitations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine; Gestati | 2009 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) in the newborn - which ones?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Hemorrhage; Humans; Ibuprofen; I | 2009 |
Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Confidence Intervals; Ductus A | 2010 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2010 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2010 |
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants.
Topics: Cardiovascular Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprof | 2011 |
Protective strategies to prevent patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Ligation; Tim | 2010 |
Patent ductus arteriosus in preterm infants.
Topics: Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofe | 2011 |
Patent ductus arteriosus: wait and see?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extre | 2011 |
Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Evidence-Based Medicine; Humans; Ibuprofen; In | 2012 |
Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indom | 2012 |
The ductus arteriosus: a refined approach!
Topics: Biomarkers; Cyclooxygenase Inhibitors; Decision Making; Ductus Arteriosus, Patent; Echocardiography; | 2012 |
Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew.
Topics: Acetaminophen; Biomarkers; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2012 |
Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2012 |
Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.
Topics: Acetazolamide; Bumetanide; Drug Therapy, Combination; Ductus Arteriosus, Patent; Extracorporeal Memb | 2012 |
Segmental absence of intestinal musculature: an increasingly reported pathology.
Topics: Abdomen, Acute; Abnormalities, Multiple; Adult; Cesarean Section; Digestive System Abnormalities; Du | 2012 |
[Progresses in treatment of patent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Wei | 2012 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2002 |
Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants.
Topics: Cardiovascular Agents; Dopamine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; I | 2002 |
Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Female; Gestational Age; Hemorrhage; Humans; Indomethacin; Infant, Newbor | 2003 |
The use of ibuprofen in neonates in the treatment of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ibu | 2003 |
Indomethacin for asymptomatic patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Indomethacin; Infan | 2003 |
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 2003 |
Should a prolonged or short course of indomethacin be used in preterm infants to treat patent ductus arteriosus?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2003 |
Is indomethacin or ibuprofen better for medical closure of the patent ductus arteriosus?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; I | 2003 |
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2004 |
The pharmacologic closure of the patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indometh | 2005 |
A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Ductus Arteriosus, Patent; Humans; Ibuprofen; I | 2005 |
[The pharmacological manipulation of Botallo's duct in the duct-dependent congenital cardiopathies and in the preterm infants with respiratory distress. A review and personal findings].
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Angiography; C | 2005 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Indometh | 2005 |
Patent ductus arteriosus: pathophysiology and management.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Comorbidity; Ductus Arteriosus, Patent; Gestatio | 2006 |
Systematic review: intravenous Ibuprofen in preterm newborns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2006 |
Patent ductus arteriosus: evidence for and against treatment.
Topics: Abnormalities, Multiple; Animals; Balloon Occlusion; Ductus Arteriosus, Patent; Female; Follow-Up St | 2007 |
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2007 |
[Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echoca | 2007 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2008 |
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 2008 |
Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; I | 2008 |
Treatment of patent ductus arteriosus: indomethacin or ibuprofen?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Human | 2008 |
The ductus arteriosus: why and how to manipulate its patency.
Topics: Alprostadil; Ductus Arteriosus, Patent; Gestational Age; Heart Defects, Congenital; Humans; Indometh | 1983 |
[Recent advances and future perspectives in the medical treatment of cardiopathies in children].
Topics: Child; Ductus Arteriosus, Patent; Heart Defects, Congenital; Heart Failure; Humans; Hypoxia; Indomet | 1984 |
A reexamination of the role of oxygen in retrolental fibroplasia.
Topics: Anencephaly; Apnea; Carbon Dioxide; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Exchange Transfu | 1984 |
[Prospects for the use of prostaglandins in pediatric cardiology].
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Epoprostenol; Humans; Indom | 1981 |
Preterm parturition. Prostaglandin synthetase inhibitors.
Topics: Amniotic Fluid; Animals; Aspirin; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, P | 1981 |
[Patent ductus arteriosus in premature infants (review of the literature)].
Topics: Aortography; Carbon Dioxide; Digoxin; Diuretics; Ductus Arteriosus, Patent; Echocardiography; Electr | 1982 |
Role of prostaglandins, prostacyclin, and thromboxanes in the control of prenatal patency and postnatal closure of the ductus arteriosus.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Arachidonic Acids; Ductus Arteriosus; Ductus Arteriosus, P | 1980 |
The inhibition of prostaglandin and prostacyclin synthesis in the clinical management of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Epoprostenol; Female; Humans; Indomethacin; Infant, Low Birth Weight; Inf | 1980 |
Effects of prostaglandins, thromboxanes, and inhibitors of their synthesis on renal and gastrointestinal function in the newborn period.
Topics: Adult; Animals; Digestive System Physiological Phenomena; Ductus Arteriosus, Patent; Female; Humans; | 1980 |
Patent ductus arteriosus: current clinical status.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Respiratory Dis | 1980 |
Neonatal manipulation: patent ductus arteriosus.
Topics: Animals; Aorta, Thoracic; Ductus Arteriosus, Patent; Heart Defects, Congenital; Heart Ventricles; Hu | 1981 |
[Prostaglandins and the treatment of congenital heart defects].
Topics: Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Indomethacin; Infant; Infant, Newborn; | 1981 |
The problem of ductal patency in prematures.
Topics: Cardiac Catheterization; Digoxin; Ductus Arteriosus, Patent; Echocardiography; Electrocardiography; | 1981 |
[Pharmacological contraction of the ductus arteriosus (author's transl)].
Topics: Animals; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Prosta | 1981 |
Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1995 |
The fetal ductus arteriosus, a review.
Topics: Betamethasone; Blood Flow Velocity; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Humans; In | 1993 |
Patent ductus arteriosus in the newborn.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1993 |
Drug disposition in neonates with patent ductus arteriosus.
Topics: Absorption; Anti-Bacterial Agents; Digoxin; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 1993 |
Patent ductus arteriosus in the preterm infant.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Prognosis | 1993 |
Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1996 |
Patent ductus arteriosus in the preterm infant.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1996 |
Prophylactic indomethacin: systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Ind | 1996 |
Pharmacokinetics and renal function in preterm infants.
Topics: Betamethasone; Diuretics; Dopamine; Ductus Arteriosus, Patent; Furosemide; Gestational Age; Glomerul | 1996 |
Neonatal cardiovascular pharmacology.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Output; Cardiotonic Agents; Cardiovascular System; | 1998 |
Furosemide in indomethacin-treated infants--systematic review and meta-analysis.
Topics: Blood Urea Nitrogen; Body Water; Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; G | 1999 |
Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2000 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2000 |
The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Ne | 2001 |
NSAID-induced nephrotoxicity from the fetus to the child.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Ductus Arteriosus, Patent; Female; | 2001 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
Comparative tolerability of pharmacological treatments for patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2001 |
Patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Diagnosis, Differential; Ductus Arteriosus, Patent; Echocardiography; Hum | 2001 |
[The patent ductus arteriosus from a perinatological viewpoint].
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fetus; Gastrointestinal Hemorrhage; Growth; Hu | 1978 |
[Drug therapy of patent ductus arteriosus in premature and newborn infants].
Topics: Apnea; Aspirin; Chloroquine; Digitalis Glycosides; Ductus Arteriosus, Patent; Humans; Indomethacin; | 1978 |
Therapeutic advances in pediatric cardiology.
Topics: Adult; Animals; Child; Digitalis Glycosides; Dogs; Ductus Arteriosus; Ductus Arteriosus, Patent; Ech | 1978 |
Prostaglandins: physiological and clinical correlations.
Topics: Animals; Autonomic Nervous System; Blood Circulation; Cricetinae; Dogs; Ductus Arteriosus, Patent; F | 1978 |
The patent ductus arteriosus.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Ductus Arteriosus; Ductus Arteriosus, Patent | 1978 |
Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis.
Topics: Adult; Aortic Valve Stenosis; Contraindications; Ductus Arteriosus; Ductus Arteriosus, Patent; Femal | 1992 |
Persistent patent ductus arteriosus.
Topics: Animals; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1991 |
Maternal, fetal, and neonatal physiology in pregnancy.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Obstetric Labor, | 1990 |
Pharmacologic management of patent ductus arteriosus.
Topics: Digoxin; Diuretics; Ductus Arteriosus, Patent; Fluid Therapy; Humans; Indomethacin; Infant, Newborn | 1989 |
The pharmacological treatment of patent ductus arteriosus. A review of the evidence.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1989 |
Role of indomethacin in ductus closure: an update evaluation.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1988 |
Cardiovascular adaptation in the very immature infant.
Topics: Blood Flow Velocity; Cardiovascular System; Ductus Arteriosus, Patent; Hemodynamics; Humans; Indomet | 1988 |
[Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients].
Topics: Abortion, Threatened; Acute Kidney Injury; Ductus Arteriosus, Patent; Female; Fetal Death; Fetus; Hu | 1988 |
The relationship of symptomatic patent ductus arteriosus to respiratory distress in premature newborn infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Ligat | 1987 |
Patent ductus arteriosus in the neonate.
Topics: Alprostadil; Blood Circulation; Clinical Trials as Topic; Digoxin; Ductus Arteriosus; Ductus Arterio | 1986 |
[Derivatives of arachidonic acid. II. Medical perspectives].
Topics: Aspirin; Dinoprostone; Ductus Arteriosus, Patent; Humans; Immunity, Cellular; Indomethacin; Leukocyt | 1986 |
Patent ductus arteriosus in the premature neonate.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Ligat | 1985 |
[Analogs of prostaglandin-related substances and inhibitors of their formation and metabolism. Clinical application to the pediatric field--arteries and prostaglandins].
Topics: Age Factors; Animals; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Indomethacin; In | 1985 |
Cardiovascular therapy in the newborn.
Topics: Digoxin; Dopamine; Ductus Arteriosus; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; | 1985 |
125 trials available for indomethacin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Platelets and ductus arteriosus closure in neonates.
Topics: Animals; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; | 2023 |
Cardiopulmonary Ultrasound-Guided Treatment of Premature Infants with Respiratory Failure and Patent Ductus Arteriosus: A Randomized, Controlled Trial.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2023 |
iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Acetaminophen; Administration, Intravenous; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethac | 2023 |
A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2021 |
Patent ductus arteriosus shunt elimination results in a reduction in adverse outcomes: a post hoc analysis of the PDA RCT cohort.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2021 |
Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).
Topics: Canada; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Low Birth Weight | 2021 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Oral indomethacin versus oral ibuprofen for treatment of patent ductus arteriosus: a randomised controlled study in very low-birthweight infants.
Topics: Administration, Oral; Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Hu | 2018 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320).
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Conservative Treatment; Ductus Art | 2019 |
Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Humans; Ibuprofen; | 2013 |
A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus.
Topics: Brain; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, Patent; Echocardiography, | 2014 |
Superior mesenteric artery blood flow velocities following medical treatment of a patent ductus arteriosus.
Topics: Blood Flow Velocity; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enteral Nutrition; Female | 2014 |
Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2014 |
Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial.
Topics: Acetaminophen; Administration, Intravenous; Adult; Ductus Arteriosus, Patent; Female; Humans; Indome | 2015 |
Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial.
Topics: Acetaminophen; Administration, Intravenous; Adult; Ductus Arteriosus, Patent; Female; Humans; Indome | 2015 |
Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial.
Topics: Acetaminophen; Administration, Intravenous; Adult; Ductus Arteriosus, Patent; Female; Humans; Indome | 2015 |
Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial.
Topics: Acetaminophen; Administration, Intravenous; Adult; Ductus Arteriosus, Patent; Female; Humans; Indome | 2015 |
Randomized Trial to Compare Renal Function and Ductal Response between Indomethacin and Ibuprofen Treatment in Extremely Low Birth Weight Infants.
Topics: Creatinine; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus; Ductus Arteriosus, Pa | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
A Comparison of Early Ibuprofen and Indomethacin Administration to Prevent Intraventricular Hemorrhage Among Preterm Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Ductus Arte | 2016 |
Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Blood Pressure; Ductus Arteriosus, Pa | 2008 |
Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2008 |
Randomized trial of sterile water by gavage drip in the fluid management of extremely low birth weight infants.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Fluid Therapy; Gestatio | 2009 |
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
Topics: Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; | 2009 |
Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography.
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Echocardiography | 2009 |
Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period.
Topics: Acute Kidney Injury; Creatinine; Cyclooxygenase Inhibitors; Drug Interactions; Ductus Arteriosus, Pa | 2010 |
Effect of indomethacin infused over 30 minutes on cerebral fractional tissue oxygen extraction in preterm newborns with a patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebrum; Ductus Arteriosus, Patent; Female | 2010 |
Effects of prophylactic indomethacin on renal and intestinal blood flows in premature infants.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infan | 2012 |
Ibuprofen prophylaxis in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Hypoxia; Ibup | 2002 |
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2002 |
Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 2003 |
Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Heart Defects, Congenita | 2003 |
Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebrovascular Circulation; Cross-Ove | 2003 |
Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2003 |
A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2003 |
High efficacy and minor renal effects of indomethacin treatment during individualized fluid intake in premature infants with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 2004 |
[Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2005 |
Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.
Topics: Drug Therapy, Combination; Ductus Arteriosus; Ductus Arteriosus, Patent; Enzyme Inhibitors; Female; | 2005 |
Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants.
Topics: Canada; Cost-Benefit Analysis; Ductus Arteriosus, Patent; Health Care Rationing; Humans; Indomethaci | 2006 |
Impact of ibuprofen administration on renal drug clearance in the first weeks of life.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Aspirin; Betamethasone; Birth Weight; Cyclooxygenase I | 2006 |
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.
Topics: Cognition Disorders; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Follow-Up Studies | 2007 |
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.
Topics: Cognition Disorders; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Follow-Up Studies | 2007 |
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.
Topics: Cognition Disorders; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Follow-Up Studies | 2007 |
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.
Topics: Cognition Disorders; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Follow-Up Studies | 2007 |
Near-infrared spectroscopy as a screening tool for patent ductus arteriosus in extremely low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 2007 |
Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardio | 2007 |
Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.
Topics: Analysis of Variance; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus | 2008 |
Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indo | 2007 |
Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
Topics: Administration, Oral; Biological Availability; Cardiovascular Agents; Ductus Arteriosus, Patent; Fem | 2007 |
Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hemorrhage; Humans; Indomethacin; Infant; Infa | 2008 |
Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?
Topics: Blood Flow Velocity; Cerebral Arteries; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Glomer | 2008 |
Decreased plasma glucose after indomethacin therapy in premature infants with patent ductus anteriosus.
Topics: Blood Glucose; Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ind | 1982 |
When to treat the patent ductus arteriosus with indomethacin in very-low-birth-weight infants.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; | 1983 |
Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Fluid Therapy; Hum | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA).
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, | 1983 |
Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus.
Topics: Arginine Vasopressin; Clinical Trials as Topic; Creatinine; Ductus Arteriosus, Patent; Humans; Indom | 1983 |
[Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants].
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1983 |
Surgical closure of patent ductus arteriosus in 268 preterm infants.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Humans; Indomethac | 1984 |
Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin.
Topics: Bronchopulmonary Dysplasia; Child Development; Clinical Trials as Topic; Combined Modality Therapy; | 1984 |
The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus.
Topics: Clinical Trials as Topic; Dopamine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1984 |
Mannheimer lecture.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1982 |
Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Blood Glucose; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1982 |
Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Follow-Up Studies; | 1980 |
Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Electrolytes; Glomerular Filtration Rate; Humans; Indomethacin; Infant, N | 1981 |
Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled study.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Indomethacin; Infa | 1981 |
Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial.
Topics: Bronchial Diseases; Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infan | 1981 |
Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Gastrointestinal Hemorrhag | 1981 |
Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Hemodynamics; Huma | 1982 |
Indomethacin for closure of patent ductus arteriosus in prematures.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembr | 1982 |
Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infant, Newb | 1982 |
Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin; Infant, New | 1982 |
A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management.
Topics: Double-Blind Method; Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newbo | 1981 |
Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Depression, Chemical; Ductus Arteriosus, Patent; E | 1995 |
Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; I | 1993 |
Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: combined near infrared spectrophotometry and Doppler ultrasound study.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Female; Humans; | 1994 |
Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weig | 1994 |
Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial.
Topics: Cerebral Hemorrhage; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; Indome | 1994 |
The hemodynamic effects of antenatal indomethacin and a beta-sympathomimetic agent on the fetus and the newborn: a randomized study.
Topics: Adult; Blood Flow Velocity; Ductus Arteriosus, Patent; Female; Fetal Diseases; Fetus; Gestational Ag | 1993 |
The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus. A randomized double-blind study.
Topics: Adult; Dexamethasone; Double-Blind Method; Ductus Arteriosus, Patent; Female; Gestational Age; Human | 1993 |
Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome.
Topics: Aspirin; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Logistic Models; Prospect | 1995 |
Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room.
Topics: Birth Weight; Ductus Arteriosus, Patent; Electrocardiography; Female; Humans; Indomethacin; Infant, | 1996 |
Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; | 1996 |
Prolonged low-dose indomethacin therapy for patent ductus arteriosus in very low birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Hu | 1997 |
Effects of early indomethacin administration on oxygenation and surfactant requirement in low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Double-Blind Method; Ductus Arteriosus | 1997 |
Treatment of patent ductus arteriosus with ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 1997 |
Furosemide does not prevent indomethacin-induced renal side effects in preterm infants.
Topics: Body Weight; Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Female; Furosemide; Ge | 1997 |
Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Pa | 1997 |
Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Dose-Response Re | 1997 |
Ibuprofen vs indomethacin for treatment of PDA in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Administration Sched | 1998 |
Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Ind | 1999 |
Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 1999 |
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.
Topics: Brain; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newb | 2000 |
Prophylactic indomethacin: factors determining permanent ductus arteriosus closure.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2000 |
Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1999 |
Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Prematu | 2000 |
Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin.
Topics: Cardiovascular Agents; Child Development; Ductus Arteriosus, Patent; Female; Follow-Up Studies; Huma | 2000 |
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Injec | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Art | 2002 |
Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2002 |
The patent ductus arteriosus.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Ductus Arteriosus; Ductus Arteriosus, Patent | 1978 |
Disposition of indomethacin in preterm infants.
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Half-Life; Humans; Indomethacin; Infant, L | 1979 |
Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus.
Topics: Creatinine; Dopamine; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Indomethacin; In | 1992 |
Long-term variability of heart rate increases with successful closure of patent ductus arteriosus in preterm infants.
Topics: Alprostadil; Ductus Arteriosus, Patent; Female; Heart Defects, Congenital; Heart Rate; Humans; Indom | 1992 |
Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography, Doppler; Humans; Indomethacin; Infant, Newborn; Infant, | 1991 |
Symptomatic patent ductus arteriosus following prophylactic indomethacin. A clinical and biochemical appraisal.
Topics: Dinoprostone; Ductus Arteriosus, Patent; Epoprostenol; High-Frequency Ventilation; Humans; Indometha | 1991 |
Ductal patency in neonates with respiratory distress syndrome. A randomized surfactant trial.
Topics: Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Indomethacin; Infant, Newborn; | 1991 |
Effects of indomethacin on cerebral haemodynamics in very preterm infants.
Topics: Blood Gas Monitoring, Transcutaneous; Blood Pressure; Blood Volume; Cerebrovascular Circulation; Dru | 1990 |
Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants.
Topics: Blood Flow Velocity; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Cerebrovascular Circulati | 1991 |
Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity.
Topics: Ductus Arteriosus, Patent; Gastrointestinal Hemorrhage; Humans; Indomethacin; Infant, Newborn; Recur | 1991 |
Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus.
Topics: Birth Weight; Drug Evaluation; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indometha | 1991 |
Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus.
Topics: Birth Weight; Double-Blind Method; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; | 1990 |
[Treatment of patent ductus arteriosus in premature infants by indomethacin].
Topics: Diuresis; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disea | 1987 |
[Effects of early therapy with indomethacin on the manifestation of a persistent ductus arteriosus in extremely underweight premature infants].
Topics: Birth Weight; Clinical Trials as Topic; Drug Administration Schedule; Ductus Arteriosus, Patent; Fem | 1988 |
Inhibition of arachidonic acid metabolism in the perinatal period: pharmacology, clinical application, and potential adverse effects.
Topics: Administration, Oral; Arachidonic Acid; Arachidonic Acids; Aspirin; Clinical Trials as Topic; Cycloo | 1986 |
Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants.
Topics: Birth Weight; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, | 1988 |
Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Random A | 1987 |
Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin.
Topics: Birth Weight; Clinical Trials as Topic; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; | 1987 |
Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weig | 1988 |
Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus.
Topics: Cerebral Hemorrhage; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; Indome | 1988 |
The silent ductus: its precursors and its aftermath.
Topics: 6-Ketoprostaglandin F1 alpha; Bronchopulmonary Dysplasia; Dinoprostone; Ductus Arteriosus, Patent; H | 1986 |
Early administration of indomethacin to preterm infants.
Topics: 6-Ketoprostaglandin F1 alpha; Clinical Trials as Topic; Double-Blind Method; Drug Administration Sch | 1986 |
Patent ductus arteriosus in the neonate.
Topics: Alprostadil; Blood Circulation; Clinical Trials as Topic; Digoxin; Ductus Arteriosus; Ductus Arterio | 1986 |
Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Echocardiography; Follow-Up Studies; Humans; Indomet | 1987 |
Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants.
Topics: 6-Ketoprostaglandin F1 alpha; Cerebral Hemorrhage; Clinical Trials as Topic; Ductus Arteriosus, Pate | 1985 |
Indomethacin therapy on the first day of life in infants with very low birth weight.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Female; Heart Septal Defects; Humans; Indomethacin; | 1985 |
566 other studies available for indomethacin and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants.
Topics: Bronchopulmonary Dysplasia; Child; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; | 2022 |
Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity.
Topics: Consensus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Prem | 2022 |
Neurodevelopment at 5 Years of Age According to Early Screening for Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Child Development; Child, Preschool; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Extrem | 2022 |
Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2022 |
Effect of fetal lung maturation on the treatment of patent ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature; Lung; P | 2023 |
Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis.
Topics: Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Incidence; Indomethacin; Infant, Newborn | 2022 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Predictors of a non-response to prophylactic indomethacin for patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infan | 2023 |
PD(AI): the role of artificial intelligence in the management of patent ductus arteriosus.
Topics: Artificial Intelligence; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, P | 2023 |
Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience.
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indomethacin; Infant, Extr | 2023 |
Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs.
Topics: Acetaminophen; Adult; Cerebral Hemorrhage; Child; Cross-Sectional Studies; Cyclooxygenase Inhibitors | 2023 |
A historical perspective of investigations into the mechanisms and management of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 2023 |
Indomethacin patent ductus arteriosus prophylaxis in the modern era: renal implications.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prematu | 2023 |
Cost-Effectiveness Analysis of Ibuprofen Versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates.
Topics: Acetaminophen; Cost-Effectiveness Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hu | 2023 |
Neonatal acute kidney injury during indomethacin therapy: does it predict ductal closure?
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Ductus Arteriosus, Patent; | 2023 |
EBNEO Commentary: Precision management of the patent ductus arteriosus in micropreemies.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 2023 |
Indomethacin Prophylaxis Is Associated with Reduced Risk of Intraventricular Hemorrhage in Extremely Preterm Infants Born in the Context of Amniotic Infection Syndrome.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; Infant, Extrem | 2023 |
Prophylactic Indomethacin in Infants Born Extremely Preterm: Risks and Benefits Revisited.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; In | 2023 |
Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study.
Topics: Bilirubin; Child; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Fetal Diseases; Hum | 2023 |
Base excess and hematocrit predict response to indomethacin in very low birth weight infants with patent ductus arteriosus.
Topics: Acid-Base Equilibrium; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Hematocrit; Humans; | 2019 |
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Ductus Arteriosus, Patent; Femal | 2019 |
Indomethacin dosing strategy and neonatal patent ductus arteriosus closure.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Female; Gest | 2019 |
Pharmacological closure of the patent ductus arteriosus: when treatment still makes sense.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Decision Making; Ductus Arteriosus, Patent; Humans; Indome | 2019 |
The relationship between antenatal indomethacin as a tocolytic drug and neonatal outcomes: a retrospective cohort study.
Topics: Cohort Studies; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; Infant, Newborn; In | 2021 |
The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Case-Control Studies; Ductus Arteriosus, Pate | 2020 |
Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness.
Topics: Animals; Dopamine; Dopamine Agonists; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fenoldop | 2020 |
High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arte | 2021 |
Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Canada; Cardiovascular Surgical Procedures; Cerebral | 2020 |
Perinatal events predicting retinopathy of prematurity in extremely pre-term infants.
Topics: Birth Weight; Cardiovascular Agents; Cellulitis; Cerebrospinal Fluid Shunts; Continuous Positive Air | 2020 |
Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
Topics: Birth Weight; Cholestasis; Ductus Arteriosus, Patent; Emulsions; Humans; Ibuprofen; Indomethacin; In | 2021 |
Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.
Topics: Acetaminophen; Administration, Oral; Drug Resistance; Drug Utilization; Ductus Arteriosus, Patent; F | 2020 |
Aminoglycosides were associated with higher rates of surgical patent ductus arteriosus closure in preterm infants.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2021 |
Predictors of successful patent ductus arteriosus closure with acetaminophen in preterm infants.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Pre | 2021 |
Outcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin.
Topics: Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; Infant; Infant, Newborn; I | 2021 |
Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2021 |
PATENT DUCTUS ARTERIOSUS CLOSURE: EXPERIENCE FROM A TERTIARY REFERRAL CENTER.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; Indomethacin; | 2020 |
Is ibuprofen superior to indomethacin for patent ductus arteriosus in Japanese preterm infants?
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Low Birth Weight; Infant | 2021 |
Effect of Beta 3 Adrenoreceptor Modulation on Patency of the Ductus Arteriosus.
Topics: Adrenergic beta-3 Receptor Antagonists; Animals; Animals, Newborn; Disease Models, Animal; Disease P | 2020 |
The patent ductus arteriosus management debate: it's not over yet.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Persistent Feta | 2021 |
Evaluation of postoperative complications for patent ductus arteriosus in extremely-low-birthweight infants.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Extremely Low Birth W | 2022 |
Inadvertent irreversible closure of arterial duct following therapeutic use of transplacental indomethacin in a fetus with severe Ebstein's anomaly and circular shunt.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteri | 2021 |
Factors associated with non-response to second course indomethacin for PDA treatment in preterm neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2018 |
Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Conservative Treatment; Cyclooxygenase Inhibitors; Ductu | 2017 |
[Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis; Female; Humans; I | 2017 |
Prophylactic Indomethacin-Is It Time to Reconsider?
Topics: Bronchopulmonary Dysplasia; Conservative Treatment; Ductus Arteriosus, Patent; Humans; Indomethacin; | 2017 |
Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants.
Topics: California; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2017 |
Changes in the Diagnosis and Management of Patent Ductus Arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units.
Topics: Cyclooxygenase Inhibitors; Databases, Factual; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomet | 2017 |
Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cytochrome P-450 CYP2C9; Drug Resista | 2017 |
Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Intraven | 2017 |
Predictors of PDA Treatment in Preterm Neonates Who Had Received Prophylactic Indomethacin.
Topics: Canada; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indom | 2018 |
Early Serum Gut Hormone Concentrations Associated With Time to Full Enteral Feedings in Preterm Infants.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Fetal Growth Retardatio | 2018 |
Is paracetamol as effective as indomethacin or ibuprofen in closing a hemodynamically significant patent ductus arteriosus in preterm infants?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, | 2018 |
Patent ductus arteriosus in preterm infants born before 30 weeks' gestation: high rate of spontaneous closure after hospital discharge.
Topics: Administration, Intravenous; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Follow-Up | 2018 |
Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing.
Topics: Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Glucuronides; Humans; Indomethacin; | 2018 |
Long-Term Neurodevelopment of Low-Birthweight, Preterm Infants with Patent Ductus Arteriosus.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2018 |
Treatment of fetal circular shunt with non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Ebstein Anomaly; Female; Gestati | 2019 |
Survey of preterm neuro-centric care practices in California neonatal intensive care units.
Topics: California; Cross-Sectional Studies; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newbor | 2019 |
What is the Most Efficacious Pharmacological Therapy for Patent Ductus Arteriosus Closure in Premature Infants?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Newborn; | 2018 |
Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; | 2019 |
Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus.
Topics: Acute Kidney Injury; Biomarkers; Cardiovascular Agents; Case-Control Studies; Creatinine; Cross-Sect | 2019 |
Comparative case studies: PDAs treated with medication, surgical ligation, and transcatheter device closure.
Topics: Cardiac Catheterization; Cardiac Surgical Procedures; Cyclooxygenase Inhibitors; Diuretics; Ductus A | 2019 |
Effectiveness and Renal Functions Safety of Treatments Used for Neonates with Patent Ductus Arteriosus: A Prospective Cohort Study.
Topics: Acetaminophen; Acute Kidney Injury; China; Cohort Studies; Ductus Arteriosus, Patent; Female; Humans | 2019 |
Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen | 2019 |
Optimal timing of video-assisted thoracoscopic surgery for patent ductus arteriosus in preterm infants born at ≤ 28 weeks of gestation.
Topics: Age Factors; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, | 2019 |
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
Topics: Case-Control Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2019 |
Reply to letter to the editor: Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Decrease in the frequency of treatment for patent ductus arteriosus after implementation of consensus guidelines: a 15-year experience.
Topics: Cardiac Surgical Procedures; Consensus; Cyclooxygenase Inhibitors; Disease Management; Ductus Arteri | 2019 |
Patent ductus arteriosus treatment in preterm infants-time to consider shunt volume?
Topics: Ductus Arteriosus, Patent; Female; Hospital Mortality; Humans; Indomethacin; Infant, Very Low Birth | 2013 |
Reply to McNamara and Jain.
Topics: Ductus Arteriosus, Patent; Female; Hospital Mortality; Humans; Indomethacin; Infant, Very Low Birth | 2013 |
Prophylactic indomethacin worsens short-term respiratory outcomes in extremely low-birth-weight infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Continuous Positive Airway Pressure; Ductus Arteriosus, | 2014 |
Preservation of the metabolic rate of oxygen in preterm infants during indomethacin therapy for closure of the ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Male; O | 2013 |
B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants.
Topics: Biomarkers; Case-Control Studies; Ductus Arteriosus, Patent; Female; Follow-Up Studies; Hemodynamics | 2013 |
Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8-year retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Breast Feeding; Cohort Studies; Ductus Arteri | 2013 |
Preoperative left ventricular internal dimension in end-diastole as earlier identification of early patent ductus arteriosus operation and postoperative intensive care in very low birth weight infants.
Topics: Cohort Studies; Ductus Arteriosus, Patent; Gestational Age; Heart Ventricles; Humans; Indomethacin; | 2013 |
Novel treatment criteria for persistent ductus arteriosus in neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Heart Ventricles; Humans | 2014 |
Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications.
Topics: Bronchopulmonary Dysplasia; Creatinine; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2014 |
Cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus: effects on cardiac and vascular indices.
Topics: Coronary Vessels; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Female; Ge | 2014 |
Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Animals; Blood Pressure; Cyclooxyg | 2014 |
Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.
Topics: Animals; Chemokine CXCL12; Ductus Arteriosus; Ductus Arteriosus, Patent; Gentamicins; Humans; In Vit | 2014 |
Hospital variation in medical and surgical treatment of patent ductus arteriosus.
Topics: Birth Weight; California; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational | 2015 |
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Ind | 2014 |
Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Creatinine; Ductus Arteriosus, Patent; Female | 2015 |
Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fe | 2015 |
Nil-per-os days and necrotizing enterocolitis in extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Case-Control Studies; Ductus Arteriosus, Patent; En | 2015 |
Indomethacin-Responsive Patent Ductus Arteriosus in an Extremely Preterm Infant at 8 Weeks Postnatal Age.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Extremel | 2015 |
Antioxidants and Biomarkers of Oxidative Stress in Preterm Infants with Symptomatic Patent Ductus Arteriosus.
Topics: Antioxidants; Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibup | 2015 |
The importance of echocardiography and an individual approach to patent ductus arteriosus treatment in extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Adequate timely treatment of patent ductus arteriosus in extremely low birth weight infants: an ongoing challenge.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches.
Topics: Bronchopulmonary Dysplasia; Canada; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Duc | 2015 |
Predictors of successful closure of patent ductus arteriosus with indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Ductus Arteriosus, Patent; Female; Gestatio | 2015 |
A prospective study of maternal preference for indomethacin prophylaxis versus symptomatic treatment of a patent ductus arteriosus in preterm infants.
Topics: Cardiovascular Agents; Decision Support Techniques; Ductus Arteriosus, Patent; Female; Humans; Indom | 2015 |
Future Benefits of Sequential Echocardiography: Unmasking the Indications for Treatment of Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Prophylactic Interventions in Neonatology: How Do They Fare in Real Life?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Canada; Cross Infection; Ductus | 2015 |
Paracetamol in Patent Ductus Arteriosus, "Flavour of the Month" or Here to Stay?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Male | 2015 |
Paracetamol for Closure of Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Male | 2015 |
Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.
Topics: Aorta; DNA; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Gene Expression Regulation, Develo | 2015 |
Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.
Topics: Cardiovascular Agents; Databases, Factual; Ductus Arteriosus, Patent; Female; Gestational Age; Human | 2015 |
Lung function in very preterm infants with patent ductus arteriosus under conservative management: an observational study.
Topics: Continuous Positive Airway Pressure; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; H | 2015 |
Treatment of Patent Ductus Arteriosus with Cyclo-oxygenase Inhibitors beyond 2 Weeks of Age in Very Low Birth Weight Infants.
Topics: Connecticut; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2016 |
Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Drug Administration Schedule; Ductus A | 2016 |
When to Close Patent Ductus arteriosus, The Ideal Time and Rationale.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Male | 2016 |
When to Close Patent Ductus Arteriosus, Authors Reply.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Male | 2016 |
Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children's hospitals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Consensus; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pa | 2016 |
Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes.
Topics: Birth Weight; Canada; Ductus Arteriosus, Patent; Enteral Nutrition; Enterocolitis, Necrotizing; Fema | 2016 |
Quantitative, Noninvasive Assessment of Patent Ductus Arteriosus Shunt Flow by Measuring Proximal Isovelocity Surface Area on Color Doppler Mapping in Very Low-Birth-Weight Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2016 |
Editorial: Patent Ductus Arteriosus in Extremely Premature Neonates.
Topics: Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Do | 2016 |
Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; | 2016 |
Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: a protocol for a systematic review and network meta-analysis.
Topics: Acetaminophen; Administration, Oral; Bayes Theorem; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pa | 2016 |
The Role of Paracetamol for Closing Patent Ductus Arteriosus. A Challenging Alternative for Ductal Closure?
Topics: Acetaminophen; Administration, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorr | 2016 |
Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Databases, Factual; Ductus Arteriosus, Patent; Female; Hospitals, Pediatr | 2016 |
Bedside PDA ligation in premature infants less than 28 weeks and 1000 grams.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; Inf | 2016 |
Effects of Prophylactic Indomethacin on Vasopressor-Dependent Hypotension in Extremely Preterm Infants.
Topics: Cardiovascular Agents; Cohort Studies; Dopamine; Ductus Arteriosus, Patent; Echocardiography; Female | 2017 |
Management of Patent Ductus Arteriosus: Are We Looking at the Right Outcomes?
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Pers | 2017 |
Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Eu | 2017 |
Patent ductus arteriosus in premature infants: to treat or not to treat?
Topics: Conservative Treatment; Cyclooxygenase Inhibitors; Databases, Factual; Disease Management; District | 2017 |
The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates.
Topics: Cardiovascular Surgical Procedures; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, | 2008 |
Role of microsomal prostaglandin E synthase-1 (mPGES1)-derived PGE2 in patency of the ductus arteriosus in the mouse.
Topics: Animals; Carbon Monoxide; Cyclooxygenase Inhibitors; Dinoprostone; Ductus Arteriosus; Ductus Arterio | 2008 |
Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants.
Topics: Birth Weight; Causality; Cohort Studies; Ductus Arteriosus, Patent; Female; Fetal Growth Retardation | 2008 |
Fluid regimens and the risk of patent ductus arteriosus in extremely low birth weight infants.
Topics: Ductus Arteriosus, Patent; Fluid Therapy; Humans; Incidence; Indomethacin; Infant, Extremely Low Bir | 2008 |
Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants.
Topics: Bilirubin; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Hemodynam | 2009 |
[Drug therapy of persistent ductus arteriosus Botalli in the premature infant from the nursing viewpoint].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Ductus Arteriosus, Patent; Echocardiography | 2008 |
Indomethacin and retinopathy of prematurity: the hidden paradox.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Retinopathy of Prematurity; Vasoco | 2008 |
[First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns].
Topics: Age Factors; Brain Diseases; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Diuretics; Ductus Art | 2008 |
Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus.
Topics: Cardiovascular Agents; Chi-Square Distribution; Ductus Arteriosus, Patent; Echocardiography; Female; | 2009 |
Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; | 2009 |
Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus.
Topics: Cohort Studies; Creatinine; Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Female; | 2009 |
Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibito | 2009 |
Fetal reversed constrictive effect of indomethacin and postnatal delayed closure of the ductus arteriosus following administration of transplacental magnesium sulfate in rats.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Drug Ant | 2009 |
The management of patent ductus arteriosus in Australia and New Zealand.
Topics: Australia; Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth | 2009 |
Serum brain natriuretic peptide for prediction of successful medical treatment of patent ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Natriuretic Pep | 2009 |
Hormonal influences of early postnatal indomethacin and ibuprofen in neonatal rats.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Corticosterone | 2010 |
[Patent ductus arteriosus in premature infants].
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hemodynamics; Huma | 2009 |
In vivo dilatation of the ductus arteriosus induced by furosemide in the rat.
Topics: Animals; Animals, Newborn; Cesarean Section; Cyclooxygenase Inhibitors; Dilatation, Pathologic; Dise | 2010 |
Indomethacin and retinopathy of prematurity.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Ductus Arteriosus, P | 2009 |
Prophylactic indomethacin in extremely premature infants between 23 and 24 weeks gestation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Dose-Response Relationship, Drug; Dru | 2010 |
N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Drug Monitoring; Ductus Arteriosus, Patent; Hum | 2010 |
Treatment of the patent ductus arteriosus: when, how, and for how long?
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indometh | 2009 |
Platelets contribute to postnatal occlusion of the ductus arteriosus.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Ductus Arterios | 2010 |
Treatment of patent ductus arteriosus: indomethacin or ibuprofen?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infan | 2010 |
Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Male; Retrospec | 2010 |
Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Biological Products; Coho | 2010 |
Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice.
Topics: Animals; Cardiovascular Agents; Cells, Cultured; Dinoprostone; Disease Models, Animal; Ductus Arteri | 2010 |
Comparison of intravenous and enteral indomethacin administration for closure of patent ductus arteriosus in extremely-low-birth-weight infants.
Topics: Child, Preschool; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; Infant, Extremely | 2010 |
Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus.
Topics: Central Nervous System; Child Development; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arter | 2010 |
Feeding practices and patent ductus arteriosus ligation preferences-are they related?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Enteral Nutrition; | 2010 |
B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus.
Topics: Cardiovascular Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age | 2010 |
Relation between infusion rate of indomethacin and cerebral blood flow velocity.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Female; Humans; Indomet | 2010 |
How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational Age; Humans; | 2010 |
Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Drug Administrati | 2010 |
Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Ligation; Male; Prospectiv | 2010 |
Does indomethacin for closure of patent ductus arteriosus affect cerebral function?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain; Ductus Arteriosus, Patent; Electroencephalography; H | 2010 |
Antenatal indomethacin tocolysis is associated with an increased need for surgical ligation of patent ductus arteriosus in preterm infants.
Topics: Adult; Case-Control Studies; Cohort Studies; Ductus Arteriosus, Patent; Female; Humans; Indomethacin | 2010 |
Antenatal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates.
Topics: Drug Administration Schedule; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Gestational Age; | 2011 |
Global shortage and rationing of indomethacin: need to refine approach.
Topics: Ductus Arteriosus, Patent; Global Health; Health Care Rationing; Humans; Indomethacin; Infant, Newbo | 2010 |
Use of echocardiography to guide the duration of indomethacin treatment of patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Ind | 2010 |
Patent ductus arteriosus management: what are the next steps?
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Ligation | 2010 |
Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; | 2010 |
Patent ductus arteriosus: when does it become a significant lesion for full-term newborns?
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Cardiovascular Agents; Diuretics; Ductus Arteriosus | 2010 |
Management of patent ductus arteriosus in term or near-term neonates with respiratory distress.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Cardiotonic Agents; Cardiovascular Agents; Diuret | 2010 |
Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Female; Gestationa | 2010 |
Clinical aspects of very-low-birthweight infants showing reopening of ductus arteriosus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Duc | 2011 |
Patent ductus arteriosus in mice with smooth muscle-specific Jag1 deletion.
Topics: Animals; Animals, Newborn; Calcium-Binding Proteins; Cardiovascular Agents; Cell Differentiation; Du | 2010 |
Doppler manifestations of ductal steal: role in decision making.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Hemodynamics; Humans; Indomethacin; Infant, Newborn; I | 2011 |
Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus.
Topics: Aquaporin 2; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibup | 2011 |
Relationship between circulating platelet counts and ductus arteriosus patency after indomethacin treatment.
Topics: Cardiovascular Agents; Cohort Studies; Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiograph | 2011 |
Indomethacin prophylaxis revisited: changing practice and supportive evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Clinical Trials as Topic; Ductus Art | 2011 |
The patent ductus arteriosus ligation decision.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; Huma | 2011 |
Why would a sane clinician not prescribe prophylactic indomethacin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Clinical Trials as Topic; Ductus Art | 2011 |
Patent ductus arteriosus in the preterm infant: a survey of clinical practices in French neonatal intensive care units.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Data Collection; Dose-Response Relations | 2011 |
Treatment of patent ductus arteriosus with bidirectional flow in neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Ductus Arteriosus, Patent; Echocardiography | 2011 |
N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indome | 2011 |
Cerebral oxygenation during different treatment strategies for a patent ductus arteriosus.
Topics: Brain; Cerebrovascular Circulation; Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiography; | 2011 |
Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Creatinine; Ductus Arteriosus, Patent; Fema | 2011 |
Indomethacin impairs coronary perfusion in infants with hemodynamically significant ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Coronary Circulation; Ductus Arteriosus, Patent; Echocardio | 2012 |
What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?
Topics: Cardiac Surgical Procedures; Cohort Studies; Combined Modality Therapy; Cyclooxygenase Inhibitors; D | 2012 |
A decision aid for considering indomethacin prophylaxis vs. symptomatic treatment of PDA for extreme low birth weight infants.
Topics: Adult; Bronchopulmonary Dysplasia; Cardiovascular Agents; Decision Support Techniques; Ductus Arteri | 2011 |
Update on management of patent ductus arteriosus in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Topics: Chronic Disease; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; | 2012 |
Patent ductus arteriosus in infants <29 weeks gestation--outcomes and factors affecting closure.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Extremely Pr | 2012 |
Patent ductus arteriosus: mechanisms and management.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; History, 16th Century; H | 2012 |
Oral ibuprofen for patent ductus arteriosus: effective and safe or just cheap? Commentary on R. Neumann et al.: Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a sys
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2012 |
Increased urinary podocytes following indomethacin suggests drug-induced glomerular injury.
Topics: Anti-Bacterial Agents; Cardiovascular Agents; Drug Therapy, Combination; Ductus Arteriosus, Patent; | 2012 |
Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants.
Topics: Analysis of Variance; Bronchopulmonary Dysplasia; Cardiac Surgical Procedures; Case-Control Studies; | 2012 |
Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?
Topics: Analysis of Variance; Blood Gas Analysis; Cerebrovascular Circulation; Chi-Square Distribution; Chro | 2012 |
Patent ductus arteriosus in premature neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2012 |
Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine | 2012 |
Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Developmental Disabilities; Ductus Arteriosus, Paten | 2013 |
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Ductus Arte | 2012 |
Urinary NT-proBNP and ductal closure in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Creatine; Ductus Arteriosus, Patent; Echocardio | 2013 |
Oral ibuprofen for treatment of patent ductus arteriosus: more than a cheap alternative?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2012 |
Surgical ligation of the patent ductus arteriosus: treatment or morbidity?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin | 2012 |
Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus.
Topics: Age Factors; Blindness; Cardiovascular Agents; Cerebral Palsy; Child, Preschool; Combined Modality T | 2012 |
Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Humans; Ibu | 2012 |
Early versus conventional treatment for patent ductus arteriosus in preterm infants.
Topics: Cardiovascular Agents; Chi-Square Distribution; Cohort Studies; Dose-Response Relationship, Drug; Dr | 2013 |
Comparative evaluation for the use of oral ibuprofen and intravenous indomethacin in Korean infants with patent ductus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Ductus Arteriosus, Paten | 2012 |
The impact of patent ductus arteriosus in neonates with late onset sepsis: a retrospective matched-case control study.
Topics: Age Factors; Bronchopulmonary Dysplasia; Case-Control Studies; Databases, Factual; Ductus Arteriosus | 2012 |
Effects of indomethacin on patent ductus arteriosus in neonates with genetic disorders and/or congenital anomalies.
Topics: Chromosomes, Human, Pair 18; Cyclooxygenase Inhibitors; Down Syndrome; Ductus Arteriosus, Patent; Ga | 2013 |
Decline in health status of extremely premature neonates with patent ductus arteriosus after second course of medical therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Ductus Arteriosus, Patent; Hea | 2013 |
Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants.
Topics: Administration, Intravenous; Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necroti | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
The effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus in the neonate.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Indometha | 2002 |
Ibuprofen for closure of patent ductus arteriosus: is it really safe in hyperbilirubinaemic infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Hyperbilirubinemia; Ibup | 2003 |
Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome.
Topics: Child; Child, Preschool; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, P | 1982 |
Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus.
Topics: Birth Weight; Cardiac Surgical Procedures; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteroc | 2003 |
Prophylactic indomethacin reduces grades III and IV intraventricular hemorrhages when compared to early indomethacin treatment of a patent ductus arteriosus.
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Ductus Arteri | 2003 |
Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Genotype; Gestational Age; Humans; Indomet | 2003 |
Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography, Doppler, Color; Hemodynamics; Humans; Indomethacin; Inf | 2003 |
Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin.
Topics: Cardiovascular Agents; Chorioamnionitis; Ductus Arteriosus, Patent; Echocardiography, Doppler; Femal | 2003 |
Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Human | 2003 |
A preliminary study on pharmacokinetics of oral indomethacin in premature infants in north India.
Topics: Administration, Oral; Birth Weight; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans | 2003 |
Pharmacological knockout of endothelin ET(A) receptors.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aor | 2003 |
Surgical management of congenital cardiac defects in neonates and young infants born with extremely low weight.
Topics: Alprostadil; Cardiac Surgical Procedures; Catecholamines; Ductus Arteriosus, Patent; Heart Defects, | 2003 |
Indomethacin and renal impairment in neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Creatinine; Ductus Arteriosus, Patent; Female | 2004 |
Indomethacin therapy for patent ductus arteriosus in premature infants: efficacy of a dosing strategy based on a second-dose peak plasma indomethacin level and estimated plasma indomethacin levels.
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Female; Humans; | 2004 |
Indomethacin-induced early patent ductus arteriosus closure cannot be predicted by a decrease in pulse pressure.
Topics: Blood Pressure; Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low | 2004 |
Age-dependent cerebral hemodynamic effects of indomethacin in the newborn piglet.
Topics: Adaptation, Physiological; Aging; Animals; Animals, Newborn; Blood Volume; Brain; Cardiovascular Age | 2004 |
Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; Infant, Newb | 2004 |
Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2005 |
Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats.
Topics: Animals; Anti-Inflammatory Agents; Dexamethasone; Drug Evaluation, Preclinical; Drug Therapy, Combin | 2005 |
Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants.
Topics: Cardiovascular Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration S | 2005 |
Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen | 2005 |
Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.
Topics: Cardiovascular Agents; Cause of Death; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; I | 2005 |
Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis.
Topics: Cause of Death; Cohort Studies; Critical Care; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2005 |
Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Cyclooxygenase 2 Inhibitors; Ductus A | 2005 |
In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Animals, Newborn; Cyclic Nucleotide Phosphodiesterases | 2006 |
Determination of indomethacin in plasma by micellar electrokinetic chromatography with UV detection for premature infants with patent ducts arteriosus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Calibration; Chromatography, Micellar | 2006 |
Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Ne | 2005 |
A rapid and sensitive microscale HPLC method for the determination of indomethacin in plasma of premature neonates with patent ductus arteriousus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calibration; Chromatography, High Pressure Liquid; Ductus A | 2006 |
Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Gestational Age; Hu | 2006 |
Management of patent ductus arteriosus in preterm infants.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography, Doppler, Pulsed; Gestational Age | 2006 |
Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prematu | 2006 |
Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth.
Topics: Brain; Brain Damage, Chronic; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Gestational Age; | 2006 |
High-dose indomethacin for patent ductus arteriosus closure: how strong is the evidence?
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2006 |
Indomethacin-associated neutropenia with subsequent Gram-negative sepsis in a preterm infant. Cause or coincidence?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterobacter cloacae; Enterobacteriaceae Infection | 2006 |
Treatment to prevent patency of the ductus arteriosus: beneficial or harmful?
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates.
Topics: Case-Control Studies; Dexamethasone; Ductus Arteriosus, Patent; Female; Humans; Hypotension; Indomet | 2006 |
Does patent ductus arteriosus affect feed tolerance in preterm neonates?
Topics: Age Factors; Analysis of Variance; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteral Nutriti | 2007 |
Predictors of failed closure of patent ductus arteriosus with indomethacin.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Empirical Research; Female; Humans; Indomethac | 2006 |
The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Extremely Low Bi | 2007 |
Effect of indomethacin on closure of ductus arteriosus in very-low-birthweight neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2006 |
Lenticulostriate vasculopathy in twin-to-twin transfusion syndrome.
Topics: Basal Ganglia Cerebrovascular Disease; Cardiovascular Agents; Continuous Positive Airway Pressure; D | 2006 |
Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Ductus Arteriosus, Patent; Humans; In | 2007 |
Renal impairment associated with indomethacin treatment for patent ductus arteriosus in extremely preterm neonates--is postnatal age at start of treatment important?
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Ductus Arteriosus, Patent; Female; | 2006 |
Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes.
Topics: Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 2007 |
Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?
Topics: Cerebral Hemorrhage; Comorbidity; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, N | 2007 |
[Effect of correlative factors for indomethacin treatment of hemodynamically significant patent ductus arteriosus in extremely low birth weight infants].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Extremely Low Birth Weight; Infant, Newborn | 2007 |
Is refractory hypotension in preterm infants a manifestation of early ductal shunting?
Topics: Anti-Inflammatory Agents; Birth Weight; Drug Administration Schedule; Ductus Arteriosus, Patent; Fem | 2007 |
The safety of prolonged indomethacin therapy.
Topics: Adolescent; Adult; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Ductus Arteriosu | 2007 |
A preliminary report--heparin counteracts indomethacin effect on ductus arteriosus in very low birthweight infants.
Topics: Anticoagulants; Cardiovascular Agents; Catheterization, Central Venous; Drug Antagonism; Ductus Arte | 2007 |
Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2007 |
The effects of caffeine on the preterm sheep ductus arteriosus.
Topics: Animals; Caffeine; Cardiovascular Agents; Cyclooxygenase Inhibitors; Dose-Response Relationship, Dru | 2007 |
Risk factors for persistent ductus arteriosus patency during indomethacin treatment.
Topics: Betamethasone; Cohort Studies; Ductus Arteriosus, Patent; Gestational Age; Glucocorticoids; Humans; | 2007 |
Multiple courses of indomethacin and neonatal outcomes in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Ductus Arteriosus, Patent; Human | 2008 |
Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Animals, Newborn; Animals, Suckling; Cyclooxy | 2008 |
Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants.
Topics: Blood Gas Analysis; Cardiac Surgical Procedures; Case-Control Studies; Cerebrovascular Circulation; | 2008 |
The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates: size matters.
Topics: Cardiovascular Surgical Procedures; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, | 2008 |
Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2008 |
Evidence for active closure of patent ductus arteriosus in very preterm infants.
Topics: Ductus Arteriosus, Patent; Female; Hemothorax; Humans; Indomethacin; Infant, Newborn; Infant, Premat | 2008 |
Patent ductus arteriosus in preterm neonates.
Topics: Cardiovascular Agents; Diagnosis, Differential; Ductus Arteriosus, Patent; Fluid Therapy; Humans; In | 2008 |
A third course of indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Ne | 2008 |
Indomethacin therapy for patent ductus arteriosus in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomet | 2008 |
Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit.
Topics: Cardiac Catheterization; Cardiovascular Agents; Ductus Arteriosus, Patent; Electrocardiography; Epid | 2009 |
Timing of indomethacin therapy in persistent ductus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Time Factors | 1980 |
PG-synthetase inhibitors in obstetrics and after.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, | 1980 |
Indomethacin for persistent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1980 |
Timing of indomethacin in patent ductus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Time Factors | 1980 |
Patent ductus and indomethacin.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn | 1981 |
[Indomethacin for closure of persisting ductus arteriosus in the premature infant].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Prost | 1981 |
Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Epoprostenol; Female; Humans; Indomethacin; Infant, Low Birth Weight; Inf | 1983 |
Evaluation of adverse renal reactions to prolonged indomethacin therapy in preterm infants with persistent ductus arteriosus.
Topics: Blood Volume; Body Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Use of ibuprofen in unusual circumstances.
Topics: Arthritis, Rheumatoid; Aspirin; Bartter Syndrome; Cyclooxygenase Inhibitors; Digoxin; Drug Hypersens | 1984 |
Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1984 |
Digoxin and indomethacin in preterm infants with PDA.
Topics: Digoxin; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseas | 1984 |
Prostaglandin synthesis inhibition in persistent pulmonary hypertension of the newborn.
Topics: Animals; Blood Pressure; Ductus Arteriosus, Patent; Female; Fetus; Humans; Hypertension, Pulmonary; | 1984 |
Management of the premature infant with a patent ductus arteriosus.
Topics: Blood Transfusion; Cardiac Catheterization; Digoxin; Diuresis; Ductus Arteriosus, Patent; Echocardio | 1984 |
Combined noninvasive assessment of the patent ductus arteriosus in the preterm infant before and after indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1984 |
[Efficacy of indomethacin in the closure of patent ductus arteriosus in premature newborn infants with cardiac insufficiency. Analysis of 14 cases].
Topics: Birth Weight; Ductus Arteriosus, Patent; Electrocardiography; Heart Failure; Heart Murmurs; Humans; | 1984 |
Urinary excretion rates of 6-keto-PGF1 alpha in preterm infants recovering from respiratory distress with and without patent ductus arteriosus.
Topics: 6-Ketoprostaglandin F1 alpha; Alprostadil; Dinoprost; Dinoprostone; Ductus Arteriosus, Patent; Femal | 1984 |
[Presumed side effects of indomethacin in 2 premature infants].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; | 1983 |
[Pharmacologic treatment of patent ductus arteriosus in premature infants].
Topics: Age Factors; Diuresis; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 1983 |
Management of patent ductus arteriosus in the premature infant: indomethacin versus ligation.
Topics: Anesthesia, Local; Birth Weight; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; | 1983 |
[Persistent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prematu | 1983 |
[Indomethacin treatment of persistent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Respi | 1983 |
[Surgical ligation of patent ductus arteriosus in the very-low-birth-weight premature infant].
Topics: Anesthesia, General; Body Temperature; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low | 1983 |
Indomethacin versus immediate ligation in the treatment of 82 newborns with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Ligation; Male; Prognosis; | 1983 |
Aortic flow velocity curves in the diagnosis and the followup of symptomatic patent ductus arteriosus in preterm infants during therapeutic interventions.
Topics: Aorta, Thoracic; Blood Flow Velocity; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newbo | 1983 |
The management of patient ductus arteriosus in very low birthweight infants.
Topics: Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infant; Infant, Low Birth Weight; Infan | 1983 |
Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia.
Topics: Alprostadil; Animals; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Ibuprofen; Indomet | 1983 |
The influence of indomethacin on retinopathy of prematurity.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Retinopathy of Prematurity | 1983 |
Cross sectional echocardiography in determining persistent patency of the ductus arteriosus in preterm infants.
Topics: Age Factors; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Indomethacin; Inf | 1984 |
Liquid-chromatographic determination of indomethacin in blood from newborns with patent ductus arteriosus.
Topics: Chromatography, High Pressure Liquid; Ductus Arteriosus, Patent; Humans; Hydrogen-Ion Concentration; | 1984 |
Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Low Birth Weight; | 1984 |
Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Glomerular Filtration Rate; Humans; Indomethacin; Infant, Newborn; Infant | 1984 |
Effects of indomethacin on digoxin pharmacokinetics in preterm infants.
Topics: Digoxin; Drug Therapy, Combination; Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infa | 1984 |
Intravenous indomethacin for patent ductus arteriosus.
Topics: Age Factors; Birth Weight; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indometh | 1984 |
Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus.
Topics: Bleeding Time; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Hemorrhage; Humans; Indometha | 1984 |
Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Indomethaci | 1980 |
Patent ductus arteriosus in premature babies.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Female; Gastrointestinal Hemorrhage; Humans; Indome | 1982 |
Patent ductus arteriosus in premature babies.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1981 |
[Therapeutic problems with indomethacin in preterm infants with persistent ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Kidne | 1983 |
Exacerbation of Cushing's disease during pregnancy.
Topics: Adrenal Glands; Adult; Cushing Syndrome; Ductus Arteriosus, Patent; Female; Glucocorticoids; Humans; | 1983 |
Indomethacin treatment in small versus large premature infants with ductus arteriosus. Comparison of plasma indomethacin concentration and clinical response.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, D | 1983 |
Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
Topics: Alprostadil; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Hypoxia; Indomethacin; In | 1982 |
Prostaglandins and the management of congenital heart disease.
Topics: Age Factors; Alprostadil; Cardiovascular Diseases; Central Nervous System Diseases; Ductus Arteriosu | 1982 |
The contribution of PDA in the neonate with severe RDS.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Phospholipids; | 1980 |
Pharmacokinetics of oral and intravenous indomethacin in preterm infants.
Topics: Administration, Oral; Adult; Ductus Arteriosus, Patent; Gestational Age; Half-Life; Humans; Indometh | 1980 |
Pharmacokinetics of indomethacin in the premature infant.
Topics: Creatinine; Ductus Arteriosus, Patent; Female; Half-Life; Humans; Indomethacin; Infant, Newborn; Inf | 1980 |
Ductus arteriosus: developmental response to endogenous prostaglandins, oxygen, and indomethacin.
Topics: Animals; Ductus Arteriosus; Ductus Arteriosus, Patent; Epoprostenol; Female; Gestational Age; Indome | 1980 |
[Closure of persistent ductus arteriosus in premature infants by drug therapy].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Inter | 1981 |
Oral aqueous suspension of indomethacin should be abandoned.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Suspensions; | 1982 |
Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy.
Topics: Body Height; Body Weight; Bronchopulmonary Dysplasia; Child Development; Child, Preschool; Ductus Ar | 1982 |
Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem | 1982 |
Early indomethacin in patent ductus of the very small premature.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Infan | 1982 |
Prophylactic indomethacin for patent ductus arteriosus.
Topics: Body Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Postoperative Complic | 1982 |
Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure.
Topics: Bacterial Infections; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Half-Life; Humans | 1982 |
Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants.
Topics: Age Factors; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Paten | 1982 |
[Treatment of patent ductus arteriosus in preterm infants].
Topics: Digoxin; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Indomethacin; Infant, Low Birth Weig | 1982 |
[Ductus arteriosus persistens in the newborn with respiratory distress syndrome. Experience with indomethacin and operative ligation].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Ligation; Respiratory Distress Syn | 1982 |
Patent ductus arteriosus: recent advances in diagnosis and management.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn | 1982 |
Patent ductus arteriosus in premature infants: a review of current management.
Topics: Ductus Arteriosus, Patent; Heart Failure; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1982 |
[Treatment of premature labor with indomethacin and its effect on the fetus].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Obstetric Labor, Premature | 1982 |
[An alternative in the management of patent ductus arteriosus using indomethacin in premature newborn infants].
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Inf | 1982 |
Pharmacology of the ductus arteriosus.
Topics: Animals; Aorta, Thoracic; Cattle; Ductus Arteriosus; Ductus Arteriosus, Patent; Gestational Age; Hea | 1981 |
Effects of prostaglandins and inhibitors of prostaglandin synthesis in the fetus and newborn infant.
Topics: Animals; Blood Circulation; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fetus; Humans; Ind | 1981 |
Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Half-Life; Humans; Indomethacin; Kinetics; Mal | 1981 |
Indomethacin and the patent ductus arteriosus.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1981 |
Indomethacin for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1981 |
Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1981 |
Gastrointestinal perforation following indomethacin therapy in very low birth weight infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1981 |
A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus.
Topics: Administration, Oral; Biological Availability; Ductus Arteriosus, Patent; Humans; Indomethacin; Infa | 1981 |
The ductus arteriosus in the preterm infant: histologic and clinical observations.
Topics: Ductus Arteriosus, Patent; Fetus; Gestational Age; Humans; Indomethacin; Infant, Newborn; Infant, Pr | 1980 |
Inulin clearance in the premature infant receiving indomethacin.
Topics: Ductus Arteriosus, Patent; Glomerular Filtration Rate; Humans; Indomethacin; Infant, Newborn; Infant | 1980 |
Plasma indomethacin levels in preterm newborns with symptomatic patent ductus arteriosus: clinical and echocardiographic assessments of response.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1980 |
Management of patent ductus arteriosus in preterm babies.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Heart Failure; Humans; Indomethacin; Infant, N | 1980 |
[Closure of ductus arteriosus by drug therapy and indomethacin dosage].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn | 1980 |
Gastric perforation associated with indomethacin therapy in a pre-term infant.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, | 1980 |
Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1980 |
Pharmacological closure of ductus arteriosus in preterm infants using indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1980 |
Toxic digitalis levels associated with indomethacin therapy in a neonate.
Topics: Creatinine; Digoxin; Ductus Arteriosus, Patent; Heart Failure; Humans; Indomethacin; Infant, Newborn | 1980 |
Patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Heart Failure; Humans; Hyaline Membrane Disease; Indomethacin; Infant, Ne | 1980 |
Use of indomethacin and its relationship to retinopathy of prematurity in very low birthweight infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1980 |
[Ductus ligation in idiopathic respiratory distress syndrome of the premature infant].
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Inf | 1980 |
The disposition of indomethacin in preterm babies.
Topics: Age Factors; Ductus Arteriosus, Patent; Female; Half-Life; Humans; Indomethacin; Infant, Newborn; In | 1980 |
Pharmacokinetics of intravenously administered indomethacin in premature infants.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; In | 1980 |
Patent ductus arteriosus in infants of low birth weight.
Topics: Ductus Arteriosus, Patent; Female; Heart Failure; Humans; Indomethacin; Infant, Low Birth Weight; In | 1980 |
Ibuprofen treatment of patent ductus arteriosus.
Topics: Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; I | 1995 |
Closure of patent ductus arteriosus decreases pulmonary myeloperoxidase in premature infants with respiratory distress syndrome.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; I | 1995 |
Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational Age; Humans; Ind | 1995 |
[Renal effects of prolonged indomethacin therapy in premature infants].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; I | 1994 |
Predicting oliguria following indomethacin for treatment of patent ductus arteriosus.
Topics: Creatinine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dis | 1994 |
Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus.
Topics: Anthropometry; Aorta, Thoracic; Ductus Arteriosus, Patent; Echocardiography, Doppler; Heart Atria; H | 1994 |
[Care of a premature infant in indomethacin therapy with an open ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1994 |
Neonatal complications after the administration of indomethacin for preterm labor.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; Fetus; Huma | 1993 |
Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1993 |
Allopurinol protects the bowel from necrosis caused by indomethacin and temporary intestinal ischemia in mice.
Topics: Allopurinol; Animals; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Gastric Lavage; In | 1993 |
Effect of dopamine on indomethacin-induced impairment of renal function in preterm neonates.
Topics: Dopamine; Drug Interactions; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infan | 1993 |
Change in blood pressure after treatment of patent ductus arteriosus with indomethacin.
Topics: Blood Pressure; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; | 1993 |
Criteria for use of indomethacin injection in neonates.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1993 |
Ductus arteriosus ligation without a tube thoracostomy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Ductus Arteriosus, Patent; Human | 1995 |
Acute effects of indomethacin on cerebral hemodynamics and oxygenation.
Topics: Blood Gas Monitoring, Transcutaneous; Blood Pressure; Blood Volume; Brain; Carbon Dioxide; Cerebrova | 1995 |
Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn | 1996 |
Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent.
Topics: Acute Kidney Injury; Adult; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn | 1996 |
Developmental changes in renal artery blood flow velocity during the first three weeks of life in preterm neonates.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Abdominal; Blood Flow Velocity | 1996 |
Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight?
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cerebral Ventricles; Chemotherapy, Adjuvant; Cycloo | 1996 |
Drug induced closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; | 1996 |
Inhibitory effect of indomethacin on neonatal lung catabolism of prostaglandin E2: possible mechanism of the re-opening of the ductus arteriosus after indomethacin therapy.
Topics: Animals; Dinoprostone; Ductus Arteriosus, Patent; Female; Hydroxyprostaglandin Dehydrogenases; Indom | 1996 |
Preterm delivery after indomethacin. A risk factor for neonatal complications?
Topics: Cohort Studies; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; Hemorrhage; Huma | 1996 |
Treatment of patent ductus arteriosus with low-dose indomethacin in very low birth weight neonates with impairment of renal function: report of three cases.
Topics: Adult; Blood Urea Nitrogen; Contraindications; Creatinine; Ductus Arteriosus, Patent; Female; Gestat | 1996 |
Simple, rapid and sensitive method for the determination of indomethacin in plasma by high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Ductus Arteriosus, Patent; Humans; Indomethac | 1997 |
Isolated ductal closure in utero diagnosed by fetal echocardiography.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Choroid Plexus; Cysts; Ductus Arterios | 1997 |
Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 1997 |
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth.
Topics: Animals; Animals, Newborn; Dinoprostone; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fetus | 1997 |
Indomethacin tocolysis.
Topics: Contraindications; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational Age; Humans; Ind | 1998 |
Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Packaging; Drug Stability; Drug Storage; Ductus Arteri | 1998 |
Antenatal indomethacin--adverse fetal effects confirmed.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Infant | 1998 |
Symptomatic patent ductus arteriosus in very low birth weight infants.
Topics: Ductus Arteriosus, Patent; Humans; Incidence; Indomethacin; Infant, Newborn; Infant, Very Low Birth | 1998 |
Fetal ductus arteriosus constriction, indomethacin, and gestational age.
Topics: Blood Flow Velocity; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Tocolytic Age | 1998 |
Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension, and vasa vasorum.
Topics: Aminoquinolines; Animals; Aorta; Calcimycin; Ductus Arteriosus; Ductus Arteriosus, Patent; Enzyme In | 1998 |
Re: The debate regarding the risks of tocolytic agents.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Kidney | 1998 |
Surgical ligation of patent ductus arteriosus in very low birth weight infants: is it safe?
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1998 |
Indomethacin tocolysis increases postnatal patent ductus arteriosus severity.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, | 1998 |
Postnatal closure of ductus venosus in preterm infants < or = 32 weeks. An ultrasonographic study.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gestational Age; Humans; | 1998 |
The contracted type of endocardial fibroelastosis.
Topics: Disease Progression; Ductus Arteriosus, Patent; Echocardiography; Endocardial Fibroelastosis; Fatal | 1999 |
Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Fatal Outcome; Humans | 1998 |
Incidence and outcome of a 10-fold indomethacin overdose in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Art | 1999 |
Doppler sonographic study of the effect of indomethacin on cardiac and pulmonary hemodynamics of the preterm infant.
Topics: Carotid Artery, Internal; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Echocardiography; | 1999 |
Indomethacin treatment decreases renal blood flow velocity in human neonates.
Topics: Birth Weight; Blood Flow Velocity; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 1999 |
Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Hypoglycemia; Indomethacin; Infant | 1999 |
Back to the drawing board.
Topics: Brain; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofen; Indomethacin; Infant, Newborn | 2000 |
Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus.
Topics: Adrenal Insufficiency; Bronchoalveolar Lavage Fluid; Bronchopulmonary Dysplasia; Chronic Disease; Du | 2000 |
Effect of patent ductus arteriosus and indomethacin treatment on serum cardiac troponin T levels in preterm infants with respiratory distress syndrome.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2000 |
In partial defense of prolonged indomethacin therapy for patent ductus arteriosus.
Topics: Cardiovascular Agents; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indomethacin | 2000 |
Ibuprofen as effective as indomethacin for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Olig | 2000 |
Ibuprofen and patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Intractable hypoglycemia following indomethacin therapy for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Hypoglycemia; In | 2000 |
Spontaneous motility in preterm infants treated with indomethacin.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2000 |
Don't discard your indomethacin yet.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Brain; Cerebral Hemorrhage; Clinical Trials a | 2000 |
Low-dose continuous indomethacin in early days of age reduce the incidence of symptomatic patent ductus arteriosus without adverse effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography; Female; Humans | 2000 |
[Patent ductus arteriosus. A common clinical problem in extremely premature infants].
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fluid Therapy; Humans; Incidence; Indomethacin | 2000 |
Ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
In utero remodeling of the fetal lamb ductus arteriosus: the role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blotting, Western; Cell Death; Cell Division; Coronary Circul | 2001 |
Diastolic flow velocity of the left pulmonary artery of patent ductus arteriosus in preterm infants.
Topics: Blood Flow Velocity; Diastole; Ductus Arteriosus, Patent; Echocardiography, Doppler, Pulsed; Female; | 2001 |
Gastroesophageal endoscopic findings and gastrointestinal symptoms in preterm neonates with and without perinatal indomethacin exposure.
Topics: Biopsy; Case-Control Studies; Ductus Arteriosus, Patent; Endoscopy, Gastrointestinal; Enteral Nutrit | 2001 |
Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants.
Topics: Anti-Inflammatory Agents; Apgar Score; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; I | 2001 |
Increased constriction of the ductus arteriosus with combined administration of indomethacin and L-NAME in fetal rats.
Topics: Animals; Cyclooxygenase Inhibitors; Dinoprostone; Ductus Arteriosus; Ductus Arteriosus, Patent; Enzy | 2001 |
Surgical closure of patent ductus arteriosus in very-low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Finland; Humans; Indomet | 2001 |
Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment.
Topics: Birth Weight; Blood Loss, Surgical; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 2001 |
Closure of the ductus arteriosus and development of pulmonary branch stenosis in babies of less than 32 weeks gestation.
Topics: Cardiovascular Agents; Disease Progression; Ductus Arteriosus, Patent; Female; Heart Murmurs; Humans | 2001 |
Preventive management of hypoglycemia in very low-birthweight infants following indomethacin therapy for patent ductus arteriosus.
Topics: Blood Glucose; Ductus Arteriosus, Patent; Female; Gestational Age; Glucose; Humans; Hypoglycemia; In | 2001 |
In utero indomethacin alters O2 delivery to the fetal ductus arteriosus: implications for postnatal patency.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Death; Ductus Arteriosus; Ductus Arteriosus, | 2002 |
Treating extremely low birthweight infants with prophylactic indomethacin. Evidence for short term benefits only.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arterios | 2002 |
Isolated neonatal ductus arteriosus aneurysm.
Topics: Aneurysm; Cardiovascular Agents; Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiography, Dop | 2002 |
Minimal effective dose of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiography | 2002 |
Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cohort Studies; Cost-Benefit Analysis; | 2002 |
Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus.
Topics: Age Factors; Algorithms; Birth Weight; Cardiovascular Agents; Dose-Response Relationship, Drug; Duct | 2002 |
Early versus late treatment of PDA with indomethacin.
Topics: Bronchopulmonary Dysplasia; Cardiovascular Agents; Ductus Arteriosus, Patent; High-Frequency Ventila | 2002 |
[Dopplersonographic findings in neonates with significant persistent ductus arteriosus].
Topics: Anterior Cerebral Artery; Ductus Arteriosus, Patent; Echocardiography, Doppler; Echocardiography, Do | 2002 |
Indomethacin: continuous versus bolus administration.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2002 |
Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy.
Topics: Cardiovascular Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
[Changes of mechanics of breathing in newborns after pharmacological ligation of persistent ductus arteriosus (PDA)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Drug Administration Schedule; Duct | 2002 |
Medical manipulation of the ductus arteriosus.
Topics: Blood Pressure; Ductus Arteriosus; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Ind | 1975 |
Letter: Indomethacin and closure of the ductus arteriosus.
Topics: Animals; Ductus Arteriosus; Ductus Arteriosus, Patent; Edema; Female; Humans; In Vitro Techniques; I | 1975 |
Problems with indomethacin for ductus closure.
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1977 |
Plasma-prostaglandins in pre-term neonates before and after treatment for patient ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Heart Failure; Humans; Indomethacin; Infant, Newborn; Infant, Premature; | 1978 |
Radiographic and echocardiographic evaluation of newborns treated with indomethacin for patent ductus arteriosus.
Topics: Diagnostic Errors; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant | 1978 |
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem.
Topics: Animals; Brain Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arterio | 1979 |
Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Ligation; Respiratory Distress Syn | 1978 |
Failure of indomethacin to close persistent ductus arteriosus in infants weighing under 1000 grams.
Topics: Anuria; Digitalis Glycosides; Ductus Arteriosus, Patent; Female; Gastrointestinal Hemorrhage; Heart | 1979 |
[Treatment of hypoxia caused by a right-lef shunt in a newborn infant (effect of indomethacin associated with distending therapy) (preliminary report)].
Topics: Arteriovenous Fistula; Ductus Arteriosus, Patent; Humans; Hypoxia; Indomethacin; Infant, Newborn; In | 1978 |
Pharmacology of the ductus arteriosus.
Topics: Aspirin; Chloroquine; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Femal | 1978 |
Pharmacologic treatment of patent ductus arteriosus.
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1979 |
Poor response to oral indomethacin therapy for persistent ductus arteriosus in very low birthweight infants.
Topics: Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethacin; Infant; Infant, Low Birth | 1979 |
Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications.
Topics: Age Factors; Ductus Arteriosus, Patent; Electrolytes; Female; Gestational Age; Humans; Indomethacin; | 1979 |
Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1979 |
Indomethacin and renal function in premature infants with persistent patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Glomerular Filtration Rate; Humans; Indomethacin; Infant, Newborn; Infant | 1979 |
Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study.
Topics: Child Development; Ductus Arteriosus, Patent; Follow-Up Studies; Growth; Health Status; Humans; Indo | 1979 |
Gestational age and indomethacin elimination in the neonate.
Topics: Blood Proteins; Ductus Arteriosus, Patent; Gestational Age; Half-Life; Humans; Indomethacin; Infant, | 1979 |
Echocardiographic findings of large patent ductus arteriosus in the very low birthweight infant before and after treatment with indomethacin.
Topics: Blood Pressure; Ductus Arteriosus, Patent; Echocardiography; Female; Heart Rate; Heart Ventricles; H | 1979 |
[Closure of the ductus arteriosus by medication in low birth weight infants].
Topics: Autopsy; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; | 1979 |
Medical treatment of the ductus arteriosus.
Topics: Animals; Aspirin; Coronary Circulation; Ductus Arteriosus; Ductus Arteriosus, Patent; Fetal Heart; F | 1977 |
Blockers of prostaglandin synthesis: a novel therapy in the management of the premature human infant with patent ductus arteriosus.
Topics: Animals; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fetus; Humans; Indomethacin; Infant, | 1978 |
[Factors of motoricity of the ductus arteriosus].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Pregnan | 1978 |
[Indomethacin in IRDS with PDA phenomenon (author's transl)].
Topics: Apnea; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Respiratory Distress Syndro | 1979 |
Medical treatment leads to closure of patent ductus arteriosus.
Topics: Age Factors; Chloroquine; Ductus Arteriosus, Patent; Humans; Indomethacin; Prostaglandin Antagonists | 1977 |
Commentary: patent ductus arteriosus and the respiratory distress syndrome--a perspective.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Respiration, Artificial; R | 1977 |
PDAs, prostaglandins, and RLF.
Topics: Aspirin; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Pregnancy; Prosta | 1978 |
Echocardiographic diagnosis: pitfalls in the premature infant with a large patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant; Infant, Newborn; Infant, | 1978 |
Relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome.
Topics: Ductus Arteriosus, Patent; Female; Fetus; Humans; Indomethacin; Infant, Newborn; Obstetric Labor Com | 1978 |
Management of premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1978 |
[Indomethacin in the closure of patent ductus arteriosus. (apropos of 3 cases)].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1978 |
Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants.
Topics: Calcium; Drug Antagonism; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Hyaline Membrane Di | 1978 |
Problem of patent ductus arteriosus in premature infants.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Ductus Arteriosus, Patent; Heart Failure; He | 1978 |
Age-dependent closure of the patent ductus arteriosus by indomethacin.
Topics: Age Factors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Urination | 1978 |
The effects of the administration of fenoprofen or indomethacin to rat dams during late pregnancy, with special reference to the ductus arteriosus of the fetuses and neonates.
Topics: Animals; Animals, Newborn; Body Weight; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fenopr | 1978 |
Operation or indomethacin for the premature ductus.
Topics: Age Factors; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin; Infant; Infant, New | 1978 |
Pharmacologic closure of patent ductus arteriosus in the premature infant.
Topics: Cyclooxygenase Inhibitors; Depression, Chemical; Drug Evaluation; Ductus Arteriosus, Patent; Female; | 1976 |
Patent ductus arteriosus.
Topics: Adolescent; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn | 1977 |
Ductal manipulation--a note of caution.
Topics: Aspirin; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Oxygen | 1977 |
Commentary: new thoughts on an old problem--patent ductus arteriosus in the premature infant.
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; | 1977 |
Breakthrough in treatment of patent ductus arteriosus.
Topics: Aspirin; Chloroquine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem | 1977 |
[New possibilities of treating patent ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Prostaglandins | 1977 |
Failure of indomethacin therapy to induce closure of patent ductus arteriosus in premature infants with respiratory distress syndrome.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature; Respira | 1977 |
Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis.
Topics: Aspirin; Depression, Chemical; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Follow-Up Studi | 1976 |
Editorial: Patent ductus revisited.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature, Disease | 1976 |
Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enteral Nutrition; Humans; Indomethacin; Infant, Ne | 1992 |
Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus.
Topics: Atrial Natriuretic Factor; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1992 |
Increase in serum digoxin concentrations after indomethacin therapy in a full-term neonate.
Topics: Creatinine; Digoxin; Drug Interactions; Ductus Arteriosus, Patent; Female; Heart Failure; Humans; In | 1992 |
Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Echocardiography, Doppl | 1992 |
Intravenous indomethacin therapy.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infusions, P | 1992 |
Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Mefen | 1992 |
[Treatment of a patent duct in neonates].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Male | 1992 |
Effects of a clinically detectable PDA on pulmonary mechanics measures in VLBW infants with RDS.
Topics: Airway Resistance; Ductus Arteriosus, Patent; Female; Follow-Up Studies; Humans; Indomethacin; Infan | 1991 |
Indomethacin.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1991 |
Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.
Topics: Blood Flow Velocity; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Splanchnic Ci | 1991 |
Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Colloids; Ductus Arteriosus, Patent; Female; Flui | 1991 |
The influence of respiratory distress syndrome on heart rate variability in very preterm infants.
Topics: Age Factors; Birth Weight; Blood Gas Monitoring, Transcutaneous; Cerebral Hemorrhage; Ductus Arterio | 1991 |
Metabolism and disposition of indomethacin in preterm infants.
Topics: Birth Weight; Chromatography, High Pressure Liquid; Ductus Arteriosus, Patent; Gestational Age; Huma | 1991 |
Day case ligation of patent ductus arteriosus in preterm infants: a 10 year review.
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Inf | 1991 |
Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption.
Topics: Animals; Animals, Newborn; Blood Flow Velocity; Ductus Arteriosus, Patent; Female; Ileum; Indomethac | 1991 |
Gut blood flow velocities in the newborn.
Topics: Blood Flow Velocity; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Splanchnic Ci | 1991 |
Effects of indomethacin on prostaglandin E2 and thromboxane B2 contents of tracheal lavage fluids in premature infants.
Topics: Body Fluids; Cyclooxygenase Inhibitors; Dinoprostone; Ductus Arteriosus, Patent; Humans; Indomethaci | 1991 |
Prolonged low dose indomethacin for persistent ductus arteriosus.
Topics: Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1991 |
The use of indomethacin in the treatment of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Education, Nursing, Continuing; Humans; Indomethacin; Infant, Newborn; In | 1991 |
Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.
Topics: Blood Flow Velocity; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Mesenteric Ar | 1991 |
[Response to the treatment with indomethacin in persistent ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Male; Retrospective Studie | 1991 |
Early screening and treatment of "silent" patent ductus arteriosus in prematures with RDS.
Topics: Birth Weight; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Humans; Indomethacin; In | 1991 |
Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Lung Compliance; Respirati | 1991 |
Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging.
Topics: Blood Flow Velocity; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prema | 1991 |
Clinical profile and management of symptomatic patent ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Incidence; India; Indomethacin; Infant, Newborn; Infant, | 1991 |
Indomethacin therapy in the newborn.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Drug Interactions; Ductus Arteriosus, Patent; Humans; Indo | 1991 |
Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure.
Topics: Biomarkers; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn | 1991 |
Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants.
Topics: Blood Flow Velocity; Blood Pressure; Carbon Dioxide; Cerebral Arteries; Cerebrovascular Circulation; | 1990 |
Contribution of color Doppler flow imaging to the evaluation of the effect of indomethacin on neonatal cerebral hemodynamics.
Topics: Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Circulation; Color; Ductus Arteriosus, Paten | 1990 |
Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.
Topics: Blood Flow Velocity; Celiac Artery; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; | 1990 |
Cerebral lesions in preterm infants after tocolytic indomethacin.
Topics: Administration, Rectal; Brain; Brain Damage, Chronic; Cerebral Hemorrhage; Dose-Response Relationshi | 1990 |
Asymmetrical pulmonary changes in premature infants with surgical closure of a persistent ductus arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethaci | 1990 |
The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus.
Topics: Acute Kidney Injury; Cerebral Hemorrhage; Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indome | 1990 |
Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response.
Topics: Algorithms; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Prospective Studies | 1990 |
Effects of highly overdosed indomethacin in a preterm infant with symptomatic patent ductus arteriosus.
Topics: Drug Overdose; Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethacin; Infant, Ne | 1990 |
Cerebral blood flow following indomethacin administration.
Topics: Animals; Animals, Newborn; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indometha | 1989 |
Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1989 |
Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Hemodynamics; Humans; I | 1989 |
Does the respiratory distress syndrome in twins and singletons run different risks of persistent ductus arteriosus?
Topics: Diseases in Twins; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Low Bi | 1989 |
Prostaglandin E2 in the lung lavage fluid of premature newborns before and after surgical or medical closure of a patent ductus arteriosus.
Topics: Bronchoalveolar Lavage Fluid; Dinoprostone; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; | 1989 |
Localized intestinal perforation following intravenous indomethacin in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Intes | 1989 |
[Indomethacin or ligation in the treatment of persistent ductus arteriosus: a report of clinical experiences].
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin | 1989 |
Indomethacin therapy in premature infants with patent ductus arteriosus--determination of therapeutic plasma levels.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1989 |
Does indomethacin affect the control of breathing in premature infants?
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature; Respira | 1989 |
Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus.
Topics: Bacterial Infections; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem | 1987 |
Patent ductus arteriosus after prolonged treatment with indomethacin during pregnancy: case report.
Topics: Adult; Diseases in Twins; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1987 |
Pulmonary function in preterm infants following treatment with intravenous indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethacin; Infant, Newborn; Infant, | 1989 |
Increased constriction of the ductus arteriosus with combined administration of indomethacin and betamethasone in fetal rats.
Topics: Animals; Betamethasone; Drug Therapy, Combination; Ductus Arteriosus; Ductus Arteriosus, Patent; Fre | 1989 |
Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Drug Administration Schedule; Ductus Arteri | 1989 |
Tolerance of intravenous indomethacin treatment for premature infants with patent ductus arteriosus.
Topics: Drug Tolerance; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1988 |
Relation between persistent patency of the ductus arteriosus and retinopathy of prematurity.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant | 1988 |
[Use of prostaglandins and indomethacin in childhood cardiac therapy].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Prostaglandins E | 1988 |
[Effect of the use of indomethacin in newborn infants with patent ductus arteriosus on the plasma level of PGE2].
Topics: Dinoprostone; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Prostaglandin Antago | 1988 |
Symptomatic patent ductus arteriosus in premature infants.
Topics: Cross-Sectional Studies; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth | 1988 |
Indomethacin and patent ductus arteriosus: effects on renal function in preterm lambs.
Topics: Animals; Arginine Vasopressin; Dinoprostone; Ductus Arteriosus, Patent; Fetus; Gestational Age; Glom | 1988 |
Ductus closure in preterm infants. Effects on cerebral hemodynamics.
Topics: Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Circulation; Ductus Arteriosus; Ductus Arter | 1986 |
Treatment of patent ductus arteriosus with indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1988 |
Late closure of the ductus arteriosus using indomethacin in the preterm infant.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1988 |
Decreased early diastolic function after indomethacin administration in premature infants.
Topics: Diastole; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant | 1988 |
Indomethacin-associated sepsis in very-low-birth-weight infants.
Topics: Bacterial Infections; Blood Bactericidal Activity; Cell Movement; Chemotaxis, Leukocyte; Ductus Arte | 1988 |
Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1.
Topics: Alprostadil; Ductus Arteriosus; Ductus Arteriosus, Patent; Heart Defects, Congenital; Humans; Indome | 1988 |
Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus.
Topics: Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infan | 1988 |
Early treatment of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiography; Female; | 1988 |
Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment.
Topics: Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; Infant, Newb | 1987 |
Prostaglandin levels: predictors of indomethacin responsiveness.
Topics: 6-Ketoprostaglandin F1 alpha; Dinoprostone; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 1986 |
Indomethacin therapy in premature infants of advanced postnatal age.
Topics: Age Factors; Ductus Arteriosus, Patent; Hemodynamics; Humans; Indomethacin; Infant, Newborn; Infant, | 1987 |
[New aspects on the pathogenesis of patent ductus arteriosus in premature infants].
Topics: 6-Ketoprostaglandin F1 alpha; Combined Modality Therapy; Dinoprostone; Ductus Arteriosus, Patent; Ep | 1986 |
Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Monit | 1987 |
[The significance of renal prostaglandins for kidney function in early childhood].
Topics: Angiotensin II; Aspirin; Child, Preschool; Creatinine; Ductus Arteriosus, Patent; Glomerular Filtrat | 1987 |
[Prostaglandins and the perinatal period].
Topics: Blood Pressure; Blood Vessels; Ductus Arteriosus; Ductus Arteriosus, Patent; Fetus; Heart Defects, C | 1987 |
Periventricular haemorrhage: association with patent ductus arteriosus and its treatment with indomethacin or surgery.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, N | 1987 |
Indomethacin therapy for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1987 |
Symptomatic patent ductus arteriosus in premature neonates: a 5 year study in Toa Payoh Hospital.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Respi | 1987 |
[Treatment with intravenous indomethacin of symptomatic ductus arteriosus in premature newborn infants].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Injec | 1987 |
[Intravenous indomethacin in the treatment of patent ductus arteriosus. A new form of preparation].
Topics: Drug Compounding; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Injectio | 1987 |
Indomethacin therapy for patent ductus arteriosus: when is prophylaxis not prophylactic?
Topics: Age Factors; Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Wei | 1987 |
In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Ductus Arteriosu | 1987 |
The effect of indomethacin on cerebral blood-flow velocity in premature infants.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; I | 1987 |
Indomethacin, patent ductus arteriosus, and cerebral blood flow.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Depression, Chemical; Ductus Arteriosus, Patent; H | 1986 |
Vancomycin pharmacokinetics in neonates.
Topics: Drug Interactions; Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Kine | 1986 |
[Indomethacin and furosemide in closure of ductus arteriosus].
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Indomethacin; Infant, Newbor | 1986 |
The management of symptomatic patient ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1986 |
Pharmacological manipulation of the ductus arteriosus.
Topics: Drug Administration Schedule; Ductus Arteriosus; Ductus Arteriosus, Patent; Heart Defects, Congenita | 1986 |
Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus.
Topics: Cardiovascular System; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Kidney; Lung | 1986 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Response of the patent ductus arteriosus to indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1987 |
Response of the patent ductus arteriosus to indomethacin treatment.
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, | 1987 |
Indomethacin therapy in premature infants with patent ductus arteriosus and oliguria.
Topics: Anuria; Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infa | 1986 |
Persistent responsiveness of the neonatal ductus arteriosus in immature lambs: a possible cause for reopening of patent ductus arteriosus after indomethacin-induced closure.
Topics: Animals; Animals, Newborn; Dinoprostone; Ductus Arteriosus, Patent; Gestational Age; In Vitro Techni | 1985 |
Aminoglycoside treatment and renal prostaglandin excretion in premature infants.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Creatinine; Dinoprost; Dinoprostone; Ductus Arteriosu | 1985 |
Does indomethacin cause extension of intracranial hemorrhages: a preliminary study.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infan | 1985 |
Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Birth Weight; Blood Glucose; Carbohydrate Metabolism; Drug Evaluation; Ductus Arteriosus, Patent; Fe | 1985 |
Angiosonography of patent ductus arteriosus in neonates.
Topics: Alprostadil; Aorta, Thoracic; Ductus Arteriosus, Patent; Glucose; Humans; Indomethacin; Infant, Newb | 1985 |
Noninvasive assessment of indomethacin therapy in patent ductus arteriosus in preterm infants.
Topics: Aorta; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, P | 1986 |
Localized intestinal perforations after enteral administration of indomethacin in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ileal Diseases; Indomethacin; Infant, Low Birth Weight; I | 1985 |
Possible indomethacin-aminoglycoside interaction in preterm infants.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Creatinine; Diuresis; Drug Interactions; Ductus Ar | 1985 |
Intestinal perforation associated with indomethacin treatment in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; | 1985 |
I.v. indomethacin approved to close patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Injections, Intravenous; Legislati | 1985 |
Severe hyponatremia with indomethacin--a more serious toxicity than previously realized?
Topics: Ductus Arteriosus, Patent; Female; Humans; Hyponatremia; Indomethacin; Infant, Low Birth Weight; Inf | 1985 |
Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1985 |